var title_f17_1_17424="High frequency EUS probe";
var content_f17_1_17424=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F74641&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F74641&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 555px\">",
"   <div class=\"ttl\">",
"    High frequency ultrasound cathether",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 535px; height: 369px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A 20 MHz ultrasound catheter (Olympus&reg; UM-3R; Olympus&reg; America Inc., Melville, NJ.) covered by a balloon sheath that may be inserted through the biopsy channel of the endoscope.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Enrique Vazquez-Sequeiros, MD and Maurits J Wiersema, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_1_17424=[""].join("\n");
var outline_f17_1_17424=null;
var title_f17_1_17425="Cytology bile duct strictures";
var content_f17_1_17425=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F56362&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F56362&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 594px\">",
"   <div class=\"ttl\">",
"    Cytologic brushing of bile duct strictures",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 574px; height: 270px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEOAj4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5hJcyMFZySx6E+tOk82JykvmI46hsgj8K7f4Lro8PxAt9U8R3lva6bo6yaiwmcAzPHzHGikgu5fado5IBra+Pl/o/iO48P+KdJ1i01C7v7MW+pKgEUv2iHCea8OSUDrjHbC0DPLBI399j+Jp+9sY3MPxNQbs0qtjvSA1NPmZZFy7EZ9a2TORC4LnpnAJrmYHIYYratF3qevIpESXUhkuZCuFdh+JzVYux/iYn60+RSuQc5HWoX6+meaZSHLIwP32+pNOacjPzsfbNVz6c0hNAyXz2zw7fmangunRuHP4saonJx1p6dRQB0lnqD5B8x8/XrXUWF5LJj94fYFs8elcNo9td6hfQWenW8t1dzHEcMKlnY/Svpf4ZfACTyor7xzcOrHDLp0D9P99/X2FNRb1MZQvsZfw60HU/Ed0i2gPkD/WTMcKo7171onhW10aWMwx+dOpBaeQZx67RW7pWk2emWkdrp9tFbWsYwiRrjA9/WrzcAgdad7bFRjYNgVix/Wkc+vGfzpVPydRxUVzMIkLD5jjIpF3JSwC5bgDmqc10S+2OoQHuiWYnYRnjpUyxqIwEAyB3piEji/jbg4zk9qS6u0t1GSAx7d2+lILpQ3lqcv0wOxrH8TtZ2Vk91qV1HDKOY88kn0AouJs1WjN9CWn+WIjJBOAK4PX/ABdbaLNPFo7LcXDHb5v8Cf4mua8SeMr3V1FrExtrJRgrGcM59Sf6VzEKFmyV4K9O3Wi7ZjKfYuT6ldXl0bi8neVy2SxP6VVlVmlk+8ecH5u1PhgbhVHINa0Vgsscb/MCeDxwT6U0RuY9pC7ylQWwRwCaP2lmaPSvh+iuwT7Hc5GeuBbY/rXTR2tvZQvNLKi7UJVfSuU/aRcPo/w6dfmDWNyR78W1KWobRZ41Ck9wMRxyyIOuwE/niomYkHGcfWvY/gZrNvpfhzXVe9s4Lx7y0kjim1NbIyKrEt8xPIA6jnPTvXn3xEks7nx1rk2m3QvLSa6eVJwoUNuOTjHGMkjPfGaRm0kk7nNoxzkEn3zVm3j3NuLHPXrTYo+TwM+9XLRACeM0yGySZz5LfM27oMGqSq2DyT+NX3APAwAKYVAGSPwpCuVQCpBYnJ96mgmLyEc7R1561XlcM+0dB1qeDCQEsB/jSuO5rRyokRwT+dZl55kvAY/TNQwzkuQc4q0WDDA4Hr60AY43hsbjnp1rT0tykoVmOD6npUUlsVYMBkdcVARhxtPQ0DbudSpzjJYZ96SdCY84Occ89KgsJd8QBPPcVfnTEOO5/Kgi5zF/FsfcuQT15rODMrcsSB6npXQ3lqzoSOaw5IiDjpSLix8LEsew9qtENgckfU1DZrzg53D2q8iYzuPGKYNmbdKcNycjpzVXkpnLbh6mtiZARg8n1rPaL5iKQJldIJJfu5I9Qa1LHTuQWBJJ9av6TaqqYfk1sJbqeQMVSE5lO3ttvTOPrWtbL8vzZP406OHH3hxViGI5+XGKCGyzBZebk5O0c81fisVDAHp61NYR/u8MD7VoxpgL93AFO5LYltGI4wuPyqeIYbHIHrmgYOCRwKZIwVhj8cUxXJ3h35Jz+dYmrWCOAcdOfrWtLdBRjtVGWTeOQOelFwON1OxQqxAxnvXDavp8iT7kLFf5V6fex+YzDn8KxrrTiysGUjPbFG5cZNHm0kDoM7iR9aIcljksMe9dXe6V5ZJC5B7elZz2PzBQMHucUmjT2hRbJQ4LfnTevVj9M9K1k087CCOfWlTTAOTk59qLE8xUiRlAK5INbujRNkMSeaitNMaSTapJz1NdXpellYkWMUWIci5piuQME5+tdBbxfKr7ulVbayEKjByfQdq0S6dSDt7iqRm2TGQvGAueO+az7glSxJ/Wr4dOoBC1mzOpdl9OlNElO4ywxk1nncJD16dzWm+GU7Dk1QlUlgc0x3PmOQ/vH/3j/Okok/1jduTSCsj3BaVetJQtAE8P3hXRWQARTnGa52L7y465rctnwijt9aTJktBLuMiU7RxVJ0bsOK2X2yplfvAd+9VmiyOBzSJUzJYEHnJ+lJg5q7PFyOMH1rX8HeDta8Yah9k0Kzadh/rJm+WKP/eb+lUlfYu63Obx09K6/wAG/D7xH4q1EWun6fLCi4825ukMcUQPck9T7CvpL4WfA3TPDBg1HXjHqmsr8wyuYYD/ALKn7x9zXqF5H+92Stu3crgYAP0p2S3Jcuxg/CT4f6J4G09I9NhSfU5ExcX8i/vJG74/ur6AV6TH0GAK56wSVHAfG8dhW/EVAB45pN3BEuKa+NuOfwp46VBKjZGGwvegZVedvNeNMZxkfWmRkDLTNuJHQ/yqRwIyuxfmPHHaq67Y5WWdw0gOVUelAiVcpLkkLCV/I1O5Lr+4K4xyT/jWVq9zHbWZk1SVYIM8KDkn6CvP/EnjG6u1W1si8Fqoxx95/rRclySNLxF4ot/Dl7P/AGdMl3cHOUzlUY+/615XrOq3mqagbnULoyyN/ebhR7elF+rvIxVQM8g+/rWVcK5YAAdqDCUrmjCNzfKwJHRs1oRLtVS3Tpk1iRkqg2/ex1zjNW7Z5Nylc4PagR0FqoMmCOD1Ga2Ypoo1w/BXkHsPesbTYrhgMRnnkluK2007zkAmySRg44H1qkM5nV7n7RI0cRWR2OMg5xVL9oyEwaL8OYSQTHYXCn3wttXZQaXbxIdiLj3HNcv+0yv+ieAwRj/Rbr+VtSkJ/Czw9UGzI4FSKhAzjJzT09+3QVKRhaRz3INo69/ar1smEyeF96qIpyMYNXseXHn8qAGSADkcjNV5nJJC8VZc4iP9apMTknpSAiCAAknnGKs4/c4A5xUO0EDnJ7ipCdpAPGe/pQMrkFSMAfhVqzkDNg5PpTNqMMcg9valhzFLv6YHPegGzTjiyCDyO3vWfcWzRvnHGeD6Vr2rqY14GTVh0jccjpQK9jCtpTG4wDjrXSWsizQKT26cVjXFttztHPX8Km0mcxMYmxg8igHqjXaFTnIAz61k3uniQHaPpxW0pJTB/L1qRI1KkkZ2/nQK5xvktBMFb5fSr0cefmxk9Oau6nEGbcF4FS2FhLffLbjJAyTQVcy3TqTg8Y6VQjgMlyuF4zW3cRPGWjYYZeDnrS6XZ5n3NnNArl20tiEX5ScD0q/DEcfUd607CyVlBY7vpVptP8vBB5PrTJuZscZwo/Cp7aLa+TkgdqtfZCME5wDUgQqeMdfzoFcntnTacDGO9XI8nOayw2yTkHB7VegkZ1IAIPTFAmWJJQic4yKz577JwnX1qO/E27hSPaqMVvJ1Pc+tAGnasZQQeTmp5LcnOeRSWEJD5BGcc1qi3JQ5wKYmc1JCBN3BFEltkZ7Vuz6d1bcM1ELL1xTC5y97a5BBUe9YF5YFXJQHH0r0C4so8/MwH4VRe2tgSCCaAucUsDsQEU8dqvwaVNKANuAf1rflt0UbkjHA7VNbljgdARxQO5HY6VDboPMI3nnmtOKJUX92uAfSo44znOdxq3HGRx6UEj0X3z605FzuzjFKiAnHOfQVIgwCec460yStMxjHHHaqJQGTufWrtywYgDgVBCDu5OeeKYEYiAGQBkVFNF8/3R9a0GTGD1571XdcP65FNAfJUn+sY+5pKc+fMb6n+dGMVke6AFGPm4pwHFOAyaAJIFzIo/StZeOB2FU7SPMin9KvKv4VJLZKp9/wpRnOM96EH5V6J8L/AAD/AMJLK19qTGPTID8sefnnb+6PRfehIzbsch4b0m21XWrWLVLh7awZsyMg+dlHJC/Xpmvs7wj/AGPa6HbxeHYIrfT0HyiNcZ+p7mvmq4tdIF4b17dYRDIdkKnDnBxjHWvbvhnpc8mL97iSO2eMLFbg/KoPOcU0yIzcnoemRTNPGNgA4wGPSpYrVQv7zJyM570QBVQcYHoKI5JpS2wbR2Y9aDVEd1L5A2QrmXGRT7K52lUncAtxj0NVbjeuRBw+eWPWqe6O2bzmJJkPPGWJ9BQK51cWQSGOT9KlIBGD0qnYSPJAvnABu3PNS3t3b2NrJc3kyQwRjc7ucACgsGTYrLGvXkHtn3rz3x34vi0JkewCXGpOMFyf3agfzrkvHvxLuNVl+w6CzW9h0ec8NL/gtc1Ist94at2K5eKQx5A9aLmMql9EXrTUr7WtTa51ScyzMeOcBfZR6VoXsCtK2HUL69qNH0w22mw3UinJ6t2B9KTUNiBJFyQ3GffNGxHqVDBbbOQWzxnNV59LheRWWJ+Rxz0rRtI4iwcsWHOMmtI7WQF+OaaAwINCgl4feAOeK6HT9Eto4VKH5ickkdCKfAqBjxwfWr8EoVce3QUwSLEFkEC4VW47+9SrbspB2cDvjinLcqMAPn2qK4vUgDFpMY9D3xRcYy7AUbgMe3fpXn/7SvzWngMjn/Rbrr9Laug1PVriUusMeDyobv0rm/2gsnR/h4WJz9huCee+22oZEn7rPHEGOD1p7YCZ65pyrgZ6n3piKWcHHekcxLaR5JJzgVK+dxyOnanM4hXjGaMB1Vs9etAFSQ/vAMnHoKY6jdz3qSTGSV/Ch+VGCAaQyAJluB/9alZiRyOO1PDYbaoGCPSkJz74oAhAz0yDV2BVI2t261DGpHCjH86mjUIvGKAHyFkf5CARVm3uc7Q3X0NUWyG4wTTjwMg0gsa0mJG/TNRm1AG5eCPSoYJezjHHGe9X0cFBgZJ9aYthbKYlwknLYrVHIHTmqCwqWDgHcOnvWjAokPHXHTNAmU72DcpIzkDFWfBVx9m1GS2cgLIuQfeppUJGcDHSqUcLRXqTJ2YUAWdYgU6nOQAQWyKr28flyDtitK7Qmdye/OagVG42r3zQFzTsp2jxjr6Yq29zuIPG0VQt1+XJzk9asKhJx2oEW1cOPl4HvT44mzxgD3qWC1WGMyTNj0Wql9f7kKIdoHGB3oELI9tAMyYZvrVG41pYAQu0Yrmr++ke4ZskAHArPeRpHDHpnFA0jbvfELynqR7g1Xi1CWX+M1iyrl+vNaullQVBA+XjFIdkbtnfyxMFcna2Pm9a6O3vCQOScjNczMqyR8jg1Y0+Zjlc9OB9KZJ2EM3mBuTn61HLkORk7TVO0dgoz0NXN4K54pklK8iYodoPXNZhRw5IGK07y7CAjPOK5nUL0iQjJ2k5wKY0bA8sKQWGOmKI5IhgAH0rIiulZB82f1qSK5UE5bnNK4GzHKFPGT/s1ZE7bcrtx6VixzqF+ZsKOfrU8dyCMZApiNDzyOd3TtTDdFXC7sbqy575ELdzjjNVba6Ek25icjtTFY6Tb0yeTTIQA5781FbXO8hHA6cGpouTuXHX5qaYidvunPNV2yGwtSSOB6Y9RUBIJ65+lNAfJcg/eP8A7xpVpZR+8bj+I/zpuKyPdHinoP8A69Rg54NTwLkjjigC9ajA5FXUXcB3/pVVO2Oa1NMtvtMuzJCqMu3TC0jOR3Xwu8Av4meXUdRVo9HtwRnoZmHZfYdzXZ6x4kttCulsdPRrZlUBFXpN7j2rnPAPja48PRyw3G06NI+xIyOQx4+X29a7y08IjxPqcd3dQ7GU5TI+4vbHvT3MXqcppXhG88Sa/Hrd4oRn2s0ajABHQ/8A1q+hdAuraysYbVwkcyKAFXofpWNHaw6DaiKQjKjh/X/69VrPT31C9hv52aJIm3xR+vuaL9ENXR3tqzMxLYEbcirkbKW28Y7Ad6w4tUhZkiZx85wjA9W9Kv27NI5AJQZ4PcGkaJ9i86GTAi257+gFRR2CQO3WR3Odx5wfT2qxbbYY3Mh2gDJJ4/E1xni/x2LNBb6LEJ5pMqZz91PoO9FxuyWpc8ReNLPRMxQxte3Y4KRn5U+p9a8m8Va9q3ibc+oO6wocrbIPkX3x3o+zMXZ2cq2dxOc5J61ahMiI5Y/Ko4J6mgybbORgjkJJVCCBkEjrXeeGbINoVxG4xjEmBVCORTCQwXr17iup8Om3ME0eCMxHAPWgSWpFqbZ8OQQrwVc8dsCseKEy2pLIwCNkcVsahLG2nxbSwAZuAOtVvNij0yONP+Wh+bNMGUFLKMMN2Oc0sk4SPB4x29KSfy40L7/lAx71UMLSna0ny9QT1IoELJqEmfkPy9fenxtdyOMS/gvekh09A+ZZR5Q6gNWnCkCDETABc4Y9aAFihZSC8jYXtnvUksTFWKg57+9MCDfkzZOOlXYovMiYeaAT1HpTAw7ofK4Afoep9u1ZXx+XGjfD0eljcD/x22rZ1G1aPpKvPasX9oIlNF+HwByfsNxz/wABtqbJl8L/AK6nkrqCuOcetNRgpPXIqMOx46g09QwX+dI5fIbKSzDByBxjFW4l2wnPYVDCmXBxwPWrEpwNvHzdqQ7lIJg8HvxSgYPSl6Z9aayktyxZjQMbhSQF5pdhBHTJ609Iipz19Km2ZUHjOOaAIkTBAY85zT5No3BevrS42jn0/OhVDc44x0pAQlRkZ4PSpB9/5RxTgoJ449acvByAM+tAClMDIwfY1NbyY6nIFRqvGTnJ96eMDjjJ70AasEwKY4Oau27g7Rnj1rBQmPJB9jWhazgZz1oEbZKlcZ7VLFbo0eBz359ap28uQD2PFa1mMqMY/wAKZOwy+tmTy2TLBhzxRb2rZHy8fyrfS18+1jPVBwad9lVE+Vf8+tAXKNrZjJ7574rRt9NVQZXAC9hViyhy20jC/ezV2cFxhDhQOKZNzmNQEhJEg+70xWDdg7WPbFdffwDBwCa4/UwVVyThQTzSGc3csC7AAA1EoOcD5jUrY7jnOc0dSBkcUiyF1VSMHn2qxZqVkLcVHIgBA6Emr0EO2MADAoAsCc7NrHgD86vaWPnDFuvrWXIUhO5ieP1qtb6gZLwqfljPSmI7kXiAbVGT0zQl4R1789KzbZtyAA5HSrON3Tg+tBAt1IWG88jFY17GHQ+uPStsx5jz149KpyQK5wRgY60xnPoxHGfY4pk7lTkMfXjtVq/sCjB0PDfpWRdRTAdDx+tAyz/aLIhOenaqp1qU4x09KolHyVOc+9V2jZW6dKQzXOpNJhiTu9MZq/YzPncfumucjz0X16it6ElEwe3Apks0ZNTdQTCeQfvVpadeytIr8kN1APFYCQFhgZrU09fKmj3dDximyTqdolX0zULoUbC/rVq1dQuMdu9Q3BORzg1aJPk6T77/AO8f50zHXFPcfvH/AN4/zp23FZnuiIuO1XrdNq5FVUXJFaES5Qc9qQEsKlmVUUszHAUdSa9/8P8AgaLRvBdux8iXU7gia7c/NtXsi/Tv71zXwc8FwXVlP4i1uP8A0NDstUPG8jq/0HQV1Go3H2zWDBp7siA4KgkZOfuj+dHkc85FLQ9Di13VLZ4bRGhjbMa7RwAeWI9TXt8C/wBn2i+Z8rIv6YrA8I6Kulx/aGUJMeWYfxGrktzLrN+q4xBFwMfxkf0oElYmS2/tedbuY5hXlY27j1NUdQ8TW1peCF8G3b5C3qf8K0NcvDpsUbRLmND++C9cegrlIbXTNe1dpE/0cyYSPPCsw9BSB9jU0ArP4h+1RFjaDBiQnIB6E/Suy17xPpfh9d97J++K5WFeWP4VwHibWn8CaQu1oJ7ybJRG+8fcDsB714tcaze6ndXF3fSmW4lfLFjz9PoKLhzW0PTPEXxLvvEF41oh+y6cRgxqfmf/AHqtROWgDYBRU+U/0ryvT42+3Bicc5JPYdzXoiyIui23lHcNxPPekQm3ubNsFRQw2noefWpr0pyxUbW7Y/nWHLeJHGFLZOB070+a9D2zrGfmUA8HPSmNMp3F4sV0I1KoN3Sum8NXCm7CbhhgRkHPavO7xs3SkfeOSSe1avhq9aLWbVTk5kwxHHWkC0Z2j3Y+xiMnK7zjPc0yb/UYIwNwwPwrnNQvCUCEspSZwBmr1pdloEWTJIGck0xk1z+5jYuc8849qzTqBd18tcrnOam1OXFu6rj5s5z2rn7eU715ORxz0I70CZtpdNIcFuO2BwKt2szLEC2fm/n9KyvM2umw/MBn86tRTE7gWwvUZ9frQBvwMJAqlcg9v61rRxhBknDY6GsDTWO8Eg7R69/etWSZnYZ/ibBIHeqQFPXRlVLE/c6g1g/H4E6H8O/+vC4/9Btq1NXnJdol/hBB9fpWb8ff+QH8PMH/AJcJ+n+7bUMmXws8hi+8afnI9/5UoXAG0igDk5/nSOa46I/OOymluHw3p701RzyRn1pZfmfHBGOmaAGPy3HSgAk89ff1qQDI+nGRSqgI9vegY4fKMj9RTkBY8j9acFyAKfEmBkgUgI2AIAOCRSKq54B+lPb5uffk0sajdxQBFjkjnrTguCO2adjJOM5pSAVJ4H4daAEA3cnOKAPmGDk+1TAfLz26UJHtOcflQAhUjGRjjpSqT8vYj1FPzuPpkVPFAzc/wjpmgRfsXLgDqRziun02HCrnr6VzdmnlbQgyc9a6fSmHGcn0pks6eziIsei8HoBQUHTk+wosphJG6eg7VJDhnxySTxQSPCeTalh94n0qqSVgyp596uX787c8KOgrOd8ggUAU7ubgkcmuT1ofKwc4yfWupl4Rs9+hrk9fBL/L2HJPrQUjE2jptz7U0qflOAM0px704BnYEcUigVfnGeT2q1eyLbwIxwXPYVTMoRtq8t1J9Khun3nDHJoCxXefzNxcnPQVXU7XBGcA8GpHUquQRz1qEnHb8qCjsNMmV4QR1rYRlaPcMZ6Y965DRLj5dhbLV0trIcAgexoRmy7G3OD92knTGNwz6Ug6E47ZpXJMS7s5/pVElSRBgqQPpVR7VGGeCfStE4xgHnFQSEA579aAMufTVfOAODyarTaWoGCOcVvKQfm654wabJGrJ70wOUGmbZQUBxVt7ZkJ45zxxW3BBmQZHToK0JLONowcHigLmBBGyFcjGeelW4EEbhiCWzxWk9sCgBAwOlQG1xINpP0p2FcuecQc9PxqQygEc4470ssYRBkZNRSHBGPSmiT5hZPnf6n+dNIqRvvt67j/ADoArM90ZGMsOpxWvZQmVo0z97gk+lZ0SEtmvT/h94aV/D194hvYnkgicW8CY4LfxH3HagicrI3vAHii+tdJfT0hWS3jfbbr/ezzgH0HX8a9L8F+GmZk1S7ADuS/lYz82ef8RXnuhSwXWqW9taKwMB2jC4y3Vjj26V7pp0tvbaP5hkC+WmADx26UHPGzK2vaikrJYWvDkZlcdETFRpdW+m20TOfKEvCj+6Oxz+tZ0OmO8rThm86Z/OlGfvDsv06VwXjbxC8muLpMyNHcnCgdOvQUht9TsdSS3vryGye8kMTAvuByc+tZHi6yuPCU9vqjXEM9inCxEYPmDkY+vc07w3pp06cSXiSDYhdz1BPoPpXnvxH8WP4k1VY7cbLG2+SKPdnce5PvSYm9DF8R65d65q0t7qEu+WT9B6D2qlZHfKVU5JOapSkggMwDH07Vc0YAXEjHO1Fz70C2R1NouwIhGH71tR3Wy0CLwOCR2Nc1YykzqrECQjJOeDWvaAyKSvbrxQK5K8hDvnjdkYJ4wav6dMzSuvOCnOP5VnmPzHQk5YdKtWY2PKSTnGKB3IL4Bp/m7DovbFP0VgNRtc9plIxUd8MkY5bByfWl0sldRt8kkB16fWgLmhrwxIyjB2yuabp11vUJuPHB45o1xgbwkDJMj4rMs5AswY8MDjOeooGdBf75ICBjdjPHvWZBEXZmPCjjn1q8ZWkTaGxt9Ov6VWTC45z+HT3pgWlyjMwbOTUsahtwOSD1qvbgyKoxyRggGr0C5kGAceg6YoEbWkAiNy3XsAeK1HVBb/M+CTx9azdPYIjjB6Ann0qS6lbyYwQwxyAPT3poZQ1uMq5ZjgsMnH86pfHoZ0H4d8f8uE/H/AbatecNPYOTkFQQuBz+FZPx4P8AxIvh2cZ/0Cf/ANBtqZMvgf8AXU8lAwQMge1DDHH8qMgnNJ6dhSOYWMYyWFLtDMD0HUUoHHI6dKF6HnPegByj0P4VKgU84x7VGBn8OaljXkkdMYoAex59vanIeR2J5pFX1BNC56557UgEwvXnikGRnPGeakIxx0zSbfUdfWgBpHOO9OC5UhvXjinIp2gkc+uakjjJ4Ib15oGJEvuT9alVGYkDPPA4qxBF83oDxVhl2nGM4H0oEQxwhBlhk+uKUZ4AyB607kjBye3WnRr8wJ4HpQIsWgzKuG6+orrdOg3xqBXKQDEg5wBzXcaHgwqeKYmaWn25SQZH3hVm2tytwSO2fxqW3GGT9c1cWPyzMfl6cDvQSY8kbNKxb7ucgDvVSQBWY9QPyrSllA4I+uKwdSn2IwTGB3HegCteTqAcsAfSuV1CUSyle3f1rQuSXJJbj61jXEkayHB3Edc9qRSIZogAGPA9+KqvJnATIHTPc1bcmQDd8y9qqSKAxXpzQMhT7+T0HaknGTlQSppzAkn/ADmgnAAzz9elAxrxZUDHbPPeqbRjJ55IrTkGUGRwB1xVSVeeme9AIZaSeVKrc4/nXW2UoYAA5yK5Bu3H69K3tKlLRjB+XGKQmdEmOMn65p4UspC/XjtVeFsr7VZU45GaokpTo+47Dhvc1mzXLQvibkY4NbjLknPOeuaoXdsHVty5pgipBeoT6etXo5lZBz9RWDLaPCxK5I6/SlimkiUYJ/xoC1zogy7/AG7irKXQbg4B7e9YVvebj8/GatLcKfTnmmSarSbsentUkRyw4796zkmxgAcfWr0Djdj8+9FxGncQgpz+VZsttuK8kDHrWrw4GzpUTx/Nzj/CqQj5RIIkYj+8f51Iig0EfvG9dx/nU0YrM9y5NbxZYKgyzEAD1PavpLT7a48MeEbTTCFYqpd0I9Rkj8zXhHg2O1k8TaWb9tlmlwrzNjoqnOa+idUu9N165jNpctvd8r6ED+lIwm7lXwhoQEst+y/NN27A9/pzV3XzNc6xaWahltrRftFwynq38K112lW8UFuizjAA+8R/WsaaO2jlu7hXb983mMx6cdvpQTYtRXbaZo8moXm3MSedKmfyArAmtbTxm8eoi3ikMOfLlyAwb0JFXfFpt38MJbrMFubghsE/ex2PtUHw/wBJj0qKSY4hjRC8g3fL60B1sct468TyaT4ah0GOYyalLuSaQnJjiz0J9T0ryRgi8DOcYHFXvF2rtrHiLUb5sYklYoFHRc4H6CspWz93PPqKRPmOkck4VfY1p6ThFJUHPKf/AF6x2mWLAYj6elTWOoKhRSn7vPJJwaAeqOitjiWOQnJT+HFbukNuhnA4I+77+tcet7hgxAPJrqPCRS9vAqMDxgjuD/hQI2BGfKVo1GCSSCf1FXVgJt1YYUk55GeKtGyEaZKHdjAI6A9qIywzGC2V4GBQPYy72PagYjGD+earaecX9uMDd5q/zrXuIvM6qSSMFfSks9PA1S0KjP70de9AWKPiBgt4Qfuln5/GsiNyGJ/Cui8SWTtdFo0yck4+prKispcjd8mTyp7UD2LllIoQH5hnqDxmllJZjs5x7UqQ7IyofPfOOntT0BLNyqjoCRQItW8ZC5B3e1XY9yJnq4HOeBiq0LKr7chmA7HFSiUt35PVSPypgathJiQqVzxnPapVzIrMwwQenrVO2YeajHOBxgH9a1WgZfMYjcAeq8fh70wK6Sea5UnEe3061nfH/I0b4f8AGP8AQrgcduLerLlR0OCMnntVb9oEg6N4AIPBsrg5/C3pil8D/rqeQHPU5I7cU9UyME9aaqszZ7AVIqc5J4FI5hG3KQQBjGOv9KVQc5xjj1qRlBxzwaAOeaAHRrgEP9BinqpDAc5HpScjBGcVLEMKxzkGgAYEkg//AKqYBnHcg/nTwozwxOKsJGQOgApARrGTnnp3NOjjY/iOKtLHlAAMj3p/lEcDqD3FAEKIu3C9KekeD07U/aUBXGcnsKlVSOowx9aAEjXauSTzSyAtz2zT9v69adjJ5wAKBEaL/dPXuamRCCMc00n5sgfjUyxtnA7ntQA0Aq24D5811eh3CrGNxArBRCF4GaRbhoZMrQJnoUV0nQGtWWdBas5PGOTXn1vqe4KcgN35roDeB9BV8/xYPvTJsJeXIwQv55rn75xhsnjr1p018i5yd38qzb25DqTuyOtIaKN/cKFI3YA45rFkcsCc9T6VPdylyTjKjsardufrigpFu1PAX+LFOukXHYVXRiADjvT7xswqB1NAEDARsR+PWmlMtnPHfApv3sDIyKe5wARketAx74MA6++KrFTkYwQKnDYjA7Adai2jOck4oAjZexA6enWp7KYwy4PCntSMo4we1QNz0P5UAddZShwvQD6VoICwwCK5XS7s/dY4Paulhl/drkc00QydgcHpn+dMkjz0705W39qfs3r700IoSQ/KRgViXMBikbHIPtXSkYB5z25qneW3mIQnb+dMEYOBzx9aUFtowammiK4Qrz7Cn20JdgDxz+dIYW8sgxtya17KdRtD8k9u1QzWu0BYiufrTbe1kjkBIwoFMk6AXiMuFOMcVC9wCR61nvFIFJFOKPkHBziqQj5xbiRj3yeKni57VAQPMfngE/zqzbrzknjrWZ7Mtjp/B+jXOptevbqNsEWXYnhQeOa9c+HOhPaSqZH80RRhe+Ac5OKy/gxjTfDGs30tuJftLhF3dCo/+ua9D8NostubhF8rcScDkHB60GDd2dLqMhbTDGik7ht6Vz1zYtK8No8rRxTOkO9RzjqR+mKW91a7S8NuskZhCnO9efwqzp9zCJbaGXJZUaXcR0NSBzHjS1J8TWECyiS3RQSnQjn/AAqx4ov9P034f6ld2cjGWZhbBWPRumPyqrq+n6jfeIL+ayQZjXYknXJIwOK8o8dzajp4h0vVnkW4DmVoj0yOAfx9aCdbmBK6784GOwHFU5ro4KxcD1qs7s+NzZJ5pmcn3pmiiPByff3p6naRjmoQwGelPDHHBoGXEnbbsBwDXS+DZZrXUluFckpyfeuXtE3zBeAByc9hXR6fcBGVBgJ1bnr75pGcz1my1SLUYyQMOnOPX3qNgSd3A5xkf1rkdLvmW8hG/G75SOK6bzmaTdyQOhNAvUeznP3sMAce/wD9etPw+RLqkCOM8k59DWPNvbJUY57mt3whbGW+jkZlBCkY7/WgaLus22yVi3fArn5LddrPuGR3/Guj1ySOS5kXzQNvBArk72QcgHIH+eaYNWGSsEjIznrnnioUfnAOz3Pao5JYgArEnP6GmxtFnlWGeh65oFcv2i7n5wFIyK0Ikxjkbfeq+nJG7FiWBA6etXRJGAR0543DigETWsfcELzjNdBFLF5Sq7oxzggH+tche3qBWiE6rn7xHb60lm+0n96vzDkg80Bc0r5o1chnwBk8jtUPx3QPofw9K9PsM/8A6Db1SmMhVw5yMZOOau/G7jw98O/QafN/6Db1RM/gf9dTylFHGARxTwmegBPanbsLnFKMY9TSOa5H2x0we1NPQjqRzTyoOQSM96FX0H/16B3EBORg8DuKlRsKB09aYgGTjOKkiVi5xyDSAkiX5uR71egQsuOcfWoYUwcPzkZFaESDg0xCwx+xP41NsC5WlXGQMYB7VOEXAGQe5GKBFV0IOVAAGCAKjK/OD/F2q+6jgnGRUbLn5yDkc8ikBV6E9fcUL83TpRICG3A5pcZ5X7voKBj0QEZ5AHerFvId3IJHQZqv95cDnHalRtjDAHv9KAL8vEbHOM1RJBGT97tip1uFYEHntioZFUZKdKBDvNWJA3TPrXQafcNN4duBnBVgfwrkN3mSEsfwNdP4bIfT7iHjkGgGjLnJ2cA/QVXwSvzEirDhgCpGCDio9m5Se+OKAMiVcMQeR+pqLPPt9Kt3kW1849zVbAPfPNBQzABOOtLKwZPcdKVVIPAp+3acHABoArlQuMfgaMkHnJ9s1Iylu/Q8cUwgLnPOaAHKeucZPWm9zzwO1OABY4AxjFIevQe9ACZ+UgdaiUDJzgVYAABz6VG3GMdMUBcE4fKnAFblpdAp1JPpWEhBwM7sD6VKJChDKaBM6iGU4HJyKtozFfl5rFsJy6jBz65rbg+71pkMkEW47iD6U9o16LwOnSiJs+/0qUjIB44FMRmT26ljxk1XaJoUztx2zWzsGS2AadLEJIvugAjjNMLmNGAFw5yal3YPXGe3tUzaa6jK9Ov1pjQP02+1AmIhJ5Y8UGRy3JwPSrXkj7OPXpVcRBZCPxpoR87+VmRunU/zq1EuORzikZcO3HGTgY96lU+mDj8qzPWbufQui+Gy3wx0WCJ/KMsXny4GSSckV0fhrSrmw0a1iEnmlY+TnNeJaB4i1SyGYruRrXyAVhY5VSDjj0r6C0G6a502CfaoKxgkZ4BxQZp3ZxVzcXiazMk8RXrjK4zVux8ULY6wLKa3LlkXG0cjgZz7Vo3OsRXmoiMldyEg4XJpJU0WTUohJGU1Hy89OTSA5/wj4iN14rv44zJGpuW+RhwMDrXkvxd1P+1fHuoz7w6RERIR02j0r3HRtN0eK/luFmMcqvJIyk43HHIr5k1+8F3rV/cD7sk7sOO2aCoJtlbdx/hS7sf41CrZ6nFBbPJ6djTNbEwYZ47U5SM4JAJ6mq69Tg05eSKAt0Ny1eJLeTy8b2wCfSp7ZwpGOSeKxYZCsm5R26VbiuFOCyE+nNBk4nX6ZJulj46EfXNdhDMWCB2BOM1weg3MYPmtuGOB3rqYJw7DypVJI78UiNjYRJHmKoykk5yOwruvCMawtLK4GyOPg561wcHKIqdSRnHWu2s5vseg3E3OXYL7YAoGjC1e4ZriVgRl2JODxis2Q+bGN457470+9DEZDHHbHf6VR3NgKQTu79KBNkLwnzMAj24zVi2gcPkjJxz2zTVQqpAD+gwOKlR3JClGBHJz1oEaMCuoYsm0H0qG8m8qJucSdMAZpoM5+8GIzjINUNT81ZE3KxBGelMZV3ksWL5bOKvW8qhWBY7Tzn1NYhkdXOfTOcYz7VYt7k8DYp3Dk96CTbW4ZY2Yk4YdPQ1t/G9g3h34dNzk6fNj/vm2rl0dXGX3DH5ZxXTfG0Z8N/DgE5b+zpsH/gNtTQP4H/XU8vVsnBxigkA8HIpgGOCcjHNPUAkcUHMKoBIbpgc0qk52noKAMcYyTQmMgHOe1ADkBZwAOtXYl2jjB7ZqGGPoc8+pFXbfaOuD/jQBLFFncfvAeoqSM88jIprcjIzmnxjJyCPTmgRaQbsd6nQfMABz/Kqkb4OM5NWo2xgjGR6UAPkUZHI96jY5GPwwKcGDdeh7etMZsFgozxgZpAV5YyW64HtSFcH5TgD0p7nDdxjnrxmo2bA5P0x3oAWMhW5FE2Q3zYGOKj3Hk9/TPang7kJJG3rk0DGgANz0x2pnmbuDyO3tTZmLeyjpTF7etAEjxk7duMV0HhpyqTAHkHIrCDYZR0I9a3PDik3MgAwHXFAmQ3sGLuRe2c5NRmLnpjHArX1WPCRvjBK4PPpWS0gwc8NQCKF8o555ArNIJ7GtK4BYljkelUJlZWwRhTQNDCORg0jDJG38acOD3pG5bOABQMRgOo/CmEEgjcfcEcVMoyDnj04pCOo7UARKBgcU4pnqB680oA5AGKJOnHFAAQPy9KiJycD9Km7EZyfSogBtPGD6GgBkfPAHenkYTtmkCYbIzTnJ446cUAy5p7mNMg/hWxBc7ivOf6Vh2pG3HQip45DFMvXHXNMlnTQZx8uf8KtcbgTxVDTrlZcEE59K022yfMMcU0QPGGwBxmpUXK4OMCqoJVgeCKuKRgH/ACKYmSIvy4P8qYtuCe2D1qSEknaO561ZAUL70xFK4jCqFC8GqM0aGT5vzrWuBlMZxis6YDIJP44poR82TEGU8dSeKEbgVDKcSOc5G4/zoD4Az93+dZHsWO68NabcXQgypSAwnDe+c19AaXsh0qGNW2x+WMtjtivO/h9qVhP8OdPlltkkvrSRrc+y54J/Ou5t7hH0o7cAbCNoOce1DMtmZ8osbPWLOeC5R2eNtw67j9avX0TXWsWd/tKxLCQG6E15u+qlDpzRRMSs8kJOPXp+FbzJ4i1C/sRZl1sVLCQZwoHp9KQrnVaWuj3k93amJZpTvUluSpI5r5b8Qaf/AGfrF5aHOIpCAT6Z4r2vRNJu7bxze3Bmd8MHK9M5GCK89+OWktpPjiVlXbBeRLPGO3ow/OhF09zg84B5/GnZwO9RZycjI/GpF6c1R0Dh19RT1PJqNTilB5ODSFYmjJJwOa07W2Drkge3aqVnEHO5xlR2ro9LgaeWNdmeQTkcUjKb6F6ztgkcahfk74Het+1t34bABxyf8KlgslWOM4DHd1J7+1W1yZfmPbAA5IpGRf0m1PmK25QcjoO9dV4i22mk2lsrH7oLe5J71l+HYd1wgILEkAKODV7xFIZLxY1P3Wx06AUx7GXuY2zhgq7Bk8c4rHknkxlXz75x+VajRs04UlXViQ3zdzVH7NjJGdgbj0//AFUCZXjllfb8+4Z69AafHOQDuAwOBk/z706VPKiJYIwHbHNVfMJmHGVU45HK0CZcS4ZpTuVhx61JqDb7RG/iB6BuarQEmY7gQvX1q6yHyHxls0DMR58njewHJDcioludrcJEa0jZMYVIHIByDWJIjI5yDkHn/GmLQ0VuSd2RkHPAGK7D42Enwx8N2Bx/xLpT/wCOW1cMrP5RPAwv1xXb/GcZ8KfDUA5/4lkvP/ALamhS+F/11PLs856DNTQ42fMcVGAM5zke9SJyQoBIxQcwrHJAFTwxZwQAPrTEXGCcZqygwMn60BcmA4GAMU7O4jHpTEUnFSxrtbBJIz1FAiaPI/LODU2eeTk+vvUCEs3OR6YqUcSZ7+lAEirhgCOexFTDIVeKjGMZPU9MUPwQwJ/+vSAmJHl4703zDkAcH36VFvPBJ5o3fLk8ntQAkjDk5xjtUfUqp79u1GCSTnJPamZ2d8kjH0oAk4AO44FRs+5cgYHoO1R8v169acoyTxnntQMU5C4IAFA4XOKXB55z3zT0Xc3YmgB1tGZH46V0GkkQ3MZ4AB9etZ0KBFGOtWlfYwb3oEbGrpttZ4x/Cd49646aQs2ecCuqurjzfIk/5ZyL5bVy1zEUlZGGCD19RQJDxyoHX8aguIwVzz7Z7VNDjGDgHGaJRuGDx7mgq5nt8xAHFM6nHOc09wA5B7dKaVGfx6YoAdkgqOuKeTxjr9KYcFjgdutL1HYexoAae3r7018gZ659qkIyB645pDjGMdOlAEeMtgY9xTig6kjBNCg8EZoJJA6fSgCDGG6j3x3p7/Ummlfmz05/SpVUHoKAFtmw2AOvWrkiFY9zAewqG1Q79x6DpmpppN3GDx0poQ2GdoWBQkcVsWWob9u7jPBrEQBkYgkfWn27MrgAY9DQJnW+YGIwcn3p4nXHHT2qlYkODnr3qWVNn3QeccVSIZqWsoyOc5q8JVLsCBkdM1zELujHBOFq9NcPhNpwCM5poVjUkcEnPXNUGyZiq88ZOKrNeEk9Se1bOl22I/NkGC/Qe1FxHylKf3jZPAY/zqIvk9ABUU0+Xb03H8OaFlXpk1B7iR6v8Gi2padr2iKokkaITxpnBbnBwfyr2rQdOFvpyxyRle+G9e9fMHgnX5/D/iCG/s2Ak2NEQx4IYV718N/FLa9asbhXM6MQ4Jz+P0oMJK0iCLQZLwXkMBjQxTbsk9Dniu18OvHaWsyPICrNtBPOG6VStbXyNauZ5JNkWVZl/vDvmori0lukuo9LcLDu3IQePXFIlaHB+M/Ed7pPihobeFmZwAzL6HvXmPjN9X1JDdasZpXtpDHuccKp6V7zqngW91LU4rsEsPKwRjvnvXQ6p4HtLrwtf6a0f7+6tiu9jk78fL+tLYcU07nx1GmO3504dcc4qWSKS3kkgnXEsbFHUjGCDg0zoao6E7gQScLzx2p8cZJyeF70pYKgAHI6mpITuYDr3x3pCb0NfSrdZGJcFo1Gdqjkn0rutNSLaD5CBVHAB4/GsHwtarLOuSArAg4P8q9Bj0xUt1MY7ZwKRzy1ZPZi0aNQ8WwnpjnFP8u0SRgSeeMhcGlW3mXY3YY980XEYjmyMjA7CgVje0LyxdPOrKRCu7GOc9BmriJa3szRybRL047nvxWfNEdL02J3YAzYdznnAFUNK1MG5MoUk54DY60FbHQtoltCpYyEkHOAMYrm71IjcOiShSrEgentXQ3mph7XIZVC9T0rzDVrxn1eSSNhjd69aBM6SaItCqEHBzlsYz/jVeOwx85IUY67uAfSsRtTlKbGcgdF+bOPX6VOZZJIm/eMy8cE5xQT6G7Y2MaEFpBg+nStcafFJbFklCnBXtg1zOmyfKM5J5z2PtXRJgWeABjbmmNCSaeqWK5fJJBBFc3rOmBZkkViN+PlxxmurQYtYhwflyQTyaoapbtJbMuHCHlWA6HvQI5j+z2WNsOOVyBjvXY/GaPb4X+G6NjK6bKOv+xbVxk4niBcbgmDg5rs/jJlvC/w2J4J02XP/fFtTJl8D/rqeWk4ycZAqWJcHcDg+gpig79ucfyqyACpAHAoOYB8xDcCplGVAOD3pkYyDxgVIFy4z90cUATryoycZNOC4PvSJ8vXNSH5mB9+3pQA5OuQBxUygls5pseCR6HOKkxkZA6mgBSSrYzwaGPAz+PvTWyuT0x0FN+bbgkf4UgFPX6DjFKOVGc4FMPA60xmGMDgCgY5pBn5f50x1JB6HvTcAqDRnDL6H3oAE68jk96cxIHHAPel+9179MUMDgg80AIh5HUA1ftIwSSRjvVa3USSEY468dxWlEhQnGQDQIkHypn1qvdSYG38AfSpZHKq1UHJLkk8dqANjSC1xYTQEnep3D3qnq0WNk2Dhxg+xFWdA3rfQ4z8x28H1rptc8OSrZTSJk7G3bfSgXU4Fc5OAeakc/Lx1PWp7i3MZDA8dxVZhyB0GPyoHcpOMt06etMAOSCADUzKA5yKZ/Hgd6BkYOSVx170/BwOmPSnYG75R0704Y6HsOaAI1GCeMHp1pXXJyOMU4DAwPSg4AHrQBGeM5Ipo9Oo96kAJ4xgfypwTPpnuR2oEVipJIwKswD5dx6UpjBXPp696WJSc4JH40AOQEO3uaJwAAByfYU+Pgcckdj1psp5PPPemIhjkBVhnipoiSeBj8KjUcn8/pT4wQy4yOaANqyOPoRmtNiZI1HOcdqxrc/Oozx61t2ZDLgn7tNEsqMojZg3HrU1u3mQFX52nOahvAfOAzyaltUYusaAndx71WxJY0qyNzcl9p2L1+ldQ67cAAAAYFTafYraWSJgbiOTUV0cNRHuI+KZGxI3bk/zoDe+aZKcyOf9o/zpAcd+ak90sRyFcFeo5FfVPwQ0PTJfCtjq9k0vm3iH7QGOQJFOCPp/jXygD0xX0L+y54gU2+q+H5pSrxuL23yex+VwPxwaCJq6Pb7vRTcSK6EA7SjZ9DUvh3SBp2UeXfk8ccCtZAGA5OPamyP5c6DB2kVBnYvBRtwMYx0FUrtccgnPWriEMvaoZxwQDyPSgZ8a/GnSzpfxG1YCIxxXLC4j9CGHJ/OuDLD1x9a+g/2mtKQ6bp2qrCDLFJ5Dyg8hTyAfxr51LYPynmqRcHdWLTNkenvTo2ww96jjyyBiPpU0YC8yd+wNBTOr8N3LpIMkgeuelesaJqSz6fwQdo5/GvCYLllIIJB7V23hPWWWZImO3d8vXqfepsc0k07npouk/jJCZ7c4qawjF5qCI2SgBJzwK4w34QqTuZicH/8AVWvc3Ulrp6SR5EtwoXGeQOtBNyHx14h865lRGIgiPlx47+prFsdayiLIdp4wwX+dYGrT+ZKATk5x/jUEM+CCSdvUHNAXb1Opnu5jvjDkL15J5rJuZNpG4DkHjvVA3u5AgOe+Rzim+YXk3kkkDkdc0xbl2STPoB6561NFdtHKCobZnkVnyOTk9QMHgflUsMhxhjxjv0FIR1ulXIwO6MevXB9K6ieRFsghC4fav65rzzRJz9oZFyVPUE9/au0M6vawRqcguBnqeKZSZuIq7hgbRjOa0VkjngMCgccjFZN1IYlYowDYAA9faltZ8TCRjkL1FAGfq1okJZFX5QDjHQCr/wAacL4a+HAUZA06YD/vm2pdWQXWmSi3++qF0+o7Uz4wE/8ACK/DXIwx0yXj32W1UKXwM80RABk4+pqXkDbwM01VxyOTTwvDHPWg5SZAoXinYAwRz3powOh5xxUiEMwGKQEq9R3NSjAG3GKjVWIz0FSRkc4//XQBMEGzI65p5bAA6Gmrkqe2KTJzj+VAgbBBL8e1R7lwR+NSy9B2xzxVaRwcLyFpDFZxkYzz14puQc/yppJ/hHbmkUAYxQMfhR369jSZOOe5/KmkEk8k8cU5cjjGCP1oAVTz04B61Lk888GoSc44+opwPIzzxQBcswGJznb2FaA+ZMEmqNqNoUggnHJq0ThQOcmgRDcuAAoPJFS6da/aJMdRntVFm3OeSeelbnh8FmYjGe9AFpolswrIfnU5BHUGuwh8RQXmlN8uZdmHUd/euT1FMryOnvWdY3ItbwFvutw2PSmIj1IFZZEGNp+YfSsxgApz19BXR6xbq0Qde3f2rAlG0t2/rSBFJzlmIzz+lRKNuQSKmYcnJwc9qaqjqAAe/tQUNHC4yB70YPp1p5XjGOO1PVMGgCBUY8jkVIqH+IZPapQBjjpSjG3rn0oEMZeecA46CkI4oIxzjnpg1JwACvOaAIwm4YC4HrTThcbehFTnrjPUcVGVwctj60xXEZgFyvXFRFi3HTn0qwVDJ1wDxioDhMjJJBoASPOTkZ9zVhF5B46ZqJMgjOMHmrEWMHI+ooBly1U5APPvmte2byXXfzkVkxEIFHQ1pbi0SH+4cGmQye9g3TbwPlFdB4Z0sjbdSjgDCg1DpVgbydEPKE7jiuxSFY4wiDCgcU9xFaf7tY904Vxmti5OAc1zmqSESALWiEfGDt+8b03H+dGcjjFNk++/+8f50KfWsj3SQH/9Vb/gfVW0fxXpd+svkiKZQ79th4bPtiueHGetSDoc+lAPVWP0D0i5W4soZUcMpUYI7ir7IkpXd0zmvPvgxffa/AekO0okYQBSfccV6AvTAx9c1L3MUyZMqSAeD09qJBkcmoxgPuOOeopznAPTPakByvjXSbHVtCvbLUo0kt5ImB3diAcMPcGviC5VIp5EBLbGKgnvg9a+3vHE0UOh3088myKKF2YnsNpr4YuZRJOzjkFiw/Omhw3LxuQY0RcDFQiY7iTz9aq7vxpysPcGnY1NGGYDGWxWpp9z5Mm7djoetYAkCjrzU1s7yOP7vekTKN0enaZdpJKlxKCYmw7ZPDe1GveJGnx5eNqnaK5S41NP7NitoTgrwT6VXuJS0aE5Ht60jnUWQ3epzGdm38GmpqUmVORx6VSuVy2cVWGVambqKaN5dSJYkcH0q9b6gSOTkjPauUMnerVvcFVUN34NAnT7HX/bEMI688A1YhkVgNjNz2NczDNuQHn1x3rV04OQr5JPOaRg00dNpEOyZn/hB4OfzrpbTLToNwURkE81iaQciNWQZB7jt6Vs2/7kEv8AxH5Rjn8aCbs2tQlEaJuIKn5hk/yrOl1FWyoIBwOBx07VQ1m+JSIbsZGMDtWTDK5lUdedxqhNs7Cx1Ly4ZpM5UAke/tW58aCr+HPh4QOG0+YgD/dt64aSVksZSAeh29jiuy+Lx3eEfhq3XOmSf+gW1CCXwP8ArqecRLkAKefzqZAAh5H0qFD83XA/nUwGQB60zmY9V2npn0xUqKRjjjvQAMDAGe1SIRtGR70CJFAIPI/GpYYwSASOTwTwBTMDfnFOUhc+nc5pAOIwCCR/hSgZwVGM/jQDu6cEU/ISMkjHHWgCG5b5VVT9arqoA5bNOAIzuPJ7mmkckjvSGIwyc/iMdqNv3R0HWnYycZqSRflAA9uTQMiyOSO9NZtpUckDk0uMnJ9PWlKnj8s0AOjwScdx1pwHdcN75pVXCYIPtSqvAJ9aAL+nxsVG4cH1q5Km1WOO2KLNcIvJOamu8+USBmgRisBuIHrW1oTLkgkk9axCrAkj1q/pkmycAnaaAZ00yLIvXn2rEu7bbk88c1rxsduckg1DKobtu9aBDdLmF3bGGRvmQYGe4rC1CBoZJEOSe3tV5SbS8WVemeRWjrtstzapdoOAMNQBx65J9PakRST079auNGqE55HvUbD5gAMAetAxNoB45H160jjjrxTzjB2nPH50mw8DnP8AKgBgX5cdRnn3oCkgtxk1OYjgFiB6CmbexxjnApgREDjrup4UbjuwT+gpwT5fl7cj2pVUgeuaQEbDGDwPQ4qJskDgn3q35ZyOwBppjAJBJB7YFMQxFJUgnkc1BIhJ47dR6VaUcFRyBTJImxlcg9OaAKq9T61aiXI3e3rUDGNCdze2BT0uE42g5piJzLjA6jsK29Kie6KRqCWcj3rnVLyOAmAa9R8D6M1tbLdXQ/euPlHoKT7ITN7S7MWdvtx8x6mrTcCpSuOaguGCqSatKxJQvn2oa52YEyFmxzWpPP50jDoo71k3syiTA6+1WI+Mpf8AWP8A7x/nTQeaWQ/vH/3j/OmZrI90mQ96cD9aiViPSlD0AfR37M2v7rC60iR8tbv5kfP8Ldf1/nX0MjZQcivg3wN4hm8O+JbK+ikKxrIFmGeGQnnNfcWlXa3dpFNGwKugYY7gjNDXUxkrMtGYhyB69PSiS7RWCSNtdhkDvWH4rM6WglgkKKnJxwSK4y/vdQOuadNHOJ7YgbmJ6H0NSS5WNjx1eR3lhc6eUDpPG0bHPqMV8Y39u9lez20md8LlD+Br7G8VW0NjLHcsSYZiFb0B9RXzp8XvDzWfiT7XbYaC7Gcj+8Ov50bDhL3tTzzdTg1PkgaJ9sgwajJVTwOlUbksY3uN3/66tiURqAmN38qzvN4xU0ThyFJ9qQGhbq0sbhfuhhk+9aly2Iou4C7cU3ToFFi4Kj5jkk+1QXsuWGTj2FIzfvOyIiw5BHUdM02GBZJFU/KTz64qr52D17Vf0tfNmY5B2jNBT0RBJZkNw4I65pqxhSATzVu6dRwGBY9cetUt/I5/HtQEW3uWonx0PT+frW1p1w3yBB6ZGf1rn4nBBBPA9K0dNf5upHehkTSaO80ufbtdSTnoPetKS/8APAKk5AwB6YrltPuwhbg1IZmMm6OQjjNBzs1b6cNAkigfKcc80WCkz/I2WIBOR0GOlR2DNcxmOQAEnOV7/hWrBaiBHlYhViGTjtRuINQmijRImJVthzz39K734u8+E/hqVGP+JZLgenyW1eQ6hqLTM7hMbcgsO/vXrnxTIPgn4ZNnH/Eqcj/v3bUwb9x/11POEXJ44NW4xxg/e9fSoI8Ngt07Yq1GMLnPPpTOYdGgPA696sKu446fTrUSkgg4z6VKMq3HJ70ASSKc8Hg9/Sm4PP6A0ueMkk46U9T2XmkIWNDjlcjqc9qjlk3cJwAe461NO+2PYKrA9d2MjofSgYzdn7o6c804L0Y5pOAPm704EAcDpQAgGeQAfapQuQcjkc4pin5j0xUkffAyaQFcg4HbtTwCxPA/Ct/T9HaVA7jrWqNCUqBhTx2oC5xoGOv69qVI97jbnmtu+0ho5CUXjFU4LN42+YGgCe13BAMfiasNIGQ57enSkIK4AHbiql1LgqinnrmgCGSEclQefSmrlCCc5HcUqygcf5NSgB8npQBq2VyGiwcg96ubSwOKxrH5JBv4Xpg966CEhkBBAHSgRSnt8r03YqfSJg260m5jYECrfknjjg85qhfQvE6ug56g+lAjJ1S0a3uXjbqDxWYd3GMDsa6++T+0dME4H7+IYcDqa5iRQjHA/OmNEYTbg8fWn8D7o60wHcckdqeOcEg0APIAzuOaMKBnGCeOetG7Ayef6UH0H60AMHXp+NBAxkDmnOQCMYNQ5A5xzQBOrAjntxTGIAB9Peot5B5P+JqCaXHOeeuKALKui8sefQCq13dfJ8gwKiR2ZiT0pswJXkHnPSmBU3Fj3qaLrz3qJB29q3PDOjzareKiKSmfmPak3YDd8DaA2oXRupVIhj6e9erRLtUKAAAMYqvpVlFY2cdvAoVVHXHWruAKcV1ZG41+Aay7+XJ2r34qxf3Kwqc1SB+XzG6npWgmZt4ogiO0c4rm3lYuXkHJrob1/Nf2/nWBqTDeAvWmuwkfIEn+sf8A3jTfqaWT/WN/vGm1ke6OFLnBpop3SgBwP4ivpz9nzxtcatZnR7vBls0UI4/iXtn3r5hFd18IfEq+GfF0FzMSLaUeTN7A9/wpoiauj7Puo1urd43GVYYxXn+raXeXFxGljAyMpILYwoFd1ZXUc9vG6NlXG7OeoqldXfk3Tbu/SosYtXKP9gyXmhra6o/mn7wx29KxfFnhayv9JEMkYDIMhu4NdpBdGRcbT7EisPxHdR2ltI8zgJg9T7UWE0rHyP8AEy1t7HxALa1ILJGDJjsa48nJrR1+9k1DWr67nzvlmY/QZ4rOPWqR0QVopCU5OtNxSg4PFBR0VlcYsVDN1PNVbiYOc5+tVIJj5e0HimtJj6560hJWdyYEdW6CrUNx5FvNhsMeBis3eSw4/CpLo4CL04yfqaB2uDzZbOaQTcjqfbNV8HPpTgOevFAGjDPkYA57GtGznCISxG09awUfHQirSTYA5JosJq509tMpYkSDB689quCYRknccAZ46CuRS52tnn8KstqJIABzxg5oMZUnfQ6y21fyZcoQe34VYuNZnaN1k+6QOQea5GKZAQ2fpWpBMkigKQSTkigiULE810BHIAg3dcjvXuvxOYv4J+FzAddJc4/7Z21eCsoCMSAw5yAa+gfiDB5/gb4ZEAjbpDcf9s7ahET0g/66nnSryGPAzWjDbjy97SIDjgZpFt0WNi8Zc9BzjHvUZVjjsMUzjuKH9sVIePqKYkbKRkY71PsLHjge9A7iLz0IAqQt5a5646UFQOCMt+hqCdtxx0X+dIBJCZDk5pFOwHHP9KME4AzQFHHp796AHbCTn+VKuDnaPwqdNijHHvTlMZ9AeooC5XA2scCrlgoadDIOBURj3MDnJ75rQtYQpBJ6UAdTaMqxqFNXop0Y8n8q52GYxocNz70jX23AJ5pknRTJE4ZuCKxrqFSTxnPpVKTVSgxk46U9bwSICpyT2pWGULuQQ71JIPYCscv5jtg9Ox5rU1BPPbjP9KzVAGcnp1pDuMKjPzNj6VahfaMYxUGMEnAA9KQdDyaAuaQcEghs8/StzSJVkwONw61yaNliCQD61f028aGdcYHamDO48k7Rv6dqqXMW5CMDPvT7S785B3yPXvVzClRnOaCTCtJGsbj5hmNuGGe1UdetPs0xeNd0Ug3K3atrUbbcrEDHeqcLLeWr2Uv+tHMZPf2oGcnJkvnPT8qcJUCjqSKW9RopHSThhxj1qs5ORgjIoGTiTcxzwO1Jv4wOag3ADJI4/SmNOcfLQBPI2BuJA46VE8ozhTnNVy5Y5bJB9O1NJwSOc0ASNNwPpUTPnHOAOOKj5IIUd+hoBPAzQBJGckDtUkhBGOoqJPlBJ/MU+BGmmEa5LE4H1pgO06ylvbtLeFSzE44Nez+GtEGjWiIoHmP944rP8D+HY9MtxcTjdcScj/Zrs1TP3hSSvqS3cVB8ozTJGwtLK4UcVTdyzbTxxWgmyvcIJnDN90Vk6lcPEwCZbd2Hate4dUjIU9KzHi3kysOe1MgoTSBITnG7vWFcZMmT1NaV+T5pbGFHb3rDu7kNJgHkelNDR8mSf6xvqabTpP8AWN/vGm1ke6KKfimDrxT6ADv1qWBtrg1HQDg0AfW3wc1/+1/B9tHJJuuLUeS2euB0ruodglIZQ+em7t618nfDLxNNoephkfEcowyk8GvpDwpry6vF5gwrAciho5pKzsdg04CgADgVwPxQgNxovmqxDRHO31rQ8V+MNJ8PRj+0bkqzfdQclvpXzr4/+Kmp+I45bK0j+w2O7naxLuPc9qVgSctEcP4iWNNYuPJIKM24Y561mUrEknJz9aSmdKVkA9DTgKbinrnFADxx3ANKcY9aj9jRk0ATJ16ZpZn3tnA44pqdz/WjtgDmgBgPPFOGOuBSDNITQA4HmpQwC4x29agyaMnHI4pDJGfj5eKlt+TUA5NTRfLg0AWC2PXHWpo5yhypIqE8jAzQnYYoEbtpcRvFiZsYzX0N4tu2k+Hvw1Yf9Ax1G7jotuK+YjkcgdOa+l/HuIfh38K1JwW0hmJ9zHbE/wA6Ec1eKUH/AF1OfguVcESkDHrVa5l8iQ5A29TWenzE/Nxjp6VWvUvCrGIeavoTg03ZHBY11ugx4bBIqdZ4xw7biO1cFJqNzFIUKvH2O4f1q7Y3kj4Mkg6dqejG42OuafccN8p68UxnwTySKyoZSQME/WrqSFgGwKQizncAB9aRmI6mmo2eQeKVjubHb8qAHKfl46etIrnBPJP86Q7VBxyP5Ume+OaQF22fkA4Oex7VrwqSBjmsSzU7xx9a6fT4fMA9KBAsJePqPeqskDg5GcHgV0cVsMZx9ahmtx6dKAucvPbFh04BpkBMcu05x3NbU1vkkAEjPJxWXdx+WmFI9STQMtkBgcAZxisu7g2EYHfnipbO4BBGQCKllbzd3cfSgDLPDYpjgk9MVOwYuQF6VMlqSp3Hr7UgKSt0HapY2CnryOamNoFzyT9artGVByOB04oA6HQ7/wCbyWIOOgxXTxyArzuJPvXnUF0LeVH6nvxXZafdCaNWB68iqEy/OWIwMYPFYt3FJFIJkbaRyMDvWwxBGSM1WulVgd3TFBJk61afbLZLyIHzAP3gFcrIpQ5rrYpja3RVxmB+GFY+u2H2WcmMExPyppFJmMSWzkAVEM9SST6GpXXaPp1pFHHHAJzQMYCRjr70EA49ccU8ISTyBTGBIGDkigBqencUMeQw4oAIbnrSlAcnj3FAxc8DHQ8dK9A8E+FSIE1G6U5PKg/zqh4K8LvqEqXN0CLccgEda9aghWOJY0ACqMAUkuYlu+iCGIbFyOlSuwUdaUkIvPAqmX3uWIxjpWiE3YSST58+nFRMWY5YYHb1pSQGLevOKqTu0rBI8+5qjMinfzJdv8C9TVN5TIzKPuDgVanYQx7QpJPpVIsoU8gGgDP1EDymA5OK4LWr9NNkHmHc7H8hXYa7eR2NvJNM46cCvFddu5L7UXld/lOcD0rWKSXMxxV3Y8kl/wBY/wDvGmU6X/WP9TTa5j3RR1p9MFPFAC9qD1zzSCloAdHK0bAoSCK9U+HXxMtNGt/smtQyxoPuz267uPRgT/KvJ+1ANMUoqW57B47+KGi6xatb6foz3MnIFxeYAHuAOa8gkYuxZvvE5NJn9KQ+tIUYqOwlHWloFBQUuKO9OUZagBQMr+lJt5qxbw73xnrV02SnoefekBSRCYxjrnnFI8eGGfrVqMeXIvA44PvU0sKvcLjpQBnSoEbGRxTcAjmlnPJ9jTU560wEIxQBn3p+zjdnikCZ7+9AAi5NTuAFGM5pI4cnJNWHiUJwT1pBcav+rXIPPtSllHQfWrEUWbYk/wALCh7ddob1oFciZwFYj0r6V+J7AfD/AOFHJA/sZv8A0Xa180OB5RAGOO1fS3xNjz8PfhOB20Zv/RVtQtzHEfA/66nBRvtbjqe9WHnyAisOOtZsjNECOCx70tvvyNxB5z1qzz7M0AkUq/vo1b3FMitLXkqFHpx0p6o23jHHWnGJiMjHHvU2Qajo4kDYwuBUoZQT9KgjU5zx0p5QnB9/WgCUSdiKUtg8VGqOOm2nmM8Y/nQA5W+YA8nPSpAc9DwPWq6q27jHWrdrGw7jk+tAF2yG0+p9a6LTp1iOxgoIrm03Zx2HTmrsLurDpTFY7CCfPHPTtVjaWUYAX3PaufsZn2qWOe1bkczFAOlFhWK9xFtXhuPXpXN6vHhDxxmuiupSFb1Heuc1Fy7Yx+tKw0YocwTBh61pRzblPrWfcRn16U2IyR4II5oHY1o4xnOPrVglVXJPA6isc3MikA4Ofeo5LqWXKkjHpRYLGmknnPhOQelT/ZgAQe9VdIQ+XuGODgVsLD8m44yaBMxrnT13DA5PpU+mztZyCORsjpV94tq544FYuoIxjLAihINzqPtgZBghjTHmZyDnrXO6PM7xFWPIOK3kXlecHg0xbDbqItk4pbVVvbVrOfG8ZMbH+VW3jLKASPrVC6iaLbIhAKmkBzd9btBM0bghhwKqZIB9R3JrrtZtlvrBbtcLIBhveuUkhIU9Pr3oGQkjHJ4PakJyBgcH9ad5ZwCcUpQk44zQMYFJbnnsK6bwd4ck1a7DOCLdD8xIqr4b0Y6pqSQs6quea9q0zT4tPtUgt1ChRyfWp3dhEOmWQs4/JT/VDoK0cbR1pwTAzxVK9lcMI04z3rRIWwkrmWTCn5R+tMkYKOSKmRAkQ4rOvywUsO1UtSGQTTMW2ocse1Twjy4/m+9Va0hIzMxyTUiOZjkcAdjS3FYbN82S1c3qchjlDO22JTnPrXRzpuOO1eX+P9Xlaf7JDlY04JJ61pCN7hY5zxlrbajOyof3SHAx3riW3STkj071qTo7KBkZPfNQNbNB/dJNEpczNYqx/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cholangiographic picture of cytologic brushing of a distal bile duct stricture secondary to pancreatic cancer (A). Cholangiographic picture of cytologic brushing of a proximal common hepatic duct stricture secondary to metastatic breast cancer (B).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Isaac Raijman, MD and Susana Escalante-Glorsky, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_1_17425=[""].join("\n");
var outline_f17_1_17425=null;
var title_f17_1_17426="Chair dip exercise";
var content_f17_1_17426=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F72489&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F72489&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Strength exercise: Chair dip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 374px; height: 306px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This pushing motion will strengthen your arm muscles even if you are not able to lift yourself up off the chair.",
"    <ol>",
"     <li>",
"      Sit in a sturdy chair with armrests with your feet flat on the floor, shoulder-width apart.",
"     </li>",
"     <li>",
"      Lean slightly forward; keep your back and shoulders straight.",
"     </li>",
"     <li>",
"      Grasp arms of chair with your hands next to you. Breathe in slowly.",
"     </li>",
"     <li>",
"      Breathe out and use your arms to push your body slowly off the chair.",
"     </li>",
"     <li>",
"      Hold position for one second.",
"     </li>",
"     <li>",
"      Breathe in as you slowly lower yourself back down.",
"     </li>",
"     <li>",
"      Repeat 10 to 15 times.",
"     </li>",
"     <li>",
"      Rest; then repeat 10 to 15 more times.",
"     </li>",
"    </ol>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Go4Life. National Institute on Aging at the National Institutes of Health. Available at: file://go4life.niapublications.org (Accessed December 2, 2011).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_1_17426=[""].join("\n");
var outline_f17_1_17426=null;
var title_f17_1_17427="Ammonium chloride: Pediatric drug information";
var content_f17_1_17427=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ammonium chloride: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?24/52/25411?source=see_link\">",
"    see \"Ammonium chloride: Drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1056498\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Metabolic Alkalosis Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Urinary Acidifying Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1056492\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/52/25411?source=see_link\">",
"      see \"Ammonium chloride: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Metabolic alkalosis:",
"     </b>",
"     I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     Ammonium chloride is an alternative treatment and should be used only after sodium and potassium chloride supplementation has been optimized. The following equations represent different methods of chloride or alkalosis correction utilizing either the serum Cl",
"     <sup>",
"      -",
"     </sup>",
"     , the serum HCO",
"     <sub>",
"      3",
"     </sub>",
"     <sup>",
"      -",
"     </sup>",
"     , or the base excess. These equations will yield different requirements of ammonium chloride. Initially, administer",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     to",
"     <sup>",
"      2",
"     </sup>",
"     /",
"     <sub>",
"      3",
"     </sub>",
"     of the calculated dose, and then re-evaluate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Dosing of mEq NH",
"      <sub>",
"       4",
"      </sub>",
"      Cl via the chloride-deficit method (hypochloremia):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     mEq NH",
"     <sub>",
"      4",
"     </sub>",
"     Cl = 0.2 L/kg x wt in kg x [103 - serum Cl",
"     <sup>",
"      -",
"     </sup>",
"     ] mEq/L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Dosing of mEq NH",
"      <sub>",
"       4",
"      </sub>",
"      Cl via the bicarbonate-excess method (refractory hypochloremic metabolic alkalosis):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     mEq NH",
"     <sub>",
"      4",
"     </sub>",
"     Cl = 0.5 L/kg x wt in kg x [serum HCO",
"     <sub>",
"      3",
"     </sub>",
"     <sup>",
"      -",
"     </sup>",
"     - 24] mEq/L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Dosing of mEq NH",
"      <sup>",
"       4",
"      </sup>",
"      Cl via the base excess method:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     mEq NH",
"     <sub>",
"      4",
"     </sub>",
"     Cl = 0.3 L/kg x wt in kg x base excess (mEq/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Urinary acidification:",
"     </b>",
"     I.V.: 75 mg/kg/day in 4 divided doses; maximum daily dose: 6 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"     <b>",
"      Metabolic alkalosis:",
"     </b>",
"     The following equations represent different methods of correction utilizing either the serum HCO",
"     <sub>",
"      3",
"     </sub>",
"     <sup>",
"      -",
"     </sup>",
"     , the serum chloride, or the base excess; administer 50% of dose over 12 hours, then re-evaluate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Dosing of mEq NH",
"      <sub>",
"       4",
"      </sub>",
"      Cl via the chloride-deficit method (hypochloremia):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Dose of mEq NH",
"     <sub>",
"      4",
"     </sub>",
"     Cl = [0.2 L/kg x body weight (kg)] x [103 - observed serum chloride;",
"     <b>",
"      Note:",
"     </b>",
"     0.2 L/kg is the estimated chloride volume of distribution and 103 is the average normal serum chloride concentration (mEq/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Dosing of mEq NH",
"      <sub>",
"       4",
"      </sub>",
"      Cl via the bicarbonate-excess method (refractory hypochloremic metabolic alkalosis):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Dose of NH",
"     <sub>",
"      4",
"     </sub>",
"     Cl = [0.5 L/kg x body weight (kg)] x (observed serum HCO",
"     <sub>",
"      3",
"     </sub>",
"     <sup>",
"      -",
"     </sup>",
"     - 24);",
"     <b>",
"      Note:",
"     </b>",
"     0.5 L/kg is the estimated bicarbonate volume of distribution and 24 is the average normal serum bicarbonate concentration (mEq/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     These equations will yield different requirements of ammonium chloride.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F134205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, solution: Ammonium 5 mEq/mL and chloride 5 mEq/mL (20 mL) [equivalent to ammonium chloride 267.5 mg/mL]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F134192\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1056501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: Dilute to 0.2 mEq/mL and infuse I.V. over 3 hours; maximum concentration: 0.4 mEq/mL; maximum rate of infusion: 1 mEq/kg/hour",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F134234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in dextran 6% in D",
"     <sub>",
"      5",
"     </sub>",
"     W, dextran 6% in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Variable (consult detailed reference):",
"     </b>",
"     Warfarin.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F16156523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store intact vials at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1056500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Diuretic or systemic and urinary acidifying agent; treatment of hypochloremia",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F134233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Coma, drowsiness, EEG abnormalities, headache, mental confusion, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Calcium-deficient tetany, hyperchloremia, hypokalemia, metabolic acidosis, potassium may be decreased, sodium may be decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, gastric irritation, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Ammonia may be increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Pain at site of injection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Twitching",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Hyperventilation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1056504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ammonium chloride or any component; severe hepatic and renal dysfunction; patients with primary respiratory acidosis",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F16337159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with primary respiratory acidosis or pulmonary insufficiency.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F16337158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor closely for signs and symptoms of ammonia toxicity, including diaphoresis, altered breathing, bradycardia, arrhythmias, retching, twitching, and coma.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6217901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Ammonium Chloride may decrease the serum concentration of Amphetamines. This effect is likely due to an enhanced excretion of amphetamines in the urine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): Ammonium Chloride may increase the excretion of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: May enhance the adverse/toxic effect of Ammonium Chloride. Specifically the risk of systemic acidosis.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Ammonium Chloride may increase the serum concentration of Salicylates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F134202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F134212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1056497\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum electrolytes, serum ammonia",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1056491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Its dissociation to ammonium and chloride ions increases acidity by increasing free hydrogen ion concentration which combines with bicarbonate ion to form CO",
"     <sub>",
"      2",
"     </sub>",
"     and water; the net result is the replacement of bicarbonate ions by chloride ions",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1056503\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: In urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12619 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-41.196.66.12-562CF1C545-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_1_17427=[""].join("\n");
var outline_f17_1_17427=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056498\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056492\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134205\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134192\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056501\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134234\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16156523\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056500\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134233\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056504\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16337159\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16337158\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298740\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6217901\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134202\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134212\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056497\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056491\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056503\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12619\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12619|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/52/25411?source=related_link\">",
"      Ammonium chloride: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_1_17428="Scale evaluate newborn suck";
var content_f17_1_17428=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76540&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76540&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Grading scale for neonatal sucking maturation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 586px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This scale is comprised of five stages based on the presence/absence of suction, the rhythmicity of suction, and expression components during nutritive sucking from a bottle in infants. Each of the above stages includes a clinical description and sample tracings with corresponding range of amplitudes.",
"    <div class=\"footnotes\">",
"     P.T.: pressure transducer; PE: polyethylene tubing; ID: internal diameter; gray outline: glove outline.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Lau, C, Kusnierczyk, I. Quantitative evaluation of infant's nonnutritive and nutritive sucking. Dysphagia 2001; 16:58. Copyright &copy; 2001 Springer.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_1_17428=[""].join("\n");
var outline_f17_1_17428=null;
var title_f17_1_17429="Telithromycin: Patient drug information";
var content_f17_1_17429=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Telithromycin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/16/41224?source=see_link\">",
"     see \"Telithromycin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F225055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ketek&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F225056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ketek&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10028491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700299",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take if you have myasthenia gravis. Very bad effects may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat bacterial infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028492\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702990",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to telithromycin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703884",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you turned yellow or had liver side effects with azithromycin, clarithromycin, erythromycin, or telithromycin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703791",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have myasthenia gravis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028497\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2858939",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid driving and doing other tasks or actions that call for you to be alert until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028498\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698007",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea). Yogurt or probiotics may help. You may get these products at health food stores or in some pharmacies.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698380",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling more or less hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, vaginal yeast infection. Report itching or discharge.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10028500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028495\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow tablet whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10028496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10028501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028502\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11430 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.97.94.19-18180375D9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_1_17429=[""].join("\n");
var outline_f17_1_17429=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225055\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225056\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028491\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028493\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028492\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028497\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028498\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028500\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028495\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028496\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028501\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028502\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/16/41224?source=related_link\">",
"      Telithromycin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_1_17430="Wound repigmentation";
var content_f17_1_17430=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F77112&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F77112&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Wound repigmentation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 403px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Repigmentation of healed wounds occurs as melanocytes migrate from the epidermal appendages across the wound bed. Skin color in a healed wound is difficult to predict. Exposure to ultraviolet radiation can permanently increase the pigmentation. Bleaching agents are discouraged because of the risk of further tissue damage.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Mulholland MW, Maier RV. Greenfield's Surgery: Scientific Principles And Practice, Fourth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_1_17430=[""].join("\n");
var outline_f17_1_17430=null;
var title_f17_1_17431="Endometritis unrelated to pregnancy";
var content_f17_1_17431=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Endometritis unrelated to pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/1/17431/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/1/17431/contributors\">",
"     Katherine T Chen, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/1/17431/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/1/17431/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/1/17431/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/1/17431/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/1/17431/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endometritis refers to inflammation of the endometrium, the inner lining of the uterus. Pathologists have traditionally classified endometritis as either acute or chronic. Acute endometritis is characterized by the presence of microabscesses or neutrophils within the endometrial glands, while chronic endometritis is distinguished by variable numbers of plasma cells within the endometrial stroma [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17431/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the absence of a tissue sample, other factors can help distinguish between acute and chronic endometrial inflammation. Symptoms alone are not useful since the clinical manifestations of both disorders are similar (abnormal vaginal bleeding and pelvic pain). An exception is fever: patients with acute endometritis frequently have fever, while it is less common in women with the chronic process. Reviewing the clinical scenario is also helpful for determining whether endometritis is acute or chronic (",
"    <a class=\"graphic graphic_table graphicRef61306 \" href=\"UTD.htm?42/53/43867\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute endometritis in the nonobstetric population is usually preceded by pelvic inflammatory disease (PID) either secondary to a sexually transmitted infection or an invasive gynecologic procedure.",
"     </li>",
"     <li>",
"      Chronic endometritis in the nonobstetric population can be due to a number of processes, including infections (eg, chlamydia, tuberculosis, other organisms related to cervicitis and PID), intrauterine foreign bodies or growths (eg, intrauterine contraception, submucous leiomyoma, polyp), and radiation therapy. No etiology is identifiable in approximately one-third of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?17/1/17431/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Endometritis unrelated to pregnancy will be discussed here. Endometritis in postpartum women is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39097?source=see_link\">",
"     \"Postpartum endometritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ACUTE ENDOMETRITIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pelvic inflammatory disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;PID affects the upper genital tract. Chlamydial infections tend to primarily involve the endosalpingeal cells that line the fallopian tubes, while gonococcal infections tend to be transluminal. Most PID results from ascending migration of pathologic lower genital tract flora to the upper genital tract. Infection may be confined to the tubes (salpingitis) or may involve the ovaries (salpingo-oophoritis)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    uterine cavity (endometritis). In general, the endometrium and ovaries are less susceptible to infection than the fallopian tube. However, either the endometrium (endometritis) or ovary (oophoritis) may occasionally be the sole focus of infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Epidemiology and pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concomitant endometritis occurs in 70 to 90 percent of laparoscopically documented cases of salpingitis. There is no correlation between the degree of tubal damage and the histopathologic severity of endometritis. Women with signs and symptoms of PID, but who have no laparoscopic evidence of the disease, may have an isolated endometritis that is responsible for their symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17431/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Endometritis is strongly associated with chlamydial colonization or infection of the cervix (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Chlamydia'",
"    </a>",
"    below)&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17431/abstract/6\">",
"     6",
"    </a>",
"    ]. Weaker, but positive, correlations exist between endometritis and cervical gonococcal infection and bacterial vaginosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17431/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. Ascending infection has been suggested as an explanation for both the association among cervicitis, endometritis, and salpingitis, and the overlap in symptomatology between these infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/45/11992?source=see_link\">",
"     \"Pathogenesis of and risk factors for pelvic inflammatory disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of acute endometritis is made clinically based upon criteria for the diagnosis of acute PID. An endometrial biopsy for microbiologic and histologic studies may be helpful for the specific diagnosis of acute endometritis, but is not necessary. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/8/131?source=see_link\">",
"     \"Endometrial sampling procedures\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The overlap in symptoms between women with laparoscopically documented PID and those with isolated endometritis is such that differential diagnosis by any specific clinical criterion is not possible. One large series of 152 women with suspected PID who underwent both laparoscopy and endometrial biopsy found that 43 (28 percent) had neither endometritis nor salpingitis, 26 (17 percent) had isolated endometritis, and 83 (55 percent) had acute salpingitis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17431/abstract/10\">",
"     10",
"    </a>",
"    ]. Histologic endometritis was present in 85 percent of patients with confirmed acute salpingitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/0/1032?source=see_link\">",
"     \"Clinical features and diagnosis of pelvic inflammatory disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although vaginal white blood cells are usually present in women with histologic endometritis (sensitivity: 91 percent), many normal women will also have white blood cells noted on saline wet mount of vaginal discharge (specificity: 26 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17431/abstract/11\">",
"     11",
"    </a>",
"    ]. Thus, this test is useful in excluding upper tract infection in the uncommon cases when it is negative (negative predictive value: 95 percent), and is seldom used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The therapy of acute endometritis related to acute PID is the same as the treatment of acute PID. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/63/35832?source=see_link\">",
"     \"Treatment of pelvic inflammatory disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;PID is associated with increased risks of infertility, ectopic pregnancy, chronic pelvic pain, and recurrent PID. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/63/35832?source=see_link\">",
"     \"Treatment of pelvic inflammatory disease\"",
"    </a>",
"    .) The presence or absence of endometritis does not appear to be a factor for whether women with a clinical diagnosis of PID who are treated with antibiotics subsequently achieve pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17431/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Gynecologic procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endometritis is an uncommon complication of transcervical diagnostic gynecologic procedures. As an example, there were only two cases of postoperative infection in a series of 927 diagnostic and operative hysteroscopies; both infections occurred in patients undergoing hysteroscopic myomectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17431/abstract/13\">",
"     13",
"    </a>",
"    ]. The most common pathogens are chlamydia and gonorrhea, but other cervicovaginal organisms can be involved.",
"   </p>",
"   <p>",
"    Screening for chlamydia and gonorrhea before minimally invasive procedures confined to the endometrium, such as hysteroscopy, intrauterine contraception insertion, and endometrial biopsy, is not necessary. If cultures are done, appropriate treatment should be administered to patients with positive results, but prophylactic treatment in the absence of culture results, or in women with negative cultures, is not indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17431/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The American College of Obstetricians and Gynecologists does not recommend routine use of antibiotic prophylaxis prior to hysteroscopy or hysteroscopic surgery, intrauterine contraception insertion, endometrial biopsy, and endometrial ablation because of the low risk of procedure associated infection [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17431/abstract/15\">",
"     15",
"    </a>",
"    ]. However, prophylactic antibiotics are recommended in the following situations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prior to hysterosalpingography (HSG) and sonohysterography in women with a history of pelvic infection &mdash; If dilated tubes are noted during the procedure,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      100 mg orally twice daily can be continued for five days to reduce the incidence of post-procedure PID. In women with no history of pelvic infection, HSG and sonohysterography can be performed without prophylactic antibiotics. However, if the procedure shows dilated fallopian tubes, doxycycline 100 mg twice daily for five days is suggested. However, data supporting use of prophylactic antibiotics in women with dilated tubes undergoing HSG are sparse [",
"      <a class=\"abstract\" href=\"UTD.htm?17/1/17431/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Before surgical termination of pregnancy &mdash; We suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      (100 mg orally) one hour before the procedure and 200 mg orally after completion of the procedure, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      500 mg orally twice daily for five days. Randomized trials have consistently shown that antibiotic prophylaxis decreases the risk of post-abortal infection [",
"      <a class=\"abstract\" href=\"UTD.htm?17/1/17431/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CHRONIC ENDOMETRITIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Unknown etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic endometritis is detected histologically in approximately 8 percent of endometrial specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17431/abstract/18\">",
"     18",
"    </a>",
"    ]. There is no apparent etiology in as many as one-third of these patients, thus making idiopathic endometritis the most common cause of chronic endometritis in women who are not",
"    <span class=\"nowrap\">",
"     pregnant/postpartum",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17431/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Clinical manifestations and diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with symptomatic chronic endometritis usually present with abnormal uterine bleeding, which may consist of intermenstrual bleeding, spotting, postcoital bleeding, menorrhagia, or amenorrhea. Vague, crampy lower abdominal pain accompanies the bleeding or it may occur alone. The most common finding on physical examination is uterine tenderness or cervical motion tenderness. However, in contrast to acute endometritis, many women have no symptoms and a completely normal examination.",
"   </p>",
"   <p>",
"    Women with abnormal vaginal bleeding often undergo an endometrial biopsy as part of their diagnostic evaluation. In these patients, histology that reveals plasma cells in the endometrial stroma is diagnostic of chronic endometritis, but it cannot be assumed that this is the cause of the abnormal vaginal bleeding. An endometrial culture should be performed and may be positive for an infectious organism, despite negative endocervical cultures. The diagnosis of chronic endometritis of unknown etiology is made if culture results are negative, ultrasound does not reveal a submucous fibroid, and there is no history of radiation therapy or recent intrauterine contraception (see below). Although culture results are negative, these women are more likely to have a history of genital tract infection than women without chronic endometritis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17431/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hysteroscopy using fluid for distending the uterine cavity may be a useful and reliable technique for detecting chronic endometritis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17431/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. When hyperemia, mucosal edema, and micropolyps were used as diagnostic parameters, hysteroscopy showed a diagnostic accuracy of 93.4 percent. These authors found over 70 percent of chronic endometritis resulted from common bacteria and mycoplasma [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17431/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Empiric antimicrobial therapy appears to improve symptoms and histology in some women with chronic endometritis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17431/abstract/23\">",
"     23",
"    </a>",
"    ]. We suggest a course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (100 mg orally twice daily for 10 to 14 days) for patients with chronic endometritis of unknown etiology [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17431/abstract/24\">",
"     24",
"    </a>",
"    ]. The rationale is that negative cultures may represent false negative tests for detecting chlamydia [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17431/abstract/6\">",
"     6",
"    </a>",
"    ] or the presence of other difficult to cultivate microbes, and doxycycline is active against some common bacteria and mycoplasma.",
"   </p>",
"   <p>",
"    If the patient remains symptomatic after treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    and cultures are negative, the provider should investigate other etiologies of abnormal uterine bleeding",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    abdominal pain.",
"   </p>",
"   <p>",
"    If the patient is allergic to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    , we suggest a five-day course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    : 500 mg orally on the first day and then 250 mg orally on days 2 through 5. This provides coverage for chlamydia, common bacteria, and mycoplasma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Chlamydia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chlamydia trachomatis is an infectious cause of chronic endometritis in the setting of PID or cervicitis. In one study, as an example, C. trachomatis was detected using polymerase chain reaction (PCR) or immunohistochemistry in 24 percent of endometrial tissue samples with plasma cell endometritis compared to 4 percent of those with no evidence of plasma cell endometritis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17431/abstract/6\">",
"     6",
"    </a>",
"    ]. By comparison, another study which used PCR to detect C. trachomatis in 43 specimens of histopathologically diagnosed chronic endometritis detected C. trachomatis in only one case in which dense plasma cell infiltrates were present; concurrent C. trachomatis infection of the cervix was documented [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17431/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptoms of chronic chlamydial endometritis (intermenstrual bleeding, dyspareunia, and pelvic pain) are similar to those of chronic PID or chronic endometritis from other etiologies. However, the Centers for Disease Control and Prevention (CDC) minimal diagnostic criteria for PID appear less sensitive for diagnosis of chronic endometritis (sensitivity 33 percent) than for PID [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17431/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The recommended treatment is 10 to 14 days administration of broad spectrum antibiotics effective against C. trachomatis and other probable pathogens. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42728?source=see_link&amp;anchor=H22#H22\">",
"     \"Genital Chlamydia trachomatis infections in women\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Tuberculous endometritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately one-third of the world's population is infected with Mycobacterium tuberculosis, and it is a leading cause of infertility in endemic countries. The global incidence of tuberculosis (TB) is growing at approximately 0.4 percent per year, and much faster in sub-Saharan Africa and in countries of the former Soviet Union [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17431/abstract/27\">",
"     27",
"    </a>",
"    ]. TB is a relatively common cause of upper genital tract infection in women from Nepal and Northern India [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17431/abstract/28\">",
"     28",
"    </a>",
"    ]. However, it is a rare cause of upper genital tract infection in developed countries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tuberculous endometritis most commonly occurs in young women from countries where TB is endemic and among older women exposed to TB before the advent of effective chemoprophylaxis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/13/18649?source=see_link\">",
"     \"Epidemiology of tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genital tract TB usually arises from hematogenous spread from a pulmonary or other nongenital tract focus. Inoculation of the genital tract from other intraperitoneal foci or from male sexual partners with tuberculous epididymitis is unusual. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/21/20826?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of extrapulmonary and miliary tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The fallopian tube and endometrium are the most frequently affected sites in the female genital tract, although the cervix and ovary can also be involved [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17431/abstract/29\">",
"     29",
"    </a>",
"    ]. The vagina and vulva are rarely infected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/54/22378?source=see_link\">",
"     \"Microbiology and pathogenesis of tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genital tract TB usually results from reactivation of a focus of infection which originated at the time of initial infection; thus, clinical manifestations may not appear until 10 years after the initial seeding of the genital tract. Infertility is the chief presenting complaint among young women with genital tract TB [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17431/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Genital involvement without renal TB is more common in women than in men [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17431/abstract/31\">",
"     31",
"    </a>",
"    ]. Unusual patterns of vaginal bleeding, such as changes in menses, amenorrhea, and postmenopausal bleeding are other common presentations of disease. Approximately 25 to 35 percent of women with pelvic TB complain of vague, chronic lower abdominal or pelvic pain. Tuberculous peritonitis and ascites, which are usually secondary to direct hematogenous seeding of the peritoneum, are infrequently observed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis should be suspected in women with symptoms suggestive of TB, residence in or travel to endemic areas, and a chest roentgenogram with evidence of healed pulmonary TB. However, a significant number of women with pelvic TB may have a normal chest x-ray and no prior history of TB [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17431/abstract/32\">",
"     32",
"    </a>",
"    ]. A skin test with a purified protein derivative of tuberculin is the best way to screen for asymptomatic infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20648?source=see_link\">",
"     \"Diagnosis of latent tuberculosis infection in HIV-negative adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39673?source=see_link\">",
"     \"Clinical manifestations and evaluation of pulmonary tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A hysterosalpingogram performed as part of an infertility evaluation may show some or all of the characteristic changes of tuberculous infection: beading; sacculation; sinus formation; and rigid pipestem patterning.",
"   </p>",
"   <p>",
"    The diagnosis should be confirmed by histologic examination of a surgical specimen (showing typical granuloma) or by an acid-fast stain or culture of menstrual blood or tissue from an endometrial biopsy. Menstrual fluid, which may be collected in a vaginal or cervical cup, is more sensitive than biopsy specimens for the diagnosis of tuberculous endometritis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17431/abstract/30\">",
"     30",
"    </a>",
"    ]. Culture and histology are also more sensitive than acid-fast stains. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9098?source=see_link&amp;anchor=H15#H15\">",
"     \"Diagnosis of pulmonary tuberculosis in HIV-negative patients\", section on 'Nucleic acid amplification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of genital tract TB is primarily medical and consists of combination drug therapy for 9 to 12 months. Surgery is indicated if the symptoms or the physical examination suggest persistence or increase in disease despite adequate therapy or if culture or biopsy results demonstrate resistant organisms. Total abdominal hysterectomy and bilateral salpingo-oophorectomy is the definitive surgical procedure for pelvic TB. However, early aggressive medical therapy may allow conservative procedures in women who wish to attempt a future pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/21/19802?source=see_link\">",
"     \"Treatment of pulmonary tuberculosis in HIV-negative patients\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Intrauterine foreign objects, intrauterine growths, and radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The copper intrauterine contraception induces a foreign body reaction in the endometrium; the resulting inflammatory response prevents viable sperm from reaching the fallopian tubes [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17431/abstract/33\">",
"     33",
"    </a>",
"    ]. This reaction subsides after removal of the device. In addition, women with noncopper intrauterine contraception who have discomforting symptoms (eg, irregular bleeding, crampy pain) are more likely to have histological evidence of endometritis compared to those who are asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17431/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intrauterine growths (eg, submucous leiomyoma or polyps) in the uterine cavity and radiation therapy can also induce chronic endometrial inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17431/abstract/33,35\">",
"     33,35",
"    </a>",
"    ]. Excision of the fibroid or polyp may lead to resolution.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pathologists have traditionally classified endometritis as either acute or chronic, based upon histological findings. Symptoms alone are not useful for distinguishing these entities since the clinical manifestations of both disorders are similar (abnormal uterine bleeding, pelvic pain, uterine tenderness). An exception is fever: patients with acute endometritis frequently have fever, while it is less common in women with the chronic process. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11667484\">",
"    <span class=\"h2\">",
"     Acute endometritis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute endometritis is a common component of acute pelvic inflammatory disease (PID); it is usually present along with acute salpingitis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pelvic inflammatory disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Transcervical gynecologic procedures are an uncommon cause of acute endometritis. For this reason, we suggest not performing tests for chlamydia and gonorrhea before minimally invasive procedures confined to the endometrium (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Gynecologic procedures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      To prevent postprocedure endometritis, we recommend antibiotic prophylaxis before pregnancy termination (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We suggest its use before hysterosalpingography or sonohysterography in women with a history of pelvic infection and after these procedures in those found to have hydrosalpinges (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Gynecologic procedures'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11667491\">",
"    <span class=\"h2\">",
"     Chronic endometritis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As many as one-third of patients with chronic endometritis have no identifiable etiology; infection, intrauterine",
"      <span class=\"nowrap\">",
"       growths/foreign",
"      </span>",
"      bodies, and radiation therapy account for the remainder. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Chronic endometritis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In contrast to acute endometritis, many women with chronic endometritis have no symptoms and a completely normal examination. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest a course of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      (100 mg orally twice daily for 10 days) for patients with chronic endometritis of unknown etiology (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Unknown etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Targeted therapy is appropriate when the cause of endometritis is known. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Chronic endometritis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Kurman, R, Mazur, M. Benign disease of the endometrium in Blaustein A, ed. Pathology of the Female Genital Tract, 2nd ed. Springer-Verlag, New York, 1982. p. 279.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17431/abstract/2\">",
"      Greenwood SM, Moran JJ. Chronic endometritis: morphologic and clinical observations. Obstet Gynecol 1981; 58:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17431/abstract/3\">",
"      Vasudeva K, Thrasher TV, Richart RM. Chronic endometritis: a clinical and electron microscopic study. Am J Obstet Gynecol 1972; 112:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17431/abstract/4\">",
"      Paavonen J, Kiviat N, Brunham RC, et al. Prevalence and manifestations of endometritis among women with cervicitis. Am J Obstet Gynecol 1985; 152:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17431/abstract/5\">",
"      W&oslash;lner-Hanssen P, M&aring;rdh PA, Svensson L, Westr&ouml;m L. Laparoscopy in women with chlamydial infection and pelvic pain: a comparison of patients with and without salpingitis. Obstet Gynecol 1983; 61:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17431/abstract/6\">",
"      Paukku M, Puolakkainen M, Paavonen T, Paavonen J. Plasma cell endometritis is associated with Chlamydia trachomatis infection. Am J Clin Pathol 1999; 112:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17431/abstract/7\">",
"      Hillier SL, Kiviat NB, Hawes SE, et al. Role of bacterial vaginosis-associated microorganisms in endometritis. Am J Obstet Gynecol 1996; 175:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17431/abstract/8\">",
"      Korn AP, Bolan G, Padian N, et al. Plasma cell endometritis in women with symptomatic bacterial vaginosis. Obstet Gynecol 1995; 85:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17431/abstract/9\">",
"      Peipert JF, Montagno AB, Cooper AS, Sung CJ. Bacterial vaginosis as a risk factor for upper genital tract infection. Am J Obstet Gynecol 1997; 177:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17431/abstract/10\">",
"      Eckert LO, Hawes SE, W&ouml;lner-Hanssen PK, et al. Endometritis: the clinical-pathologic syndrome. Am J Obstet Gynecol 2002; 186:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17431/abstract/11\">",
"      Yudin MH, Hillier SL, Wiesenfeld HC, et al. Vaginal polymorphonuclear leukocytes and bacterial vaginosis as markers for histologic endometritis among women without symptoms of pelvic inflammatory disease. Am J Obstet Gynecol 2003; 188:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17431/abstract/12\">",
"      Haggerty CL, Ness RB, Amortegui A, et al. Endometritis does not predict reproductive morbidity after pelvic inflammatory disease. Am J Obstet Gynecol 2003; 188:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17431/abstract/13\">",
"      Propst AM, Liberman RF, Harlow BL, Ginsburg ES. Complications of hysteroscopic surgery: predicting patients at risk. Obstet Gynecol 2000; 96:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17431/abstract/14\">",
"      Grimes DA, Lopez LM, Schulz KF. Antibiotic prophylaxis for intrauterine contraceptive device insertion. Cochrane Database Syst Rev 2012; :CD001327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17431/abstract/15\">",
"      ACOG Committee on Practice Bulletins--Gynecology. ACOG practice bulletin No. 104: antibiotic prophylaxis for gynecologic procedures. Obstet Gynecol 2009; 113:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17431/abstract/16\">",
"      Pittaway DE, Winfield AC, Maxson W, et al. Prevention of acute pelvic inflammatory disease after hysterosalpingography: efficacy of doxycycline prophylaxis. Am J Obstet Gynecol 1983; 147:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17431/abstract/17\">",
"      Sawaya GF, Grady D, Kerlikowske K, Grimes DA. Antibiotics at the time of induced abortion: the case for universal prophylaxis based on a meta-analysis. Obstet Gynecol 1996; 87:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17431/abstract/18\">",
"      Michels TC. Chronic endometritis. Am Fam Physician 1995; 52:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17431/abstract/19\">",
"      Pitsos M, Skurnick J, Heller D. Association of pathologic diagnoses with clinical findings in chronic endometritis. J Reprod Med 2009; 54:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17431/abstract/20\">",
"      Cicinelli E, Resta L, Nicoletti R, et al. Detection of chronic endometritis at fluid hysteroscopy. J Minim Invasive Gynecol 2005; 12:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17431/abstract/21\">",
"      Cicinelli E, Resta L, Nicoletti R, et al. Endometrial micropolyps at fluid hysteroscopy suggest the existence of chronic endometritis. Hum Reprod 2005; 20:1386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17431/abstract/22\">",
"      Cicinelli E, De Ziegler D, Nicoletti R, et al. Chronic endometritis: correlation among hysteroscopic, histologic, and bacteriologic findings in a prospective trial with 2190 consecutive office hysteroscopies. Fertil Steril 2008; 89:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17431/abstract/23\">",
"      Eckert LO, Thwin SS, Hillier SL, et al. The antimicrobial treatment of subacute endometritis: a proof of concept study. Am J Obstet Gynecol 2004; 190:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17431/abstract/24\">",
"      Johnston-MacAnanny EB, Hartnett J, Engmann LL, et al. Chronic endometritis is a frequent finding in women with recurrent implantation failure after in vitro fertilization. Fertil Steril 2010; 93:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17431/abstract/25\">",
"      Stern RA, Svoboda-Newman SM, Frank TS. Analysis of chronic endometritis for Chlamydia trachomatis by polymerase chain reaction. Hum Pathol 1996; 27:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17431/abstract/26\">",
"      Korn AP, Hessol N, Padian N, et al. Commonly used diagnostic criteria for pelvic inflammatory disease have poor sensitivity for plasma cell endometritis. Sex Transm Dis 1995; 22:335.",
"     </a>",
"    </li>",
"    <li>",
"     www.who.int/gtb/publications/globrep/index.html (Accessed 3/7/05).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17431/abstract/28\">",
"      Jindal UN, Verma S, Bala Y. Favorable infertility outcomes following anti-tubercular treatment prescribed on the sole basis of a positive polymerase chain reaction test for endometrial tuberculosis. Hum Reprod 2012; 27:1368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17431/abstract/29\">",
"      Agarwal J, Gupta JK. Female genital tuberculosis--a retrospective clinico-pathologic study of 501 cases. Indian J Pathol Microbiol 1993; 36:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17431/abstract/30\">",
"      Oosthuizen AP, Wessels PH, Hefer JN. Tuberculosis of the female genital tract in patients attending an infertility clinic. S Afr Med J 1990; 77:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17431/abstract/31\">",
"      Simon HB, Weinstein AJ, Pasternak MS, et al. Genitourinary tuberculosis. Clinical features in a general hospital population. Am J Med 1977; 63:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17431/abstract/32\">",
"      Saracoglu OF, Mungan T, Tanzer F. Pelvic tuberculosis. Int J Gynaecol Obstet 1992; 37:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17431/abstract/33\">",
"      Ortiz ME, Croxatto HB. The mode of action of IUDs. Contraception 1987; 36:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17431/abstract/34\">",
"      Ober WB, Sobrero AJ, De Chabon AB, Goodman J. Polyethylene intrauterine contraceptive device. Endometrial changes following long-term use. JAMA 1970; 212:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17431/abstract/35\">",
"      Patterson-Keels LM, Selvaggi SM, Haefner HK, Randolph JF Jr. Morphologic assessment of endometrium overlying submucosal leiomyomas. J Reprod Med 1994; 39:579.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5462 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-6BEDC4A8C2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_1_17431=[""].join("\n");
var outline_f17_1_17431=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ACUTE ENDOMETRITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Gynecologic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CHRONIC ENDOMETRITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Unknown etiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Chlamydia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Tuberculous endometritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Intrauterine foreign objects, intrauterine growths, and radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11667484\">",
"      Acute endometritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11667491\">",
"      Chronic endometritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5462\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5462|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/53/43867\" title=\"table 1\">",
"      Causes of endometritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/0/1032?source=related_link\">",
"      Clinical features and diagnosis of pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39673?source=related_link\">",
"      Clinical manifestations and evaluation of pulmonary tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/21/20826?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of extrapulmonary and miliary tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20648?source=related_link\">",
"      Diagnosis of latent tuberculosis infection in HIV-negative adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9098?source=related_link\">",
"      Diagnosis of pulmonary tuberculosis in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/8/131?source=related_link\">",
"      Endometrial sampling procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/13/18649?source=related_link\">",
"      Epidemiology of tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42728?source=related_link\">",
"      Genital Chlamydia trachomatis infections in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/54/22378?source=related_link\">",
"      Microbiology and pathogenesis of tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/45/11992?source=related_link\">",
"      Pathogenesis of and risk factors for pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39097?source=related_link\">",
"      Postpartum endometritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/63/35832?source=related_link\">",
"      Treatment of pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/21/19802?source=related_link\">",
"      Treatment of pulmonary tuberculosis in HIV-negative patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_1_17432="Neuromusc motor unit";
var content_f17_1_17432=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F62641&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F62641&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 551px\">",
"   <div class=\"ttl\">",
"    Schematic diagram of neuromuscular motor function",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 531px; height: 697px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The motor unit (neuromuscular apparatus). Voluntary muscle control begins with a nerve impulse from the brain, which is relayed by an upper motor neuron to muscle by a lower motor neuron. A) Detail of the motor end plate, where nerve meets muscle. A nerve impulse causes discharge of acetylcholine into the synaptic space, where it attaches to receptors on muscle cells and causes muscle fiber contraction. B) Detail of skeletal muscle. In this microscopic depiction, type 1 (slow twitch) fibers are pale and type 2 (fast twitch) are dark.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: McConnell, TH. The nature of disease pathology for the health professions, Philadelphia: Lippincott Williams &amp; Wilkins, 2007. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_1_17432=[""].join("\n");
var outline_f17_1_17432=null;
var title_f17_1_17433="Acquired pure red cell aplasia";
var content_f17_1_17433=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acquired pure red cell aplasia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/1/17433/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/1/17433/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/1/17433/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/1/17433/contributors\">",
"     William C Mentzer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/1/17433/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/1/17433/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/1/17433/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acquired pure red cell aplasia (PRCA) is a rare, generally chronic condition of profound anemia characterized by a severe reduction in the number of reticulocytes in the peripheral blood and the virtual absence of erythroid precursors in the bone marrow. All other cell lineages are present and appear morphologically normal.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A similar but usually self-limited condition seen during the first years of life, transient erythroblastopenia of childhood, is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26954?source=see_link&amp;anchor=H11#H11\">",
"       \"Anemia in children due to decreased red blood cell production\", section on 'Transient erythroblastopenia of childhood (TEC)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The congenital form of the disease is known as Diamond-Blackfan",
"      <span class=\"nowrap\">",
"       anemia/syndrome,",
"      </span>",
"      and is associated with a number of congenital abnormalities [",
"      <a class=\"abstract\" href=\"UTD.htm?17/1/17433/abstract/1,2\">",
"       1,2",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26954?source=see_link&amp;anchor=H3#H3\">",
"       \"Anemia in children due to decreased red blood cell production\", section on 'Diamond-Blackfan anemia'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Acquired PRCA will be discussed here. Acquired PRCA due to the presence of anti-erythropoietin antibodies secondary to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/48/2825?source=see_link\">",
"     recombinant human erythropoietin",
"    </a>",
"    is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/4/8265?source=see_link\">",
"     \"Pure red cell aplasia due to anti-erythropoietin antibodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND PATHOGENESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Associated disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acquired PRCA in the adult is most often idiopathic, although a number of underlying causes can exist (",
"    <a class=\"graphic graphic_table graphicRef57655 \" href=\"UTD.htm?37/44/38604\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17433/abstract/1,3\">",
"     1,3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Large granular lymphocyte leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a Mayo Clinic series of 47 adults with acquired pure red blood cell aplasia, large granular lymphocyte (LGL) leukemia was the most common underlying cause [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17433/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21018?source=see_link&amp;anchor=H458740684#H458740684\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of T cell large granular lymphocyte leukemia\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Myelodysplastic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 4 to 20 percent of idiopathic cases, PRCA represents the prodrome to a myelodysplastic syndrome (MDS) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17433/abstract/1,4-6\">",
"     1,4-6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical manifestations and diagnosis of the myelodysplastic syndromes\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Thymoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thymoma is present in about 5 percent of patients with PRCA [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17433/abstract/1,4,7\">",
"     1,4,7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/17/8474?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical presentation and management of thymoma and thymic carcinoma\", section on 'Pure red cell aplasia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of cases of coexisting myasthenia gravis and PRCA have been described in the literature; all were thymoma-associated except for one with thymic hyperplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17433/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Hematopoietic cell transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;PRCA may complicate ABO-incompatible hematopoietic cell transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=see_link&amp;anchor=H12#H12\">",
"     \"Donor selection for hematopoietic cell transplantation\", section on 'ABO and Rh status'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Development of anti-erythropoietin antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acquired PRCA may occur due to the presence of anti-erythropoietin antibodies secondary to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/48/2825?source=see_link\">",
"     recombinant human erythropoietin",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/4/8265?source=see_link\">",
"     \"Pure red cell aplasia due to anti-erythropoietin antibodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;PRCA has been described in a number of T cell and B cell lymphoproliferative disorders. As an example, in chronic lymphocytic leukemia, as many as 6 percent of patients have PRCA when tested for presence of this disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/6/24680?source=see_link&amp;anchor=H13#H13\">",
"     \"Epidemiology and clinical manifestations of chronic lymphocytic leukemia\", section on 'Laboratory abnormalities'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain drugs (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    , valproic acid,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil) have been associated with PRCA (",
"    <a class=\"graphic graphic_table graphicRef57655 \" href=\"UTD.htm?37/44/38604\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17433/abstract/1,9,10\">",
"     1,9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Viral illness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient episodes of red cell aplasia have been described following a number of viral illnesses, such as hepatitis A, HCV, HIV,",
"    <span class=\"nowrap\">",
"     HIV/HCV",
"    </span>",
"    coinfection, EBV, and cytomegalovirus, but often are not recognized clinically [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17433/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32980?source=see_link&amp;anchor=H5#H5\">",
"     \"Atypical manifestations of hepatitis A virus infection\", section on 'Extrahepatic manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Autoimmune disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;PRCA has been described in patients with autoimmune diseases, such as rheumatoid arthritis and systemic lupus erythematosus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36616?source=see_link&amp;anchor=H8#H8\">",
"     \"Hematologic manifestations of rheumatoid arthritis\", section on 'Pure red cell aplasia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14106?source=see_link&amp;anchor=H7#H7\">",
"     \"Hematologic manifestations of systemic lupus erythematosus in adults\", section on 'Red cell aplasia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In some of these patients, their serum and its IgG fraction inhibit the growth of patient and normal erythroid progenitors. As an example, a growing number of cases of neutralizing antibodies to exogenous recombinant EPO, causing pure red cell aplasia and refractory anemia in hemodialysis patients, have been described. In other patients, there is no serum inhibitory activity and the suppression seems to be mediated by T lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17433/abstract/1,3\">",
"     1,3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Parvovirus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The B19 parvovirus is another cause of PRCA but a different mechanism is involved [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17433/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. The parvovirus is thought to directly attack and destroy proerythroblasts by attaching to the blood group P antigen (globoside) receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17433/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]; cytotoxic antibodies are not found, nor is there evidence of T cell-mediated immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17433/abstract/15\">",
"     15",
"    </a>",
"    ]. Severe anemia is most likely to occur in individuals with underlying hemolytic anemia (eg, sickle cell disease, hereditary spherocytosis) or general immunocompromise (HIV infection). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/1/31767?source=see_link\">",
"     \"Treatment and prevention of parvovirus B19 infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/3/18489?source=see_link&amp;anchor=H5#H5\">",
"     \"Approach to the diagnosis of hemolytic anemia in the adult\", section on 'Clinical example: transient aplasia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The aplasia associated with B19 parvovirus often produces a characteristic morphologic finding: the presence of giant proerythroblasts in the bone marrow (",
"    <a class=\"graphic graphic_picture graphicRef51435 \" href=\"UTD.htm?26/42/27304\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17433/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Recent exposure to the virus is confirmed by the presence of anti-B19 IgM antibodies in the serum [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17433/abstract/16\">",
"     16",
"    </a>",
"    ]. The diagnosis can also be established by the presence of B19 DNA. In one retrospective study, for example, B19 DNA was found in the serum of 8 of 57 patients (14 percent) with PRCA [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17433/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/54/22377?source=see_link\">",
"     \"Clinical manifestations and pathogenesis of human parvovirus B19 infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Site of suppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pluripotent hematopoietic stem cell is not the target of attack in PRCA since lymphopoiesis, granulopoiesis, and megakaryocytopoiesis are all normal. When marrow from patients with PRCA is grown in semisolid media, the committed erythroid progenitor cells Burst Forming Unit erythroid (BFUe) and Colony Forming Unit erythroid (CFUe) are present even though the marrow is devoid of erythroid precursors [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17433/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25129?source=see_link\">",
"     \"Overview of hematopoiesis and stem cell function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The first morphologically identifiable erythroid precursor in normal marrow is the proerythroblast, which is absent in PRCA marrow. Thus, the site of suppression is usually at the stage between CFUe and the proerythroblast, although arrest between BFUe and CFUe has been demonstrated in a few cases [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17433/abstract/1\">",
"     1",
"    </a>",
"    ]. Very rarely, BFUe are also decreased [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17433/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Mediators of suppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;In approximately 60 percent of patients with PRCA, their serum and its IgG fraction inhibits the growth of patient and normal erythroid progenitors in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17433/abstract/1,20\">",
"     1,20",
"    </a>",
"    ]. The target antigen is usually not known; in a few cases, however, the IgG fraction contains an inhibitor of erythropoietin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/4/8265?source=see_link&amp;anchor=H10#H10\">",
"     \"Pure red cell aplasia due to anti-erythropoietin antibodies\", section on 'Anti-EPO antibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In other cases of autoimmune PRCA, suppression of erythropoiesis seems to be mediated by T lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17433/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. A subset of T lymphocytes has been implicated and clonal changes may be seen [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17433/abstract/1\">",
"     1",
"    </a>",
"    ]. One study evaluated 14 of 47 patients with PRCA for T cell receptor gene rearrangements: clonal rearrangement was noted in nine [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17433/abstract/3\">",
"     3",
"    </a>",
"    ]. Clonal abnormalities were also identified by karyotypic studies in 4 of 28 patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/46/2793?source=see_link\">",
"     \"Treatment of large granular lymphocyte leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Onset of anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The net result of the immune attack in PRCA is a marked reduction or absence of all recognizable red cell precursors in the bone marrow and absence of reticulocytes in the peripheral blood. This immunologic attack spares more mature red cell precursors in the bone marrow as well as circulating red cells, such that ineffective erythropoiesis and hemolytic anemia do not occur. The net result is an anemia due solely to the complete or nearly complete cessation of red cell production.",
"   </p>",
"   <p>",
"    Since red cells normally survive for approximately 120 days in the circulation, anemia develops at a rate of 0.8 percent per day (ie,",
"    <span class=\"nowrap\">",
"     1/120th",
"    </span>",
"    of the circulating red cells die each day but are not replaced). This pace is slow enough to allow the body to compensate for a reduced oxygen-carrying capacity. Accordingly, the patient with PRCA may not present until a significant degree of anemia is present, often to a hematocrit &lt;10 percent, a point at which these compensatory changes are no longer sufficient. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5961?source=see_link&amp;anchor=H2#H2\">",
"     \"Indications for red cell transfusion in the adult\", section on 'Physiology of anemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PRESENTATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6631632\">",
"    <span class=\"h2\">",
"     Clinical findings",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As the onset of anemia in PRCA is insidious, patients may have little in the way of signs and symptoms until the anemia becomes severe. Extreme pallor or decreased exercise tolerance may be the first signs of this disorder in a previously healthy individual.",
"     </li>",
"     <li>",
"      No physical findings will be present unless there is an associated or underlying disorder (eg, chronic lymphocytic leukemia, rheumatoid arthritis).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6631639\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anemia is often severe and is normocytic and normochromic. Spherocytes, red cell fragments, macrocytes, and polychromatophilic red cells are not seen on routine peripheral blood smears. An exception is parvovirus-associated transient suppression of erythropoiesis seen in subjects with chronic hemolytic anemia, in which cells typical of the underlying anemia (eg, spherocytes in the case of hereditary spherocytosis) are evident on the smear. Reticulocytes are markedly decreased and are often absent.",
"     </li>",
"     <li>",
"      There are no changes in white blood cell or platelet counts; abnormal circulating white blood cells are not present in idiopathic cases, but may be seen in patients with an underlying hematologic disorder (eg, chronic lymphocytic leukemia, large granular lymphocyte leukemia).",
"     </li>",
"     <li>",
"      As ineffective erythropoiesis and hemolytic anemia are not seen in PRCA, levels of indirect bilirubin, haptoglobin, and lactate dehydrogenase are normal.",
"     </li>",
"     <li>",
"      Once the bone marrow stops making red cells, the transfer of iron from plasma to the bone marrow also ceases, resulting in an increase in serum iron concentration, often to the level of the total iron binding capacity, such that transferrin saturation approaches 100 percent and the unsaturated iron binding capacity approaches zero. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35129?source=see_link&amp;anchor=H6#H6\">",
"       \"Pathophysiology and diagnosis of iron overload syndromes\", section on 'Routine iron studies'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bone marrow examination shows normal overall cellularity, with complete or virtually complete absence of red cell precursors. In patients with PRCA due to parvovirus infection, characteristic giant proerythroblasts can be seen (",
"      <a class=\"graphic graphic_picture graphicRef51435 \" href=\"UTD.htm?26/42/27304\">",
"       picture 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Parvovirus'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In all cases of PRCA, a search should be made for an underlying condition, including certain drugs, thymoma, hypoplastic myelodysplastic syndrome, large granular lymphocyte (LGL) leukemia, and viral infection (",
"    <a class=\"graphic graphic_table graphicRef57655 \" href=\"UTD.htm?37/44/38604\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Presentation'",
"    </a>",
"    above.) Appropriate initial studies for such patients include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete blood count, examination of the peripheral smear, reticulocyte count",
"     </li>",
"     <li>",
"      Chest CT to rule out thymoma",
"     </li>",
"     <li>",
"      Viral studies as appropriate, including parvovirus",
"     </li>",
"     <li>",
"      Bone marrow aspiration and biopsy",
"     </li>",
"     <li>",
"      Antinuclear antibody testing",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnosis of PRCA is established when",
"    <strong>",
"     all",
"    </strong>",
"    of the following are present:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Normocytic, normochromic anemia; rarely, macrocytic",
"     </li>",
"     <li>",
"      A very low (or zero) reticulocyte percentage, and an absolute reticulocyte count",
"      <span class=\"nowrap\">",
"       &lt;10,000/microL",
"      </span>",
"     </li>",
"     <li>",
"      Normal white blood cell and platelet counts",
"     </li>",
"     <li>",
"      A normocellular bone marrow that shows normal myelopoiesis, lymphopoiesis, and megakaryocytopoiesis, but few if any erythroid precursors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2568967\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2568989\">",
"    <span class=\"h2\">",
"     Adult patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;If an adult patient fulfills all of the diagnostic criteria for PRCA as enumerated above, the differential diagnosis is limited to the occasional patient with severe autoimmune hemolytic anemia in whom the bone marrow erythropoietic response has been transiently suppressed. Such patients present with severe hemolytic anemia (eg, increased lactate dehydrogenase and indirect bilirubin, decreased haptoglobin), spherocytic red cells, and a positive direct antiglobulin (Coombs) test. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/3/18489?source=see_link&amp;anchor=H25#H25\">",
"     \"Approach to the diagnosis of hemolytic anemia in the adult\", section on 'Hemolysis without reticulocytosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2568996\">",
"    <span class=\"h2\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of severe reticulocytopenia in children includes a number of etiologies in addition to those enumerated above (eg, idiopathic, thymoma, parvovirus infection, viral hepatitis). These disorders are discussed in depth elsewhere and include the following (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26954?source=see_link\">",
"     \"Anemia in children due to decreased red blood cell production\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Transient erythroblastopenia of childhood",
"     </li>",
"     <li>",
"      Aplastic anemia, Fanconi anemia",
"     </li>",
"     <li>",
"      Anemia of (chronic) inflammation",
"     </li>",
"     <li>",
"      Congenital pure red cell aplasia (Diamond-Blackfan anemia)",
"     </li>",
"     <li>",
"      Congenital dyserythropoietic anemia",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In one of the largest available series, 5 of 37 patients (14 percent) with PRCA had spontaneously-remitting disease (eg, pregnancy, some cases of parvovirus infection, drugs), requiring no specific therapy other than transfusion for symptomatic anemia and cessation of possible offending drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17433/abstract/4,21-23\">",
"     4,21-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For the remaining patients, acquired pure red cell aplasia is most often a chronic condition. Although remissions can be attained with the use of immunosuppressive or cytotoxic agents, there is a high propensity for relapse following discontinuation of treatment. Relapse-free survivals (ie, survival without the need for red cell transfusion) can be as short as three months or longer than eight years, depending upon the treatment program employed and whether or not maintenance treatment is given [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17433/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study reported in 1984, overall survival in patients with idiopathic PRCA was &gt;10 years, whereas it was four years in those with PRCA secondary to another condition (eg, leukemia, lymphoma) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/1/17433/abstract/21\">",
"       21",
"      </a>",
"      ]. Infection was the most common cause of morbidity and mortality, likely due to the side effects of treatment with agents such as glucocorticoids and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      A 2007 report in 62 patients with primary (idiopathic) PRCA indicated a 10-year overall survival of 95 percent, with no significant difference between those treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      or those treated with glucocorticoids [",
"      <a class=\"abstract\" href=\"UTD.htm?17/1/17433/abstract/25\">",
"       25",
"      </a>",
"      ]. In a separate 2008 report on 41 patients with thymoma and PRCA, median overall survival was 12 years [",
"      <a class=\"abstract\" href=\"UTD.htm?17/1/17433/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6631738\">",
"    <span class=\"h2\">",
"     Initial management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial management of PRCA includes all of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Red cell transfusions for symptomatic anemia",
"     </li>",
"     <li>",
"      Cessation of possible offending drugs (",
"      <a class=\"graphic graphic_table graphicRef57655 \" href=\"UTD.htm?37/44/38604\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Search for an associated condition",
"     </li>",
"     <li>",
"      Immediate hematologic consultation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In one of the largest available series, 5 of 37 patients (14 percent) with PRCA had spontaneously-remitting disease (eg, pregnancy, some cases of parvovirus infection, drugs), requiring no specific therapy other than the above [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17433/abstract/4,21-23\">",
"     4,21-23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Presence of associated conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of conditions may be associated with PRCA. Management of these conditions is individualized, as discussed below (",
"    <a class=\"graphic graphic_table graphicRef57655 \" href=\"UTD.htm?37/44/38604\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     ABO incompatible hematopoietic cell transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;PRCA that occurs following ABO incompatible bone marrow transplantation is usually a self-limited complication. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=see_link&amp;anchor=H12#H12\">",
"     \"Donor selection for hematopoietic cell transplantation\", section on 'ABO and Rh status'",
"    </a>",
"    .) Occasional cases may have a delayed onset, prolonged course, and poor response to treatment. Anecdotal reports have described responses to plasma exchange, immunoadsorption columns, reduction in the dose of immunosuppressive agents, donor lymphocyte infusion, steroids, erythropoietin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , and intravenous immunoglobulin [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17433/abstract/27-33\">",
"     27-33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Thymoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a well documented association of PRCA with thymoma, with an incidence of about 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17433/abstract/21\">",
"     21",
"    </a>",
"    ]. Even if a thymoma is present, surgical resection only occasionally results in improvement or cure of the PRCA, and additional treatment (eg, glucocorticoids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ), is needed in most cases [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17433/abstract/1,4,7,34,35\">",
"     1,4,7,34,35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/17/8474?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical presentation and management of thymoma and thymic carcinoma\", section on 'Pure red cell aplasia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Parvovirus infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usual course of parvovirus associated-anemia is spontaneous resolution within two to three weeks. If spontaneous improvement does not occur during this time, the patient may be an immunocompromised host. Intravenous immune globulin (IVIG) contains antibodies to parvovirus. A single infusion of 400",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of IVIG given over two to three hours may be effective in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17433/abstract/36\">",
"     36",
"    </a>",
"    ]. Discussions of this infection in patients with malignancy and anemia can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/1/31767?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment and prevention of parvovirus B19 infection\", section on 'Chronic infection with anemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23914?source=see_link&amp;anchor=H17#H17\">",
"     \"Hematologic consequences of malignancy: Anemia and bleeding\", section on 'Parvovirus B19 infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Anti-EPO antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of patients with acquired pure red cell aplasia secondary to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/48/2825?source=see_link\">",
"     recombinant human erythropoietin",
"    </a>",
"    (EPO) is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/4/8265?source=see_link\">",
"     \"Pure red cell aplasia due to anti-erythropoietin antibodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Presence of immune-mediated disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of PRCA with no other associated disorder (ie, idiopathic PRCA)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    which has not remitted spontaneously following a short period of observation is based upon the supposition that the attack is immune mediated and therefore might respond to immunosuppressive therapy. Response to such treatment is characterized by a brisk reticulocytosis followed by an increase in hemoglobin concentration and a decreased need for red cell transfusions.",
"   </p>",
"   <p>",
"    Several different regimens have been used for the initial treatment of PRCA. The most commonly employed regimens include glucocorticoids, glucocorticoids plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and glucocorticoids plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    . These regimens are largely empiric since there are no randomized clinical trials comparing the various therapeutic alternatives for this uncommon condition. Regimen selection is dependent upon an assessment of their short-term and long-term toxicities, need for hospitalization and drug monitoring, underlying disorder(s), and cost. Non-randomized studies suggest that those with an underlying T cell large granular lymphocyte leukemia respond better to cyclophosphamide-based regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17433/abstract/37\">",
"     37",
"    </a>",
"    ], while those with an underlying B cell lymphoma may respond better to a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    -containing regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17433/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/46/2793?source=see_link&amp;anchor=H35829049#H35829049\">",
"     \"Treatment of large granular lymphocyte leukemia\", section on 'Cyclophosphamide'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6632060\">",
"    <span class=\"h3\">",
"     Initial treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment should be initiated with glucocorticoids (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    at an oral dose of 60",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in divided doses). In one retrospective study, 9 of 25 patients (36 percent) responded in one to three months to this treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17433/abstract/3\">",
"     3",
"    </a>",
"    ], while overall response rates to the use of glucocorticoids alone have been in the range of 30 to 62 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17433/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. However, most patients treated with this medication relapse during tapering of therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6632067\">",
"    <span class=\"h4\">",
"     Addition of cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;If no response to glucocorticoids occurs after one to two months, as measured by the absence of an increase in reticulocytes and hemoglobin, we and others prefer to treat patients with a trial of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , since response rates to this agent in the available literature for idiopathic PRCA are better than those following treatment with alkylating agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17433/abstract/25,41\">",
"     25,41",
"    </a>",
"    ]. The recommended oral dose of cyclosporine is 12",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day divided into two equal doses [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17433/abstract/42\">",
"     42",
"    </a>",
"    ]. However, virtually none of our patients can tolerate this dose. We prefer a starting dose of 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day divided into two equal doses, aiming for a trough cyclosporine level of 200",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    at six hours following drug ingestion. These doses have been toxic for Japanese patients, who have responded to lower doses, in the range of 3 to 8",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17433/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    is reported to produce a response in 65 to 87 percent of otherwise refractory patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17433/abstract/4,24,25,42\">",
"     4,24,25,42",
"    </a>",
"    ]. It should be continued for approximately three months if there is a response; slow tapering is then instituted as relapse is common when this medication is discontinued [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17433/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. In one report, relapse was noted within three months in 12 of 14 patients (86 percent) in whom cyclosporine was discontinued, while relapse was noted in only 3 of 27 patients (11 percent) given cyclosporine-containing maintenance therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17433/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6632074\">",
"    <span class=\"h4\">",
"     Addition of cyclophosphamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;If no response occurs after two to three months of treatment with glucocorticoids, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    use is contraindicated or not tolerated, an alternative treatment program is to add",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    at an oral dose of 2 to 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17433/abstract/3\">",
"     3",
"    </a>",
"    ]. Our practice is to taper",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    rapidly in this setting to avoid its well-known complications.",
"   </p>",
"   <p>",
"    In one report, 8 of 15 patients (53 percent) with LGL leukemia and PRCA responded to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    in one to three months [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17433/abstract/3\">",
"     3",
"    </a>",
"    ]. Similar response rates to the use of glucocorticoids in combination with cytotoxic drugs were noted in 18 of 32 patients (56 percent) with idiopathic PRCA [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17433/abstract/21\">",
"     21",
"    </a>",
"    ]. If a response is achieved, we empirically taper cyclophosphamide slowly over two to three months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Relapsed and resistant disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall long-term response and relapse rates following immunosuppression in PRCA are not known. One report suggested that the relapse rate may be as high as 80 percent at 24 months after achieving an initial response [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17433/abstract/1\">",
"     1",
"    </a>",
"    ], while a second report indicated relapse in 13 of 23 patients (57 percent) whose remissions were induced by cytotoxic agents in combination with glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?17/1/17433/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with resistant PRCA may respond to a single course of intravenous immunoglobulin (IVIG, 400",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      given daily for five days), while others have responded to a single dose [",
"      <a class=\"abstract\" href=\"UTD.htm?17/1/17433/abstract/4,43\">",
"       4,43",
"      </a>",
"      ]. There are no data upon which one can base a choice of IVIG as primary or third or fourth line therapy. We occasionally begin therapy with IVIG if the anemia is symptomatic and a rapid response is clinically desirable. In the United States, financial issues may constrain this approach, since IVIG is expensive and is not approved by the FDA for this indication.",
"     </li>",
"     <li>",
"      Other drugs that have been used in refractory cases include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      (2 to 3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day), antilymphocyte globulin, antithymocyte globulin, the anti-CD20 monoclonal antibody",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      , the monoclonal anti-CD52 antibody",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      , and the monoclonal anti-interleukin 2 receptor antibody daclizumab [",
"      <a class=\"abstract\" href=\"UTD.htm?17/1/17433/abstract/4,38,44-54\">",
"       4,38,44-54",
"      </a>",
"      ]. Hematopoietic cell transplantation may be effective in selected patients with refractory disease [",
"      <a class=\"abstract\" href=\"UTD.htm?17/1/17433/abstract/55\">",
"       55",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29930?source=see_link\">",
"       \"Aplastic anemia: Prognosis and treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A patient with inoperable thymoma and red cell aplasia responded well to a combination of the somatostatin analogue",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"       octreotide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?17/1/17433/abstract/56\">",
"       56",
"      </a>",
"      ]. The general applicability of this approach has since been confirmed [",
"      <a class=\"abstract\" href=\"UTD.htm?17/1/17433/abstract/57,58\">",
"       57,58",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/17/8474?source=see_link&amp;anchor=H1628035#H1628035\">",
"       \"Clinical presentation and management of thymoma and thymic carcinoma\", section on 'Systemic therapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of pure red cell aplasia (PRCA) is suspected in a patient with normocytic, normochromic anemia and a very low (or zero) reticulocyte percentage. PRCA is confirmed when all of the following are present:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Normocytic, normochromic anemia",
"     </li>",
"     <li>",
"      A very low (or zero) reticulocyte percentage and an absolute reticulocyte count",
"      <span class=\"nowrap\">",
"       &lt;10,000/microL",
"      </span>",
"     </li>",
"     <li>",
"      Normal white blood cell and platelet counts",
"     </li>",
"     <li>",
"      A normocellular bone marrow that shows normal myelopoiesis, lymphopoiesis, and megakaryocytopoiesis, but few if any erythroid precursors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While the majority of patients with PRCA have no associated condition (ie, acquired idiopathic PRCA), some will have PRCA in association with another disorder. The major associated conditions to be considered include certain drugs, thymoma, hypoplastic myelodysplastic syndrome, large granular lymphocyte (LGL) leukemia, and parvovirus infection (",
"    <a class=\"graphic graphic_table graphicRef57655 \" href=\"UTD.htm?37/44/38604\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Presentation'",
"    </a>",
"    above.) Appropriate initial studies for such patients include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      CBC, examination of the peripheral smear, reticulocyte percentage and absolute reticulocyte count",
"     </li>",
"     <li>",
"      Chest CT to rule out thymoma",
"     </li>",
"     <li>",
"      Viral studies as appropriate, including parvovirus",
"     </li>",
"     <li>",
"      Bone marrow aspiration and biopsy",
"     </li>",
"     <li>",
"      Antinuclear antibody testing",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no standard treatment for PRCA, either for initial treatment or for relapsed disease. Further, there are no prospective randomized studies comparing transfusion alone to any of the available regimens and none comparing one regimen to another. However, all patients with PRCA and symptomatic anemia should be treated with red cell transfusions as needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Initial management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial management of PRCA includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Red cell transfusions for symptomatic anemia",
"     </li>",
"     <li>",
"      Cessation of possible offending drugs (",
"      <a class=\"graphic graphic_table graphicRef57655 \" href=\"UTD.htm?37/44/38604\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Immediate hematologic consultation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A minority of patients with PRCA will respond to this approach alone. The vast majority will have a protracted remitting and relapsing course, requiring long-term support of their anemia with red cell transfusions and long-term treatment with immunosuppressive or cytotoxic agents. Treatment of the underlying condition, if present, may be effective (",
"    <a class=\"graphic graphic_table graphicRef57655 \" href=\"UTD.htm?37/44/38604\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Associated disorders'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Immunosuppressive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to red cell transfusions, we suggest that treatment be initiated with glucocorticoids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , alone or in combination (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ). We prefer a graded approach to treatment, starting with glucocorticoids alone, and adding cyclosporine if there is no initial response. (See",
"    <a class=\"local\" href=\"#H6632060\">",
"     'Initial treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Resistant or relapsed disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of agents are available for patients with resistant or relapsed disease who have failed treatment with the first-line agents glucocorticoids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    . These include intravenous immune globulin (IVIG),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , antilymphocyte globulin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    , daclizumab, and hematopoietic cell transplantation. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Relapsed and resistant disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Chronic parvovirus infection with anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of patients with chronic infection and anemia due to parvovirus is discussed separately, but generally includes the use of red cell transfusions and intravenous immunoglobulin (IVIG). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/1/31767?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment and prevention of parvovirus B19 infection\", section on 'Transient aplastic crisis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/1/31767?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment and prevention of parvovirus B19 infection\", section on 'Chronic infection with anemia'",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17433/abstract/1\">",
"      Dessypris EN. The biology of pure red cell aplasia. Semin Hematol 1991; 28:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17433/abstract/2\">",
"      Fisch P, Handgretinger R, Schaefer HE. Pure red cell aplasia. Br J Haematol 2000; 111:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17433/abstract/3\">",
"      Lacy MQ, Kurtin PJ, Tefferi A. Pure red cell aplasia: association with large granular lymphocyte leukemia and the prognostic value of cytogenetic abnormalities. Blood 1996; 87:3000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17433/abstract/4\">",
"      Marmont AM. Therapy of pure red cell aplasia. Semin Hematol 1991; 28:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17433/abstract/5\">",
"      Wang SA, Yue G, Hutchinson L, et al. Myelodysplastic syndrome with pure red cell aplasia shows characteristic clinicopathological features and clonal T-cell expansion. Br J Haematol 2007; 138:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17433/abstract/6\">",
"      Inui Y, Yamamoto K, Okamura A, et al. Isolated isochromosome 17q in myelodysplastic syndromes with pure red cell aplasia and basophilia. Intern Med 2012; 51:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17433/abstract/7\">",
"      Thompson CA, Steensma DP. Pure red cell aplasia associated with thymoma: clinical insights from a 50-year single-institution experience. Br J Haematol 2006; 135:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17433/abstract/8\">",
"      Suzuki S, Utsugisawa K, Suzuki N. Overlooked non-motor symptoms in myasthenia gravis. J Neurol Neurosurg Psychiatry 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17433/abstract/9\">",
"      Thompson DF, Gales MA. Drug-induced pure red cell aplasia. Pharmacotherapy 1996; 16:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17433/abstract/10\">",
"      Bartakke S, Abdelhaleem M, Carcao M. Valproate-induced pure red cell aplasia and megakaryocyte dysplasia. Br J Haematol 2008; 141:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17433/abstract/11\">",
"      al-Awami Y, Sears DA, Carrum G, et al. Pure red cell aplasia associated with hepatitis C infection. Am J Med Sci 1997; 314:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17433/abstract/12\">",
"      Martins A, Costa A, Oliveira MJ, et al. Pure red cell aplasia due to persistent B19 parvovirus infection in patient infected with human immunodeficiency virus type 1. Recovery with alpha-interferon therapy. Sangre (Barc) 1998; 43:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17433/abstract/13\">",
"      Davidovitz Y, Halpern Z, Vardi J, et al. Pure red cell aplasia responsive to interferon-alpha in a patient with hepatitis C virus infection. Acta Haematol 1998; 100:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17433/abstract/14\">",
"      Ramos-Casals M, Garc&iacute;a-Carrasco M, L&oacute;pez-Medrano F, et al. Severe autoimmune cytopenias in treatment-naive hepatitis C virus infection: clinical description of 35 cases. Medicine (Baltimore) 2003; 82:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17433/abstract/15\">",
"      Kurtzman G, Young N. Viruses and bone marrow failure. Baillieres Clin Haematol 1989; 2:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17433/abstract/16\">",
"      Frickhofen N, Chen ZJ, Young NS, et al. Parvovirus B19 as a cause of acquired chronic pure red cell aplasia. Br J Haematol 1994; 87:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17433/abstract/17\">",
"      Brown KE, Young NS. Parvovirus B19 infection and hematopoiesis. Blood Rev 1995; 9:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17433/abstract/18\">",
"      Brown KE, Anderson SM, Young NS. Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science 1993; 262:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17433/abstract/19\">",
"      Brown KE, Hibbs JR, Gallinella G, et al. Resistance to parvovirus B19 infection due to lack of virus receptor (erythrocyte P antigen). N Engl J Med 1994; 330:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17433/abstract/20\">",
"      Charles RJ, Sabo KM, Kidd PG, Abkowitz JL. The pathophysiology of pure red cell aplasia: implications for therapy. Blood 1996; 87:4831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17433/abstract/21\">",
"      Clark DA, Dessypris EN, Krantz SB. Studies on pure red cell aplasia. XI. Results of immunosuppressive treatment of 37 patients. Blood 1984; 63:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17433/abstract/22\">",
"      Baker RI, Manoharan A, de Luca E, Begley CG. Pure red cell aplasia of pregnancy: a distinct clinical entity. Br J Haematol 1993; 85:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17433/abstract/23\">",
"      Choudry MA, Moffett BK, Laber DA. Pure red-cell aplasia secondary to pregnancy, characterization of a syndrome. Ann Hematol 2007; 86:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17433/abstract/24\">",
"      Sawada K, Fujishima N, Hirokawa M. Acquired pure red cell aplasia: updated review of treatment. Br J Haematol 2008; 142:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17433/abstract/25\">",
"      Sawada K, Hirokawa M, Fujishima N, et al. Long-term outcome of patients with acquired primary idiopathic pure red cell aplasia receiving cyclosporine A. A nationwide cohort study in Japan for the PRCA Collaborative Study Group. Haematologica 2007; 92:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17433/abstract/26\">",
"      Hirokawa M, Sawada K, Fujishima N, et al. Long-term response and outcome following immunosuppressive therapy in thymoma-associated pure red cell aplasia: a nationwide cohort study in Japan by the PRCA collaborative study group. Haematologica 2008; 93:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17433/abstract/27\">",
"      Fujiwara T, Yamada M, Miyamura K, et al. Fludarabine- and cyclophosphamide-based nonmyeloablative conditioning regimen for transplantation of chronic granulomatous disease: possible correlation with prolonged pure red cell aplasia. Int J Hematol 2004; 79:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17433/abstract/28\">",
"      Rabitsch W, Kn&ouml;bl P, Prinz E, et al. Prolonged red cell aplasia after major ABO-incompatible allogeneic hematopoietic stem cell transplantation: removal of persisting isohemagglutinins with Ig-Therasorb immunoadsorption. Bone Marrow Transplant 2003; 32:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17433/abstract/29\">",
"      Bolan CD, Leitman SF, Griffith LM, et al. Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation. Blood 2001; 98:1687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17433/abstract/30\">",
"      Verholen F, Stalder M, Helg C, Chalandon Y. Resistant pure red cell aplasia after allogeneic stem cell transplantation with major ABO mismatch treated by escalating dose donor leukocyte infusion. Eur J Haematol 2004; 73:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17433/abstract/31\">",
"      Yang MH, Hsu HC. Pure red cell aplasia after ABO-incompatible allogeneic stem cell transplantation in severe aplastic anemia with response to steroids: a case report and literature review. Ann Hematol 2001; 80:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17433/abstract/32\">",
"      Sor&agrave; F, De Matteis S, Piccirillo N, et al. Rituximab for pure red cell aplasia after ABO-mismatched allogeneic peripheral blood progenitor cell transplantation. Transfusion 2005; 45:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17433/abstract/33\">",
"      Aung FM, Lichtiger B, Bassett R, et al. Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation. Br J Haematol 2013; 160:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17433/abstract/34\">",
"      van der Marel J, Pahlplatz PV, Steup WH, Hendriks ER. Thymoma with paraneoplastic syndromes, Good's syndrome, and pure red cell aplasia. J Thorac Oncol 2007; 2:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17433/abstract/35\">",
"      Bhargava R, Dolai TK, Singhal D, et al. Pure red cell aplasia associated with thymoma: Is thymectomy the cure? Leuk Res 2009; 33:e17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17433/abstract/36\">",
"      Kurtzman G, Frickhofen N, Kimball J, et al. Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. N Engl J Med 1989; 321:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17433/abstract/37\">",
"      Fujishima N, Sawada K, Hirokawa M, et al. Long-term responses and outcomes following immunosuppressive therapy in large granular lymphocyte leukemia-associated pure red cell aplasia: a Nationwide Cohort Study in Japan for the PRCA Collaborative Study Group. Haematologica 2008; 93:1555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17433/abstract/38\">",
"      Ghazal H. Successful treatment of pure red cell aplasia with rituximab in patients with chronic lymphocytic leukemia. Blood 2002; 99:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17433/abstract/39\">",
"      D'Arena G, Vigliotti ML, Dell'Olio M, et al. Rituximab to treat chronic lymphoproliferative disorder-associated pure red cell aplasia. Eur J Haematol 2009; 82:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17433/abstract/40\">",
"      Narra K, Borghaei H, Al-Saleem T, et al. Pure red cell aplasia in B-cell lymphoproliferative disorder treated with rituximab: report of two cases and review of the literature. Leuk Res 2006; 30:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17433/abstract/41\">",
"      Sawada K, Hirokawa M, Fujishima N. Diagnosis and management of acquired pure red cell aplasia. Hematol Oncol Clin North Am 2009; 23:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17433/abstract/42\">",
"      Raghavachar A. Pure red cell aplasia: review of treatment and proposal for a treatment strategy. Blut 1990; 61:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17433/abstract/43\">",
"      Ballester OF, Saba HI, Moscinski LC, et al. Pure red cell aplasia: treatment with intravenous immunoglobulin concentrate. Semin Hematol 1992; 29:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17433/abstract/44\">",
"      Zecca M, De Stefano P, Nobili B, Locatelli F. Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia. Blood 2001; 97:3995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17433/abstract/45\">",
"      Willis F, Marsh JC, Bevan DH, et al. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol 2001; 114:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17433/abstract/46\">",
"      Ru X, Liebman HA. Successful treatment of refractory pure red cell aplasia associated with lymphoproliferative disorders with the anti-CD52 monoclonal antibody alemtuzumab (Campath-1H). Br J Haematol 2003; 123:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17433/abstract/47\">",
"      Sloand EM, Scheinberg P, Maciejewski J, Young NS. Brief communication: Successful treatment of pure red-cell aplasia with an anti-interleukin-2 receptor antibody (daclizumab). Ann Intern Med 2006; 144:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17433/abstract/48\">",
"      Au WY, Lam CC, Chim CS, et al. Alemtuzumab induced complete remission of therapy-resistant pure red cell aplasia. Leuk Res 2005; 29:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17433/abstract/49\">",
"      Abkowitz JL, Powell JS, Nakamura JM, et al. Pure red cell aplasia: response to therapy with anti-thymocyte globulin. Am J Hematol 1986; 23:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17433/abstract/50\">",
"      Risitano AM, Selleri C, Serio B, et al. Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA. Br J Haematol 2010; 148:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17433/abstract/51\">",
"      Sloand EM, Olnes MJ, Weinstein B, et al. Long-term follow-up of patients with moderate aplastic anemia and pure red cell aplasia treated with daclizumab. Haematologica 2010; 95:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17433/abstract/52\">",
"      Gupta RK, Ezeonyeji AN, Thomas AS, et al. A case of pure red cell aplasia and immune thrombocytopenia complicating systemic lupus erythematosus: response to rituximab and cyclophosphamide. Lupus 2011; 20:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17433/abstract/53\">",
"      Michallet AS, Rossignol J, Cazin B, Ysebaert L. Rituximab-cyclophosphamide-dexamethasone combination in management of autoimmune cytopenias associated with chronic lymphocytic leukemia. Leuk Lymphoma 2011; 52:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17433/abstract/54\">",
"      Rossignol J, Michallet AS, Oberic L, et al. Rituximab-cyclophosphamide-dexamethasone combination in the management of autoimmune cytopenias associated with chronic lymphocytic leukemia. Leukemia 2011; 25:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17433/abstract/55\">",
"      M&uuml;ller BU, Tichelli A, Passweg JR, et al. Successful treatment of refractory acquired pure red cell aplasia (PRCA) by allogeneic bone marrow transplantation. Bone Marrow Transplant 1999; 23:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17433/abstract/56\">",
"      Palmieri G, Lastoria S, Montella L, et al. Role of somatostatin analogue-based therapy in unresponsive malignant thymomas. Ann Med 1999; 31 Suppl 2:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17433/abstract/57\">",
"      Palmieri G, Montella L, Martignetti A, et al. Somatostatin analogs and prednisone in advanced refractory thymic tumors. Cancer 2002; 94:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/1/17433/abstract/58\">",
"      Zaucha R, Zaucha JM, Jassem J. Resolution of thymoma-related pure red cell aplasia after octreotide treatment. Acta Oncol 2007; 46:864.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7120 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-189.44.181.18-7163832E31-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_1_17433=[""].join("\n");
var outline_f17_1_17433=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Associated disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Large granular lymphocyte leukemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Myelodysplastic syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Thymoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Development of anti-erythropoietin antibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Lymphoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Viral illness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Autoimmune disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Parvovirus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Site of suppression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Mediators of suppression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Onset of anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6631632\">",
"      Clinical findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6631639\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2568967\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2568989\">",
"      Adult patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2568996\">",
"      Children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6631738\">",
"      Initial management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Presence of associated conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - ABO incompatible hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Thymoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Parvovirus infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Anti-EPO antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Presence of immune-mediated disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6632060\">",
"      - Initial treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H6632067\">",
"      Addition of cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H6632074\">",
"      Addition of cyclophosphamide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Relapsed and resistant disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Initial management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Immunosuppressive therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Resistant or relapsed disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Chronic parvovirus infection with anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7120\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7120|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/42/27304\" title=\"picture 1\">",
"      Giant proerythroblast in PRCA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7120|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/44/38604\" title=\"table 1\">",
"      Causes of acquired pure red cell aplasia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26954?source=related_link\">",
"      Anemia in children due to decreased red blood cell production",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29930?source=related_link\">",
"      Aplastic anemia: Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/3/18489?source=related_link\">",
"      Approach to the diagnosis of hemolytic anemia in the adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32980?source=related_link\">",
"      Atypical manifestations of hepatitis A virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=related_link\">",
"      Clinical manifestations and diagnosis of the myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/54/22377?source=related_link\">",
"      Clinical manifestations and pathogenesis of human parvovirus B19 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21018?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of T cell large granular lymphocyte leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/17/8474?source=related_link\">",
"      Clinical presentation and management of thymoma and thymic carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=related_link\">",
"      Donor selection for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/6/24680?source=related_link\">",
"      Epidemiology and clinical manifestations of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23914?source=related_link\">",
"      Hematologic consequences of malignancy: Anemia and bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36616?source=related_link\">",
"      Hematologic manifestations of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14106?source=related_link\">",
"      Hematologic manifestations of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5961?source=related_link\">",
"      Indications for red cell transfusion in the adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25129?source=related_link\">",
"      Overview of hematopoiesis and stem cell function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35129?source=related_link\">",
"      Pathophysiology and diagnosis of iron overload syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/4/8265?source=related_link\">",
"      Pure red cell aplasia due to anti-erythropoietin antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/1/31767?source=related_link\">",
"      Treatment and prevention of parvovirus B19 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/46/2793?source=related_link\">",
"      Treatment of large granular lymphocyte leukemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_1_17434="Imatinib: Drug information";
var content_f17_1_17434=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Imatinib: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?3/49/3862?source=see_link\">",
"    see \"Imatinib: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35352?source=see_link\">",
"    see \"Imatinib: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F181929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Gleevec&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F181930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Gleevec&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F181958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Tyrosine Kinase Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F181934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Treatment may be continued until disease progression or unacceptable toxicity. The optimal duration of therapy for chronic myeloid leukemia (CML) in complete remission is not yet determined. Discontinuing CML treatment is not recommended unless part of a clinical trial (Baccarani, 2009; NCCN CML guidelines v.3.2013).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ph+ CML:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Chronic phase: 400 mg once daily; may be increased to 600 mg daily, if tolerated, for disease progression, lack of hematologic response after 3 months, lack of cytogenetic response after 6-12 months, or loss of previous hematologic or cytogenetic response; a range of up to 800 mg daily is included in the NCCN CML guidelines (v.3.2013)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     400 mg once daily; may be increased to 600-800 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Accelerated phase or blast crisis: 600 mg once daily; may be increased to 800 mg daily (400 mg twice daily), if tolerated, for disease progression, lack of hematologic response after 3 months, lack of cytogenetic response after 6-12 months, or loss of previous hematologic or cytogenetic response",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ph+ ALL (relapsed or refractory):",
"     </b>",
"     Oral: 600 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      GIST (adjuvant treatment following complete resection):",
"     </b>",
"     Oral: 400 mg once daily; recommended treatment duration: 3 years",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      GIST (unresectable and/or metastatic malignant):",
"     </b>",
"     Oral: 400 mg once daily; may be increased up to 800 mg daily (400 mg twice daily), if tolerated, for disease progression.",
"     <b>",
"      Note:",
"     </b>",
"     Significant improvement (progression-free survival, objective response rate) was demonstrated in patients with KIT exon 9 mutation with 800 mg (versus 400 mg), although overall survival (OS) was not impacted. The higher dose did not demonstrate a difference in time to progression or OS patients with Kit exon 11 mutation or wild-type status (Debiec-Rychter, 2006; Heinrich, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     400-600 mg daily (depending on disease stage/progression); may be increased to 600-800 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      ASM with eosinophilia:",
"     </b>",
"     Oral: Initiate at 100 mg once daily; titrate up to a maximum of 400 mg once daily (if tolerated) for insufficient response to lower dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      ASM without D816V c-Kit mutation or c-Kit mutation status unknown:",
"     </b>",
"     Oral: 400 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      DFSP:",
"     </b>",
"     Oral: 400 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      HES/CEL:",
"     </b>",
"     Oral: 400 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      HES/CEL with FIP1L1-PDGFR&alpha; fusion kinase:",
"     </b>",
"     Oral: Initiate at 100 mg once daily; titrate up to a maximum of 400 mg once daily (if tolerated) if insufficient response to lower dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      MDS/MPD:",
"     </b>",
"     Oral: 400 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ph+ ALL (induction, newly diagnosed):",
"     </b>",
"     <i>",
"      Canadian labeling (not an approved use in the U.S.):",
"     </i>",
"     Oral: 600 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chordoma, progressive, advanced, or metastatic expressing PDGFRB and/or PDGFB (unlabeled use):",
"     </b>",
"     Oral: 400 mg twice daily (Stacchiotti, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Desmoid tumors, unresectable and/or progressive (unlabeled use):",
"     </b>",
"     Oral: 300 mg twice daily (BSA &ge;1.5 m",
"     <sup>",
"      2",
"     </sup>",
"     ), 200 mg twice daily (BSA 1-1.49 m",
"     <sup>",
"      2",
"     </sup>",
"     ), 100 mg twice daily (BSA &lt;1 m",
"     <sup>",
"      2",
"     </sup>",
"     ) (Chugh, 2010)",
"     <b>",
"      or",
"     </b>",
"     400 mg once daily; may increase to 400 mg twice daily if progressive disease on 400 mg daily (Penel, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Melanoma, advanced or metastatic with C-KIT mutation (unlabeled use):",
"     </b>",
"     Oral: 400 mg twice daily (Carvajal, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Stem cell transplant (SCT, unlabeled use) for CML (in patients who have not failed imatinib therapy prior to transplant):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Prophylactic use to prevent relapse post SCT:",
"     </i>",
"     400 mg daily starting after engraftment for 1 year post transplant (Carpenter, 2007)",
"     <b>",
"      or",
"     </b>",
"     300 mg daily starting on day +35 post SCT (increased to 400 mg within 4 weeks) and continued until 12 months post transplant (Olavarria, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Relapse post SCT:",
"     </i>",
"     Initial: 400 mg daily; if inferior response after 3 months, dose may be increased to 600-800 mg daily (Hess, 2005)",
"     <b>",
"      or",
"     </b>",
"     400-600 mg daily (chronic phase)",
"     <b>",
"      or",
"     </b>",
"     600 mg daily (blast or accelerated phase) (DeAngelo, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment with concomitant strong CYP3A4 inducers:",
"     </b>",
"     Avoid concomitant use of strong CYP3A4 inducers (eg, dexamethasone, carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin); if concomitant use cannot be avoided, increase imatinib dose by at least 50% with careful monitoring.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F181948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35352?source=see_link\">",
"      see \"Imatinib: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Notes:",
"     </b>",
"     Treatment may be continued until disease progression or unacceptable toxicity. The optimal duration of therapy for CML in complete remission is not yet determined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ph+ ALL (newly diagnosed):",
"     </b>",
"     Children &ge;1 year and Adolescents: Oral: 340 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day (in combination with chemotherapy); maximum: 600 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ph+ CML, chronic phase, newly diagnosed:",
"     </b>",
"     Children &ge;1 year and Adolescents: Oral: 340 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day; maximum: 600 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment with concomitant strong CYP3A4 inducers:",
"     </b>",
"     Avoid concomitant use of strong CYP3A4 inducers (eg, dexamethasone, carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin); if concomitant use cannot be avoided, increase imatinib dose by at least 50% with careful monitoring.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment for hepatotoxicity:",
"     </b>",
"     Refer to &ldquo;Hepatic Impairment&rdquo; dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment for hematologic adverse reactions:",
"     </b>",
"     Refer to dosing adjustment for toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment for nonhematologic adverse reactions:",
"     </b>",
"     Refer to dosing adjustment for toxicity.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F181935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F6797530\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Mild impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     40-59 mL/minute): Maximum recommended dose: 600 mg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Moderate impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     20-39 mL/minute): Decrease recommended starting dose by 50%; dose may be increased as tolerated; maximum recommended dose: 400 mg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Severe impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;20 mL/minute): Use caution; a dose of 100 mg daily has been tolerated in a limited number of patients with severe impairment (Gibbons, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Mild impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     40-59 mL/minute): Initial dose: 400 mg once daily (minimum effective dose); titrate to efficacy and tolerability.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Moderate impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     20-39 mL/minute): Initial dose: 400 mg once daily (minimum effective dose); titrate to efficacy and tolerability; the use of 800 mg dose is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Severe impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;20 mL/minute): Use is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F181936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Mild-to-moderate impairment: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Severe impairment: Reduce dose by 25%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Mild-to-moderate impairment: Initial dose: 400 mg once daily (minimum effective dose).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Severe impairment: Initial dose: 200 mg once daily; may increase up to 300 mg once daily in the absence of severe toxicity; decrease dose with unacceptable toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment for hepatotoxicity (during therapy):",
"     </b>",
"     If elevations of bilirubin &gt;3 times ULN or transaminases &gt;5 times ULN occur, withhold treatment until bilirubin &lt;1.5 times ULN and transaminases &lt;2.5 times ULN. Resume treatment at a reduced dose as follows  (",
"     <b>",
"      Note:",
"     </b>",
"     The decision to resume treatment should take into consideration the initial severity of hepatoxicity):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;1 year and Adolescents: If current dose 340 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day, reduce dose to 260 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     If current dose 400 mg daily, reduce dose to 300 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     If current dose 600 mg daily, reduce dose to 400 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     If current dose 800 mg daily, reduce dose to 600 mg daily",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F181959\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Hematologic toxicity:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Chronic phase CML (initial dose 400 mg daily in adults or 340 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day in children); ASM, MDS/MPD, and HES/CEL (initial dose 400 mg daily); or GIST (initial dose 400 mg daily [U.S. labeling] or 400-600 mg daily [Canadian labeling]): If ANC &lt;1 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L and/or platelets &lt;50 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L: Withhold until ANC &ge;1.5 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L and platelets &ge;75 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L; resume treatment at original starting dose. For recurrent neutropenia and/or thrombocytopenia, withhold until recovery, and reinstitute treatment at a reduced dose as follows:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;1 year and Adolescents: If initial dose 340 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day, reduce dose to 260 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     If initial dose 400 mg daily, reduce dose to 300 mg daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     If initial dose 600 mg daily (Canadian labeling; not in U.S. labeling), reduce dose to 400 mg daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     CML (accelerated phase or blast crisis) and Ph+ ALL: Adults (initial dose 600 mg daily): If ANC &lt;0.5 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L and/or platelets &lt;10 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L, establish whether cytopenia is related to leukemia (bone marrow aspirate or biopsy). If unrelated to leukemia, reduce dose to 400 mg daily. If cytopenia persists for an additional 2 weeks, further reduce dose to 300 mg daily. If cytopenia persists for 4 weeks and is still unrelated to leukemia, withhold treatment until ANC &ge;1 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L and platelets &ge;20 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L, then resume treatment at 300 mg daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     ASM associated with eosinophilia and HES/CEL with FIP1L1-PDGFR&alpha; fusion kinase: Adults (starting dose 100 mg daily): If ANC &lt;1 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L and/or platelets &lt;50 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L: Withhold until ANC &ge;1.5 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L and platelets &ge;75 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L; resume treatment at previous dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     DFSP: Adults (initial dose 800 mg daily): If ANC &lt;1 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L and/or platelets &lt;50 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L , withhold until ANC &ge;1.5 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L and platelets &ge;75 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L; resume treatment at reduced dose of 600 mg daily.  For recurrent neutropenia and/or thrombocytopenia, withhold until recovery, and reinstitute treatment with a further dose reduction to 400 mg daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Nonhematologic toxicity (eg, severe edema):",
"      </i>",
"     </b>",
"     Withhold treatment until toxicity resolves; may resume if appropriate (depending on initial severity of adverse event).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F181906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gleevec&reg;: 100 mg, 400 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F181892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F181909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be administered with a meal and a large glass of water; do not crush tablets. In adults, doses &le;600 mg may be given once daily; 800 mg dose should be administered as 400 mg twice daily. Dosing in children may be once or twice daily for CML and once daily for Ph+ ALL. Tablets may be dispersed in water or apple juice (using ~50 mL for 100 mg tablet, ~200 mL for 400 mg tablet); stir until dissolved and administer immediately. For daily dosing &ge;800 mg, the 400 mg tablets should be used in order to reduce iron exposure.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F181908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal stromal tumors (GIST) kit-positive (CD117), including unresectable and/or metastatic malignant and adjuvant treatment following complete resection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (newly-diagnosed) in children and adults",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ph+ CML in blast crisis, accelerated phase, or chronic phase after failure of interferon therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ph+ acute lymphoblastic leukemia (ALL) (relapsed or refractory)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ph+ ALL (newly diagnosed; in combination with chemotherapy) in children",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aggressive systemic mastocytosis (ASM) without D816V c-Kit mutation (or c-Kit mutation status unknown)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatofibrosarcoma protuberans (DFSP) (unresectable, recurrent and/or metastatic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Myelodysplastic/myeloproliferative disease (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene rearrangements",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canadian labeling (not an approved indication in the U.S.): Ph+ ALL induction therapy (newly diagnosed; as a single agent)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F6797529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of desmoid tumors or chordoma (soft tissue sarcomas); post-stem cell transplant (allogeneic) follow-up treatment for recurrence in CML; treatment of advanced or metastatic melanoma (C-KIT mutated tumors)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3401645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Imatinib may be confused with axitinib, dasatinib, erlotinib, gefitinib, nilotinib, ponatinib, SORAfenib, SUNItinib, vandetanib",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F181956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Adverse reactions listed as a composite of data across many trials, except where noted for a specific indication.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema/fluid retention (11% to 86%; grades 3/4: 3% to 13%; includes aggravated edema, anasarca, ascites, pericardial effusion, peripheral edema, pulmonary edema, and superficial edema); facial edema (&le;17%), chest pain (7% to 11%), hypotension (Ph+ ALL [pediatric] grades 3/4: 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue (29% to 75%), pain (&le;47%), fever (6% to 41%), headache (8% to 37%), dizziness (5% to 19%), insomnia (10% to 15%), depression (&le;15%), anxiety (8% to 12%), chills (&le;11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (9% to 50%; grades 3/4: 1% to 9%), dermatitis (GIST &le;39%), pruritus (8% to 26%), alopecia (GIST 10% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: LDH increased (GIST &le;60%), hypokalemia (6% to 13%; Ph+ ALL [pediatric] grades 3/4: 34%), hypoproteinemia (&le;32%), albumin decreased (&le;21%; grade 3: &le;4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (42% to 73%; Ph+ ALL [pediatric] grades 3/4: 16%), diarrhea (25% to 59%; Ph+ ALL [pediatric] grades 3/4: 9%), vomiting (11% to 58%), abdominal pain (3% to 57%), anorexia (&le;36%), weight gain (5% to 32%), dyspepsia (11% to 27%), flatulence (&le;25%), abdominal distension (&le;19%), stomatitis/mucositis (&le;10% to 16%), constipation (9% to 16%), taste disturbance (&le;13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia (25% to 80%; grade 3: 1% to 42%; grade 4: &le;11%), leukopenia (GIST 5% to 47%; grades 3/4: 2%), hemorrhage (3% to 53%; grades 3/4: &le;19%), neutropenia (12% to 16%, grade 3: 7% to 27%; grade 4: 3% to 48%), thrombocytopenia (grade 3: 1% to 31%; grade 4: &lt;1% to 33%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Transaminases and/or bilirubin increased (Ph+ ALL [pediatric] grades 3/4: 57%), AST increased (&le;38%; grade 3: 2% to 5%; grade 4: &le;3%), ALT increased (&le;34%; grade 3: 2% to 7%; grade 4: &lt;3%), alkaline phosphatase increased (&le;17%; grade 3: &le;6%; grade 4: &lt;1%), bilirubin increased (&le;13%; grade 3: 1% to 4%; grade 4: &le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle cramps (16% to 62%), arthralgia (&le;40%), musculoskeletal pain (children 21%; adults 38% to 49%), myalgia (9% to 32%), joint pain (11% to 31%), weakness (&le;21%),  rigors (10% to 12%), paresthesia (&le;12%), bone pain (&le;11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Periorbital edema (29% to &le;74%), lacrimation increased (DFSP 25%; GIST &le;18%), blurred vision (&le;11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Serum creatinine increased (&le;44%; grade 3: &le;3%; DFSP: grade 4: 8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Nasopharyngitis (1% to 31%), cough (11% to 27%), dyspnea (&le;21%), upper respiratory tract infection (3% to 21%), pharyngolaryngeal pain (&le;18%), rhinitis (DFSP 17%), pharyngitis (CML 10% to 15%), pneumonia (CML 4% to 13%), sinusitis (4% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infection (Ph+ ALL [pediatric] grades 3/4: 53%; GIST &le;28%), night sweats (CML 13% to 17%), flu-like syndrome (1% to 14%), diaphoresis (GIST &le;13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Pleural effusion (Ph+ ALL [pediatric] grades 3/4: 7%), palpitation (&le;5%), flushing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: CNS/cerebral hemorrhage (&le;9%), depression (&le;8%), hypoesthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Photosensitivity reaction (4% to 7%), dry skin (&le;7%), erythema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperglycemia (&le;10%), hypocalcemia (GIST &le;6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Appetite decreased (10%), weight loss (&le;10%), gastrointestinal hemorrhage (2% to 8%), gastritis, gastroesophageal reflux, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Lymphopenia (GIST &le;10%; grades 3/4: 1% to 2%), neutropenic fever, pancytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (GIST &le;7%), limb pain (GIST &le;7%), peripheral neuropathy, joint swelling",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Conjunctivitis (5% to 8%), conjunctival hemorrhage, dry eyes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Hypoxia (9%), pneumonitis (Ph+ ALL [pediatric] grades 3/4: 8%), epistaxis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Acute febrile neutropenic dermatosis (Sweet&rsquo;s syndrome), anaphylactic shock, angina, angioedema, aplastic anemia, arrhythmia, arthritis, ascites, atrial fibrillation, avascular necrosis, bullous eruption, cardiac arrest, cardiac tamponade, cardiogenic shock, cataract, cellulitis, cerebral edema, diverticulitis, embolism, eosinophilia, erythema multiforme, exanthematous pustulosis (acute generalized), exfoliative dermatitis, fungal infection, gastric ulcer, gastrointestinal obstruction, gastrointestinal perforation, glaucoma, gout, growth retardation (children), hearing loss, heart failure (severe), hematoma, hematemesis, hematuria, hemolytic anemia, hemorrhagic corpus luteum, hemorrhagic ovarian cyst, hepatic failure, hepatic necrosis, hepatitis, hepatotoxicity, herpes simplex, herpes zoster, hip osteonecrosis, hypercalcemia, hyperkalemia, hyperuricemia, hypertension, hypomagnesemia, hyponatremia, hypophosphatemia, hypothyroidism, ileus, inflammatory bowel disease, interstitial lung disease, interstitial pneumonitis, intracranial pressure increased, left ventricular dysfunction, leukocytoclastic vasculitis, lichen planus, lichenoid keratosis, lymphadenopathy, macular edema, melena, memory impairment, menorrhagia, MI, migraine, myopathy, optic neuritis, ovarian cyst (hemorrhagic), palmar-plantar erythrodysesthesia syndrome, pancreatitis, papilledema, pericarditis, psoriasis, pulmonary fibrosis, pulmonary hemorrhage, pulmonary hypertension, Raynaud's phenomenon, renal failure, respiratory failure, respiratory tract (lower) infection, restless leg syndrome, retinal hemorrhage, rhabdomyolysis, sciatica, scleral hemorrhage, seizure, sepsis, skin pigment changes, Stevens-Johnson syndrome, subdural hematoma, syncope, tachycardia, thrombocythemia, thrombosis, toxic epidermal necrolysis, tumor hemorrhage (GIST), tumor lysis syndrome, tumor necrosis, urinary tract infection, vitreous hemorrhage",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F181912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed within the FDA-approved manufacturer's labeling.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canadian labeling: Hypersensitivity to imatinib or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F181896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression: May cause bone marrow suppression (anemia, neutropenia, and thrombocytopenia), usually occurring within the first several months of treatment. Median duration of neutropenia is 2-3 weeks; median duration of thrombocytopenia is 3-4 weeks. Monitor blood counts weekly for the first month, biweekly for the second month, and as clinically necessary thereafter. In CML, cytopenias are more common in accelerated or blast phase than in chronic phase.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular effects: Severe heart failure (HF) and left ventricular dysfunction (LVD) have been reported (occasionally), usually in patients with comorbidities and/or risk factors. Carefully monitor patients with preexisting cardiac disease or risk factors for HF or history of renal failure. With initiation of imatinib treatment, cardiogenic shock and/or LVD have been reported in patients with hypereosinophilic syndrome and cardiac involvement (reversible with systemic steroids, circulatory support and temporary cessation of imatinib). Patients with high eosinophil levels and an abnormal echocardiogram or abnormal serum troponin level may benefit from prophylactic systemic steroids (for 1-2 weeks) with the initiation of imatinib.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dermatologic reactions: Severe bullous dermatologic reactions, including erythema multiforme and Stevens-Johnson syndrome, have been reported; recurrence has been described with rechallenge. Case reports of successful resumption at a lower dose (with corticosteroids and/or antihistamine) have been described; however, some patients may experience recurrent reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Driving /heavy machinery: Caution is recommended while driving/operating motor vehicles and heavy machinery when taking imatinib; advise patients regarding side effects such as dizziness, blurred vision, or somnolence. Reports of accidents have been received, but it is unclear if imatinib has been the direct cause in any case.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fluid retention/edema: Often associated with fluid retention, weight gain, and edema (risk increases with higher doses and age &gt;65 years); occasionally serious and may lead to significant complications, including pleural effusion, pericardial effusion, pulmonary edema, and ascites. Monitor regularly for rapid weight gain or other signs/symptoms of fluid retention. Use with caution in patients where fluid accumulation may be poorly tolerated, such as in cardiovascular disease (HF or hypertension) and pulmonary disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; GI irritation:  May cause GI irritation; take with food and water to minimize irritation. There have been rare reports (including fatalities) of GI perforation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hemorrhage: Severe hemorrhage (grades 3 and 4) has been reported  with use, including gastrointestinal hemorrhage and/or tumor hemorrhage. The incidence of hemorrhage is higher in patients with GIST (gastrointestinal tumors may have been hemorrhage source). Monitor for GI symptoms with treatment initiation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity: Hepatotoxicity may occur; fatal hepatic failure and severe hepatic injury requiring liver transplantation have been reported with both short- and long-term use; monitor liver function prior to initiation and monthly or as needed thereafter; therapy interruption or dose reduction may be necessary. Transaminase and bilirubin elevations, and acute liver failure have been observed with imatinib in combination with chemotherapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tumor lysis syndrome: Tumor lysis syndrome (TLS), including fatalities, has been reported in patients with ALL, CML eosinophilic leukemias, and GIST. Risk for TLS is higher in patients with a high tumor burden or high proliferation rate; monitor closely. Correct clinically significant dehydration and treat high uric acid levels prior to initiation of imatinib.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; dosage adjustment recommended in patients with severe impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastric surgery: Imatinib exposure may be reduced in patients who have had gastric surgery (eg, bypass, major gastrectomy, or resection); monitor imatinib trough concentrations (Liu, 2011; Pavlovsky, 2009, Yoo, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment recommended for moderate and severe renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid disease: Hypothyroidism has been reported in thyroidectomy patients who were receiving thyroid hormone replacement therapy prior to initiation of imatinib; monitor thyroid function. The average onset for imatinib-induced hypothyroidism is 2 weeks; consider doubling levothyroxine doses upon initiation of imatinib (Hamnvik, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Growth retardation has been reported in children receiving imatinib for the treatment of CML; generally where treatment was initiated in prepubertal children; growth velocity was usually restored as pubertal age was reached (Shima, 2010). Monitor growth closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F181952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     BCRP, CYP2C9 (weak), CYP2D6 (moderate), CYP3A4 (moderate), P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F181900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetaminophen: May enhance the hepatotoxic effect of Imatinib. Imatinib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May increase the serum concentration of Imatinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avanafil.  Management: The maximum avanafil adult dose is 50 mg per 24-hour period when used together with a moderate CYP3A4 inhibitor.  Patients receiving such a combination should also be monitored more closely for evidence of adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Antineoplastic Agents may decrease the absorption of Cardiac Glycosides. This may only affect digoxin tablets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Digitoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Codeine: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.  Management: Reduce colchicine dose as directed when using with a moderate CYP3A4 inhibitor, and increase monitoring for colchicine-related toxicity.  Use extra caution in patients with impaired renal and/or hepatic function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Imatinib may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Moderate) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May decrease the serum concentration of Imatinib. Management: Avoid concurrent use of imatinib with strong CYP3A4 inducers when possible.  If such a combination must be used, increase imatinib dose by at least 50% and monitor the patient's clinical response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.  Management: When used concomitantly with moderate inhibitors of CYP3A4, eplerenone dosing recommendations may vary depending on international labeling. Consult appropriate labeling for specific recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fludarabine: Imatinib may diminish the myelosuppressive effect of Fludarabine. Imatinib may decrease the serum concentration of Fludarabine. More specifically, imatinib may decrease the formation of fludarabine active metabolite F-ara-ATP  Management: Due to the risk for impaired fludarabine response, consider discontinuing imatinib therapy at least 5 days prior to initiating fludarabine conditioning therapy in CML patients undergoing HSCT.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibuprofen: May decrease the serum concentration of Imatinib. Specifically, ibuprofen may decrease intracellular concentrations of imatinib, leading to decreased clinical response. Management: Consider using an alternative to ibuprofen in patients who are being treated with imatinib.  Available evidence suggests other NSAIDs do not interact in a similar manner.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivabradine.  Management: In patients with a resting heart rate over 60 beats per minute receiving a moderate CYP3A4 inhibitor, ivabradine initiation at an adult dose of 2.5 mg twice daily may be considered.  Monitor heart rate closely under these circumstances.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg daily in patients also receiving moderate CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lansoprazole: May enhance the dermatologic adverse effect of Imatinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurasidone.  Management: U.S. labeling: start at 20 mg/day and limit to max of 80 mg/day with moderate CYP3A4 inhibitor.  Canadian labeling: limit to max of 40 mg/day with moderate CYP3A4 inhibitor; avoid concomitant use of grapefruit products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nebivolol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Nebivolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May increase the serum concentration of CYP2D6 Inhibitors (Moderate).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine.  Management: Limit the ranolazine adult dose to a maximum of 500 mg twice daily in patients concurrently receiving moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil, erythromycin, etc.).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Imatinib. Management: Avoid concurrent use of imatinib with the rifamycin derivatives when possible.  If such a combination must be used, increase imatinib dose by at least 50% and monitor the patient's clinical response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: Imatinib may decrease the metabolism of Simvastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of Imatinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.  Management: Consider alternatives with less of an inhibitory effect on CYP2D6 activity when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: BCRP/ABCG2 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vilazodone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antineoplastic Agents may enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: Imatinib may enhance the anticoagulant effect of Warfarin. Imatinib may decrease the metabolism of Warfarin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F181926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Management: Avoid ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Food may reduce GI irritation. Grapefruit juice may increase imatinib plasma concentration. Management: Take with a meal and a large glass of water. Avoid grapefruit juice. Maintain adequate hydration, unless instructed to restrict fluid intake.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may increase metabolism and decrease imatinib plasma concentration. Management: Avoid St John's wort.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F181902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F181916\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have demonstrated teratogenic effects and fetal loss. Women of childbearing potential are advised not to become pregnant (female patients and female partners of male patients); highly effective contraception is recommended. Case reports of pregnancies while on therapy (both males and females) include reports of spontaneous abortion, minor abnormalities (hypospadias, pyloric stenosis, and small intestine rotation) at or shortly after birth, and other congenital abnormalities including skeletal malformations, hypoplastic lungs, exomphalos, kidney abnormalities, hydrocephalus, cerebellar hypoplasia, and cardiac defects.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Retrospective case reports of women with CML in complete hematologic response (CHR) with cytogenic response (partial or complete) who interrupted imatinib therapy due to pregnancy, demonstrated a loss of response in some patients while off treatment. At 18 months after treatment reinitiation following delivery, CHR was again achieved in all patients and cytogenic response was achieved in some patients. Cytogenetic response rates may not be at as high as compared to patients with 18 months of uninterrupted therapy (Ault, 2006; Pye, 2008).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F181941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F3339989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Imatinib and its active metabolite are found in human breast milk; the milk/plasma ratio is 0.5 for imatinib and 0.9 for the active metabolite. Based on body weight, up to 10% of a therapeutic maternal dose could potentially be received by a breastfed infant, the decision to discontinue breast-feeding during therapy or to discontinue imatinib should take into account the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F181917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken with food and a large glass of water to decrease gastrointestinal irritation. Avoid grapefruit juice.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F181915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Gleevec Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (90): $6389.11",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (30): $7674.12",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F181904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC (weekly for first month, biweekly for second month, then periodically thereafter), liver function tests (at baseline and monthly or as clinically indicated; more frequently [at least weekly] in patients with moderate-to-severe hepatic impairment [Ramanathan, 2008]), renal function, serum electrolytes (including calcium, phosphorus, potassium and sodium levels); bone marrow cytogenetics (in CML; at 6-, 12-, and 18 months); fatigue, weight, and edema/fluid status; consider echocardiogram and serum troponin levels in patients with HES/CEL, and in patients with MDS/MPD or ASM with high eosinophil levels; in pediatric patients, also monitor serum glucose, albumin, and growth",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Gastric surgery (eg, bypass, major gastrectomy, or resection) patients: Monitor imatinib trough concentrations (Liu, 2011; Pavlovsky, 2009, Yoo, 2010)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Thyroid function testing (Hamnvik, 2011):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Preexisting levothyroxine therapy: Obtain baseline TSH levels, then monitor every 4 weeks until levels and levothyroxine dose are stable, then monitor every 2 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Without pre-existing thyroid hormone replacement: TSH at baseline, then every 4 weeks for 4 months, then every 2-3 months",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Monitor for signs/symptoms of CHF in patients with at risk for cardiac failure or patients with pre-existing cardiac disease. In Canada, a baseline evaluation of left ventricular ejection fraction is recommended prior to initiation of imatinib therapy in all patients with known underlying heart disease or in elderly patients. Monitor for signs/symptoms of gastrointestinal irritation or perforation and dermatologic toxicities.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F181918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Gleevec (JP);",
"     </li>",
"     <li>",
"      Glivec (AR, AT, AU, BE, BG, BR, CH, CL, CN, CO, CZ, DE, DK, EC, EE, ES, FI, FR, GB, GR, HK, HN, ID, IE, IL, IT, KP, MT, MX, MY, NL, NO, PE, PH, PK, PL, PT, PY, RU, SE, SG, SK, TH, TR, TW, UY, VE);",
"     </li>",
"     <li>",
"      Glivic (NZ);",
"     </li>",
"     <li>",
"      Milatus (PE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F181895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits Bcr-Abl tyrosine kinase, the constitutive abnormal gene product of the Philadelphia chromosome in chronic myeloid leukemia (CML). Inhibition of this enzyme blocks proliferation and induces apoptosis in Bcr-Abl positive cell lines as well as in fresh leukemic cells in Philadelphia chromosome positive CML. Also inhibits tyrosine kinase for platelet-derived growth factor (PDGF), stem cell factor (SCF), c-Kit, and cellular events mediated by PDGF and SCF.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F181911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Parent drug and metabolite: ~95% to albumin and alpha",
"     <sub>",
"      1",
"     </sub>",
"     -acid glycoprotein",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP3A4 (minor metabolism via CYP1A2, CYP2D6, CYP2C9, CYP2C19); primary metabolite (active): N-demethylated piperazine derivative (CGP74588); severe hepatic impairment (bilirubin &gt;3-10 times ULN) increases AUC  by 45% to 55% for imatinib and its active metabolite, respectively",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability:  98%; may be decreased in patients who have had gastric surgery (eg, bypass, total or partial resection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Adults: Parent drug: ~18 hours; N-desmethyl metabolite: ~40 hours; Children: Parent drug: ~15 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (68% primarily as metabolites, 20% as unchanged drug); urine (13% primarily as metabolites, 5% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Atallah E, Durand JB, Kantarjian H, et al, &ldquo;Congestive Heart Failure is a Rare Event in Patients Receiving Imatinib Therapy,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2007, 110(4):1233-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/1/17434/abstract-text/17449798/pubmed\" id=\"17449798\" target=\"_blank\">",
"        17449798",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ault P, Kantarjian H, O&rsquo;Brien S, et al, &ldquo;Pregnancy Among Patients with Chronic Myeloid Leukemia Treated With Imatinib,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(7):1204-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/1/17434/abstract-text/16446320/pubmed\" id=\"16446320\" target=\"_blank\">",
"        16446320",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Baccarani M, Cortes J, Pane F, et al, &ldquo;Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(35):6041-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/1/17434/abstract-text/19884523/pubmed\" id=\"19884523\" target=\"_blank\">",
"        19884523",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berman E, Nicolaides M, Maki RG, et al, &ldquo;Altered Bone and Mineral Metabolism in Patients Receiving Imatinib Mesylate,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354(19):2006-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/1/17434/abstract-text/16687713/pubmed\" id=\"16687713\" target=\"_blank\">",
"        16687713",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bilgi N, Bell K, Ananthakrishnan AN, et al, &ldquo;Imatinib and Panax Ginseng: A Potential Interaction Resulting in Liver Toxicity,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2010, 44(5):926-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/1/17434/abstract-text/20332334/pubmed\" id=\"20332334\" target=\"_blank\">",
"        20332334",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brunstein CG and McGlave PB, &ldquo;The Biology and Treatment of Chronic Myelogenous Leukemia,&rdquo;",
"      <i>",
"       Oncology",
"      </i>",
"      , 2001, 15:23-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/1/17434/abstract-text/11271979/pubmed\" id=\"11271979\" target=\"_blank\">",
"        11271979",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Carpenter PA, Snyder DS, Flowers ME, et al, &ldquo;Prophylactic Administration of Imatinib After Hematopoietic Cell Transplantation for High-Risk Philadelphia Chromosome-Positive Leukemia,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2007, 109(7):2791-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/1/17434/abstract-text/17119111/pubmed\" id=\"17119111\" target=\"_blank\">",
"        17119111",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Carvajal RD, Antonescu CR, Wolchok JD, et al, &ldquo;KIT as a Therapeutic Target in Metastatic Melanoma,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2011, 305(22):2327-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/1/17434/abstract-text/21642685/pubmed\" id=\"21642685\" target=\"_blank\">",
"        21642685",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Casali PG, Stacchiotti S, Grosso F, et al, &ldquo;Adding Cisplatin (CDDP) to Imatinib (IM) Re-Establishes Tumor Response Following Secondary Resistance to IM in Advanced Chordoma,&rdquo; J Clin Oncol, 2007, 25(Suppl 18):10038 [abstract 10038 from the 2007 ASCO Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chugh R, Wathen JK, Patel SR, et al, &ldquo;Efficacy of Imatinib in Aggressive Fibromatosis: Results of a Phase II Multicenter Sarcoma Alliance for Research Through Collaboration (SARC) Trial,&rdquo;",
"      <i>",
"       Clin Cancer Res",
"      </i>",
"      , 2010, 16(19):4884-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/1/17434/abstract-text/20724445/pubmed\" id=\"20724445\" target=\"_blank\">",
"        20724445",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cornelison M, Jabbour EJ, and Welch MA, &ldquo;Managing Side Effects of Tyrosine Kinase Inhibitor Therapy to Optimize Adherence in Patients With Chronic Myeloid Leukemia: The Role of the Midlevel Practitioner,&rdquo;",
"      <i>",
"       J Support Oncol",
"      </i>",
"      , 2012, 10(1):14-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/1/17434/abstract-text/22244674/pubmed\" id=\"22244674\" target=\"_blank\">",
"        22244674",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DeAngelo DJ, Hochberg EP, Alyea EP, et al, &ldquo;Extended Follow-Up of Patients Treated With Imatinib Mesylate (Gleevec) for Chronic Myelogenous Leukemia Relapse After Allogeneic Transplantation: Durable Cytogenetic Remission and Conversion to Complete Donor Chimerism Without Graft-Versus-Host Disease,&rdquo;",
"      <i>",
"       Clin Cancer Res",
"      </i>",
"      , 2004, 10(15):5065-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/1/17434/abstract-text/15297408/pubmed\" id=\"15297408\" target=\"_blank\">",
"        15297408",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Debiec-Rychter M, Sciot R, Le Cesne A, et al, &ldquo;KIT mutations and Dose Selection for Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors,&rdquo;",
"      <i>",
"       Eur J Cancer",
"      </i>",
"      , 2006, 42(8):1093-103.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/1/17434/abstract-text/16624552/pubmed\" id=\"16624552\" target=\"_blank\">",
"        16624552",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      de Groot JW, Zonnenberg BA, Plukker JT, et al,  \"Imatinib Induces Hypothyroidism in Patients Receiving Levothyroxine,\"",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 2005, 78(4):433-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/1/17434/abstract-text/16198662/pubmed\" id=\"16198662\" target=\"_blank\">",
"        16198662",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dematteo RP, Ballman KV, Antonescu CR, et al, &ldquo;Adjuvant Imatinib Mesylate After Resection of Localised, Primary Gastrointestinal Stromal Tumour: a Randomised, Double-Blind, Placebo-Controlled Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      ,  2009, 373(9669):1097-104.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/1/17434/abstract-text/19303137/pubmed\" id=\"19303137\" target=\"_blank\">",
"        19303137",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DeMatteo R, Owzar K, Maki R, et al, &ldquo;Adjuvant Imatinib Mesylate Increases Recurrence Free Survival (RFS) in Patients With Completely Resected Localized Primary Gastrointestinal Stromal Tumor (GIST): North American Intergroup Phase III Trial ACOSOG Z9001,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 28(18 Supp):10079 [abstract 10079 from 2007 ASCO Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dewar AL, Farrugia AN, Condina MR, et al, &ldquo;Imatinib as a Potential Antiresorptive Therapy for Bone Disease,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2006, 107(11):4334-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/1/17434/abstract-text/16449525/pubmed\" id=\"16449525\" target=\"_blank\">",
"        16449525",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Droogendijk HJ, Kluin-Nelemans HJ, van Doormaal JJ, et al, &ldquo;Imatinib Mesylate in the Treatment of Systemic Mastocytosis: A Phase II Trial,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2006, 107(2):345-51",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/1/17434/abstract-text/16779792/pubmed\" id=\"16779792\" target=\"_blank\">",
"        16779792",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Druker BJ, Sawyers CL, Kantarjian H, et al, &ldquo;Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia With the Philadelphia Chromosome,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 344(14):1038-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/1/17434/abstract-text/11287973/pubmed\" id=\"11287973\" target=\"_blank\">",
"        11287973",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Druker BJ, Talpaz M, Resta DJ, et al, &ldquo;Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 344(14):1031-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/1/17434/abstract-text/11287972/pubmed\" id=\"11287972\" target=\"_blank\">",
"        11287972",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eechoute K, Fransson MN, Reyners AK, et al, &ldquo;A Long-Term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients,&rdquo;",
"      <i>",
"       Clin Cancer Res",
"      </i>",
"      , 2012, 18(20):5780-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/1/17434/abstract-text/22850565/pubmed\" id=\"22850565\" target=\"_blank\">",
"        22850565",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gambacorti-Passerini C, Antolini L, Mahon FX, et al, &ldquo;Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2011, 103(7):553-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/1/17434/abstract-text/21422402/pubmed\" id=\"21422402\" target=\"_blank\">",
"        21422402",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gibbons J, Egorin MJ, Ramanathan RK, et al, &ldquo;Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Renal Dysfunction: A Study by the National Cancer Institute Organ Dysfunction Working Group,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(4):570-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/1/17434/abstract-text/18235116/pubmed\" id=\"18235116\" target=\"_blank\">",
"        18235116",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gotlib J, Cools J, Malone JM 3rd, et al, &ldquo;The FIP1L1-PDGFRalpha Fusion Tyrosine Kinase in Hypereosinophilic Syndrome and Chronic Eosinophilic Leukemia: Implications for Diagnosis, Classification, and Management,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2004, 103(8):2879-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/1/17434/abstract-text/15070659/pubmed\" id=\"15070659\" target=\"_blank\">",
"        15070659",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hamnvik OP, Larsen PR, and Marqusee E, &ldquo;Thyroid Dysfunction From Antineoplastic Agents,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2011, 103(21):1572-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/1/17434/abstract-text/22010182/pubmed\" id=\"22010182\" target=\"_blank\">",
"        22010182",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hehlmann R, Hochhaus A, Berger U, et al, &ldquo;Current Trends in the Management of Chronic Myelogenous Leukemia,&rdquo;",
"      <i>",
"       Ann Hematol",
"      </i>",
"      , 2000, 79:345-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/1/17434/abstract-text/10965782/pubmed\" id=\"10965782\" target=\"_blank\">",
"        10965782",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heinrich MC, Owzar K, Corless CL, et al, &ldquo;Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(33):5360-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/1/17434/abstract-text/18955451/pubmed\" id=\"18955451\" target=\"_blank\">",
"        18955451",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hess G, Bunjes D, Siegert W, et al, &ldquo;Sustained Complete Molecular Remissions After Treatment With Imatinib-Mesylate in Patients With Failure After Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia: Results of a Prospective Phase II Open-Label Multicenter Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(30):7583-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/1/17434/abstract-text/16234522/pubmed\" id=\"16234522\" target=\"_blank\">",
"        16234522",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hochhaus A, O'Brien SG, Guilhot F, et al, &ldquo;Six-Year Follow-Up of Patients Receiving Imatinib for the First-Line Treatment of Chronic Myeloid Leukemia,&rdquo;",
"      <i>",
"       Leukemia",
"      </i>",
"      , 2009, 23(6):1054-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/1/17434/abstract-text/19282833/pubmed\" id=\"19282833\" target=\"_blank\">",
"        19282833",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ibrahim AR, Eliasson L, Apperley JF, et al, &ldquo;Poor Adherence is the Main Reason for Loss of CCyR and Imatinib Failure for Chronic Myeloid Leukemia Patients on Long-Term Therapy,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2011, 117(14):3733-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/1/17434/abstract-text/21346253/pubmed\" id=\"21346253\" target=\"_blank\">",
"        21346253",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Joensuu H, Eriksson M, Sundby Hall K, et al, &ldquo;One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor: A Randomized Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2012, 307(12):1265-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/1/17434/abstract-text/22453568/pubmed\" id=\"22453568\" target=\"_blank\">",
"        22453568",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al, &ldquo;Effect of the Tyrosine Kinase Inhibitor STI571 in a Patient With a Metastatic Gastrointestinal Stromal Tumor,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 344(14):1052-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/1/17434/abstract-text/11287975/pubmed\" id=\"11287975\" target=\"_blank\">",
"        11287975",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kantarjian HM, O'Brien S, Cortes JE, et al, &ldquo;Imatinib Mesylate Therapy for Relapse After Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2002, 100(5):1590-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/1/17434/abstract-text/12176876/pubmed\" id=\"12176876\" target=\"_blank\">",
"        12176876",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kantarjian H, Sawyers C, Hochhaus A, et al, &ldquo;Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2002, 346:645-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/1/17434/abstract-text/11870241/pubmed\" id=\"11870241\" target=\"_blank\">",
"        11870241",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kerkela R, Grazette L, Yacobi R, et al, &ldquo;Cardiotoxicity of the Cancer Therapeutic Agent Imatinib Mesylate,&rdquo;",
"      <i>",
"       Nat Med",
"      </i>",
"      , 2006, 12(8):908-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/1/17434/abstract-text/16862153/pubmed\" id=\"16862153\" target=\"_blank\">",
"        16862153",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Larson RA, Druker BJ, Guilhot F, et al, &ldquo;Imatinib Pharmacokinetics and its Correlation With Response and Safety in Chronic-Phase Chronic Myeloid Leukemia: A Subanalysis of the IRIS Study,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2008, 111(8):4022-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/1/17434/abstract-text/18256322/pubmed\" id=\"18256322\" target=\"_blank\">",
"        18256322",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Le Cesne A, Ray-Coquard I, Bui BN, et al, &ldquo;Discontinuation of Imatinib in Patients With Advanced Gastrointestinal Stromal Tumours After 3 Years of Treatment: An Open-Label Multicentre Randomised Phase 3 Trial,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2010, 11(10):942-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/1/17434/abstract-text/20864406/pubmed\" id=\"20864406\" target=\"_blank\">",
"        20864406",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Le Cesne A, Van Glabbeke M, Verweij J, et al, &ldquo;Absence of Progression as Assessed by Response Evaluation Criteria in Solid Tumors Predicts Survival in Advanced GI Stromal Tumors Treated With Imatinib Mesylate: The Intergroup EORTC-ISG-AGITG Phase III Trial,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(24):3969-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/1/17434/abstract-text/19620483/pubmed\" id=\"19620483\" target=\"_blank\">",
"        19620483",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Liu H and Artz AS, &ldquo;Reduction of Imatinib Absorption After Gastric Bypass Surgery,&rdquo;",
"      <i>",
"       Leuk Lymphoma",
"      </i>",
"      , 2011, 52(2):310-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/1/17434/abstract-text/21133728/pubmed\" id=\"21133728\" target=\"_blank\">",
"        21133728",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mahon FX, R&eacute;a D, Guilhot J, et al, &ldquo;Discontinuation of Imatinib in Patients With Chronic Myeloid Leukaemia Who Have Maintained Complete Molecular Remission for at Least 2 Years: the Prospective, Multicentre Stop Imatinib (STIM) Trial,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2010, 11(11):1029-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/1/17434/abstract-text/20965785/pubmed\" id=\"20965785\" target=\"_blank\">",
"        20965785",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McArthur GA, Demetri GD, van Oosterom A, et al, &ldquo;Molecular and Clinical Analysis of Locally Advanced Dermatofibrosarcoma Protuberans Treated with Imatinib: Imatinib Target Exploration Consortium Study B2225,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(4):866-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/1/17434/abstract-text/15681532/pubmed\" id=\"15681532\" target=\"_blank\">",
"        15681532",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN) &ldquo;Practice Guidelines in Oncology&trade;: Chronic Myelogenous Leukemia Version 3.2013.&rdquo; Available at file://www.nccn.org/professionals/physician_gls/PDF/cml.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Olavarria E, Siddique S, Griffiths MJ, et al, &ldquo;Posttransplantation Imatinib as a Strategy to Postpone the Requirement for Immunotherapy in Patients Undergoing Reduced-Intensity Allografts for Chronic Myeloid Leukemia,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2007, 110(13):4614-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/1/17434/abstract-text/17881635/pubmed\" id=\"17881635\" target=\"_blank\">",
"        17881635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ottmann OG, Wassmann B, Pfeifer H, et al, &ldquo;Imatinib Compared With Chemotherapy as Front-Line Treatment of Elderly Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL),&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2007, 109(10):2068-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/1/17434/abstract-text/17429836/pubmed\" id=\"17429836\" target=\"_blank\">",
"        17429836",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pavlovsky C, Egorin MJ, Shah DD, et al, &ldquo;Imatinib Mesylate Pharmacokinetics Before and After Sleeve Gastrectomy in a Morbidly Obese Patient With Chronic Myeloid Leukemia,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2009, 29(9):1152-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/1/17434/abstract-text/19698017/pubmed\" id=\"19698017\" target=\"_blank\">",
"        19698017",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Penel N, Le Cesne A, Bui BN, et al, &ldquo;Imatinib for Progressive and Recurrent Aggressive Fibromatosis (Desmoid Tumors): An FNCLCC/French Sarcoma Group Phase II trial With a Long-Term Follow-up,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2011, 22(2):452-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/1/17434/abstract-text/20622000/pubmed\" id=\"20622000\" target=\"_blank\">",
"        20622000",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pye SM, Cortes J, Ault P, et al, &ldquo;The Effects of Imatinib on Pregnancy Outcome,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2008, 111(12):5505-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/1/17434/abstract-text/18322153/pubmed\" id=\"18322153\" target=\"_blank\">",
"        18322153",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ramanathan RK, Egorin MJ, Takimoto CH, et al, &ldquo;Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Liver Dysfunction: A Study by the National Cancer Institute Organ Dysfunction Working Group,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(4):563-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/1/17434/abstract-text/18235115/pubmed\" id=\"18235115\" target=\"_blank\">",
"        18235115",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shima H, Tokuyama M, Tanizawa A, et al, &ldquo;Distinct Impact of Imatinib on Growth at Prepubertal and Pubertal Ages of Children With Chronic Myeloid Leukemia,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2011, 159(4):676-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/1/17434/abstract-text/21592517/pubmed\" id=\"21592517\" target=\"_blank\">",
"        21592517",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stacchiotti S, Longhi A, Ferraresi V, et al, &ldquo;Phase II Study of Imatinib in Advanced Chordoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2012, 30(9):914-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/1/17434/abstract-text/22331945/pubmed\" id=\"22331945\" target=\"_blank\">",
"        22331945",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stacchiotti S, Marrari A, Tamborini E, et al, &ldquo;Response to Imatinib Plus Sirolimus in Advanced Chordoma,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2009, 20(11):1886-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/1/17434/abstract-text/19570961/pubmed\" id=\"19570961\" target=\"_blank\">",
"        19570961",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thomas DA, Faderl S, Cortes J, et al, &ldquo;Treatment of Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia With Hyper-CVAD and Imatinib Mesylate,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2004, 103(12):4396-407.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/1/17434/abstract-text/14551133/pubmed\" id=\"14551133\" target=\"_blank\">",
"        14551133",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      von Mehren M and Widmer N, &ldquo;Correlations Between Imatinib Pharmacokinetics, Pharmacodynamics, Adherence, and Clinical Response in Advanced Metastatic Gastrointestinal Stromal Tumor (GIST): An Emerging Role for Drug Blood Level Testing?&rdquo;",
"      <i>",
"       Cancer Treat Rev",
"      </i>",
"      , 2011, 37(4):291-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/1/17434/abstract-text/21078547/pubmed\" id=\"21078547\" target=\"_blank\">",
"        21078547",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yanada M, Takeuchi J, Sugiura I, et al, &ldquo;High Complete Remission Rate and Promising Outcome by Combination of Imatinib and Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia: A Phase II Study by the Japan Adult Leukemia Study Group,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(3):460-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/1/17434/abstract-text/16344315/pubmed\" id=\"16344315\" target=\"_blank\">",
"        16344315",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yoo C, Ryu MH, Kang BW, et al, &ldquo;Cross-Sectional Study of Imatinib Plasma Trough Levels in Patients With Advanced Gastrointestinal Stromal Tumors: Impact of Gastrointestinal Resection on Exposure to Imatinib,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(9):1554-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/1/17434/abstract-text/20177019/pubmed\" id=\"20177019\" target=\"_blank\">",
"        20177019",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8961 Version 52.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-D438A33F91-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_1_17434=[""].join("\n");
var outline_f17_1_17434=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181929\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181930\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181958\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181934\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181948\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181935\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6797530\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181936\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181959\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181906\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181892\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181909\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181908\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6797529\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3401645\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181956\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181912\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181896\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181952\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181900\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181926\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181902\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181916\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181941\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3339989\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181917\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181915\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181904\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181918\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181895\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181911\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8961\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8961|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/49/3862?source=related_link\">",
"      Imatinib: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35352?source=related_link\">",
"      Imatinib: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_1_17435="Muscles of thumb movement";
var content_f17_1_17435=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F77180&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F77180&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Muscles involved in thumb movement",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Muscle",
"       </td>",
"       <td class=\"subtitle1\">",
"        Function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        EPL - Extensor pollicis longus",
"       </td>",
"       <td>",
"        Extends IP joint",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        FPL - Flexor pollicis longus",
"       </td>",
"       <td>",
"        Flexes IP joint",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        EPB - Extensor pollicis brevis",
"       </td>",
"       <td>",
"        Extends MCP joint",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        FPB - Flexor pollicis brevis",
"       </td>",
"       <td>",
"        Flexes MCP joint",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         APL - Abductor pollicis longus",
"        </p>",
"        <p>",
"         APB - Abductor pollicis brevis",
"        </p>",
"       </td>",
"       <td>",
"        Abducts thumb metacarpal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        AP - Adductor pollicis",
"       </td>",
"       <td>",
"        Adducts thumb metacarpal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        OP - Opponens pollicis",
"       </td>",
"       <td>",
"        Flexes and abducts thumb metacarpal (pinch with little finger isolates OP)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1st interosseus",
"       </td>",
"       <td>",
"        Works with OP to enable pinch against index finger",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IP: interphalangeal; MCP: metacarpophalangeal.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_1_17435=[""].join("\n");
var outline_f17_1_17435=null;
var title_f17_1_17436="Pneu vaccine patients rec infec";
var content_f17_1_17436=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F57070&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F57070&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pneumococcal immunization in patients with recurrent infections",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Vaccine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Conjugate (CV)*",
"       </td>",
"       <td class=\"subtitle2\">",
"        Polysaccharide (PV)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Normal infants",
"       </td>",
"       <td>",
"        2, 4, 6, 12-15 months",
"       </td>",
"       <td>",
"        Not given to patients this age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7 to 11 months",
"       </td>",
"       <td>",
"        3 doses&bull;",
"       </td>",
"       <td>",
"        Not given to patients this age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12 to 23 months",
"       </td>",
"       <td>",
"        2 doses",
"       </td>",
"       <td>",
"        Not given to patients this age&Delta;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2 to 5 years",
"       </td>",
"       <td>",
"        1 dose&loz;",
"       </td>",
"       <td>",
"        1 dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;5 years",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        1 dose&sect;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The measurement of pre-immunization immunoglobulin and serotype-specific antibody concentrations, as well as 4-to-6-week post-immunization serotype-specific antibody concentrations are recommended.",
"    <div class=\"footnotes\">",
"     * Recommendations for the use of CV are based upon the recommendations of the CDC Advisory Committee (press release 10/22/99), FDA (HHS News release 2/17/00) and of the American Council on Immunization Practices (CDC 2002 [ACIP] MMWR 2002; 51:31).",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Intervals between doses of any vaccine combination should be &ge;2 months.",
"      <br>",
"       &Delta; One study showed excellent serological responses to 22 of the 23 serotypes in the PV vaccine in 56 12-month old children. (Balloch A, Licciardi P, Russell F, et al. J Allergy Clin Immunol 2010; 126:395). These results support personal observations (Sorensen RU) of good responses to PV in younger children. The use of PV in patients 12-24 months of age could be considered when CVs are not available.",
"       <br>",
"        <span class=\"lozenge\">",
"         &loz;",
"        </span>",
"        Patients with IgG2 deficiency may require 2 doses at any age. (Zielen S, Buhring I, Strand N, et al. Infect Immun 2000; 68:1435).",
"        <br>",
"         &sect; If there is no antibody response to PV, give CV; repeating PV is not effective. (Sorensen RU, Leiva LE, Giangrosso PA, et al. Pediatr Infect Dis J 1998; 17:685).",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Sorensen RU, Moore C. Peds Clin N A 2000; 42:1225.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_1_17436=[""].join("\n");
var outline_f17_1_17436=null;
var title_f17_1_17437="Bisoprolol in HF CIBIS II";
var content_f17_1_17437=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F63774&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F63774&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bisoprolol reduces mortality in HF",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 429px; height: 286px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CIBIS-II enrolled 2647 patients with class III and IV heart failure (HF) who were receiving therapy with angiotensin converting enzyme inhibitors and diuretics. Compared to placebo, bisoprolol significantly reduced all-cause mortality (11.8 versus 17.3 percent, p",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: CIBIS-II Investigators and Committees. Lancet 1999; 353:9.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_1_17437=[""].join("\n");
var outline_f17_1_17437=null;
var title_f17_1_17438="Dietary fiber content of frequently consumed foods";
var content_f17_1_17438=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F82094&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F82094&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Dietary fiber content of frequently consumed foods",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Food",
"       </td>",
"       <td class=\"subtitle1\">",
"        Fiber, g/serving",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Fruits",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Apple (with skin)",
"       </td>",
"       <td>",
"        3.5/1 medium-sized apple",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Apricot (fresh)",
"       </td>",
"       <td>",
"        1.8/3 apricots",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Banana",
"       </td>",
"       <td>",
"        2.5/1 banana",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cantaloupe",
"       </td>",
"       <td>",
"        2.7/half edible portion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dates",
"       </td>",
"       <td>",
"        13.5/1 cup (chopped)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Grapefruit",
"       </td>",
"       <td>",
"        1.6/half edible portion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Grapes",
"       </td>",
"       <td>",
"        2.6/10 grapes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Oranges",
"       </td>",
"       <td>",
"        2.6/1 orange",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Peach (with skin)",
"       </td>",
"       <td>",
"        2.1/1 peach",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pear (with skin)",
"       </td>",
"       <td>",
"        4.6/1 pear",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pineapple",
"       </td>",
"       <td>",
"        2.2/1 cup (diced)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Prunes",
"       </td>",
"       <td>",
"        11.9/11 dried prunes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Raisins",
"       </td>",
"       <td>",
"        2.2/packet",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Strawberries",
"       </td>",
"       <td>",
"        3.0/1 cup",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Juices",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Apple",
"       </td>",
"       <td>",
"        0.74/1 cup",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Grapefruit",
"       </td>",
"       <td>",
"        1.0/1 cup",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Grape",
"       </td>",
"       <td>",
"        1.3/1 cup",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Orange",
"       </td>",
"       <td>",
"        1.0/1 cup",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Vegetables",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"2\">",
"        Cooked",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Asparagus",
"       </td>",
"       <td>",
"        1.5/7 spears",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Beans, string, green",
"       </td>",
"       <td>",
"        3.4/1 cup",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Broccoli",
"       </td>",
"       <td>",
"        5.0/1 stalk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Brussels sprouts",
"       </td>",
"       <td>",
"        4.6/7-8 sprouts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Cabbage",
"       </td>",
"       <td>",
"        2.9/1 cup (cooked)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Carrots",
"       </td>",
"       <td>",
"        4.6/1 cup",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Cauliflower",
"       </td>",
"       <td>",
"        2.1/1 cup",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Peas",
"       </td>",
"       <td>",
"        7.2/1 cup (cooked)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Potato (with skin)",
"       </td>",
"       <td>",
"        2.3/1 boiled",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Spinach",
"       </td>",
"       <td>",
"        4.1/1 cup (raw)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Squash, summer",
"       </td>",
"       <td>",
"        3.4/1 cup (cooked, diced)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Sweet potatoes",
"       </td>",
"       <td>",
"        2.7/1 baked",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Zucchini",
"       </td>",
"       <td>",
"        4.2/1 cup (cooked, diced)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"2\">",
"        Raw",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Cucumber",
"       </td>",
"       <td>",
"        0.2/6-8 slices with skin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Lettuce",
"       </td>",
"       <td>",
"        2.0/1 wedge iceberg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Mushrooms",
"       </td>",
"       <td>",
"        0.8/half cup (sliced)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Onions",
"       </td>",
"       <td>",
"        1.3/1 cup",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Peppers, green",
"       </td>",
"       <td>",
"        1.0/1 pod",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Tomato",
"       </td>",
"       <td>",
"        1.8/1 tomato",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Spinach",
"       </td>",
"       <td>",
"        8.0/1 cup (chopped)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"2\">",
"        Legumes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Baked beans",
"       </td>",
"       <td>",
"        18.6/1 cup",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Dried peas",
"       </td>",
"       <td>",
"        4.7/half cup (cooked)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Kidney beans",
"       </td>",
"       <td>",
"        7.4/half cup (cooked)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Lima beans",
"       </td>",
"       <td>",
"        2.6/half cup (cooked)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Lentils",
"       </td>",
"       <td>",
"        1.9/half cup (cooked)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Breads, pastas, and flours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bagels",
"       </td>",
"       <td>",
"        1.1/half bagel",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bran muffins",
"       </td>",
"       <td>",
"        6.3/muffin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cracked wheat",
"       </td>",
"       <td>",
"        4.1/slice",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Oatmeal",
"       </td>",
"       <td>",
"        5.3/1 cup",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pumpernickel bread",
"       </td>",
"       <td>",
"        1.0/slice",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        White bread",
"       </td>",
"       <td>",
"        0.55/slice",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Whole-wheat bread",
"       </td>",
"       <td>",
"        1.66/slice",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"2\">",
"        Pasta and rice cooked",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Macaroni",
"       </td>",
"       <td>",
"        1.0/1 cup (cooked)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Rice, brown",
"       </td>",
"       <td>",
"        2.4/1 cup (cooked)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Rice, polished",
"       </td>",
"       <td>",
"        0.6/1 cup (cooked)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Spaghetti (regular)",
"       </td>",
"       <td>",
"        1.0/1 cup (cooked)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"2\">",
"        Flours and grains",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Bran, oat",
"       </td>",
"       <td>",
"        8.3/oz",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Bran, wheat",
"       </td>",
"       <td>",
"        12.4/oz",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Rolled oats",
"       </td>",
"       <td>",
"        13.7/1 cup (cooked)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Nuts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Almonds",
"       </td>",
"       <td>",
"        3.6/half cup (slivered)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Peanuts",
"       </td>",
"       <td>",
"        11.7/1 cup",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: the American Gastroenterological Association, Kim YI. AGA technical review: impact of dietary fiber on colon cancer occurrence. Gastroenterology 2000; 118:1235.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_1_17438=[""].join("\n");
var outline_f17_1_17438=null;
var title_f17_1_17439="Lymph node Hodgkin lymphoma";
var content_f17_1_17439=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F76378&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F76378&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lymph node in Hodgkin lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 312px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cut section of a lymph node from a patient with the nodular sclerosis subtype of Hodgkin lymphoma shows distinct separation into nodules by fibrous bands.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Warnke RA, Weiss LM, Chan JK, et al. Tumors of the lymph nodes and spleen. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 14, 1995, Washington, DC. Armed Forces Institute of Pathology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_1_17439=[""].join("\n");
var outline_f17_1_17439=null;
